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Abstract
Development of Advanced MR-Guided Adaptive Radiation Therapy Methods for Head &
Neck Cancers on the 1.5T MR-Linac

Brigid A. McDonald, B.S.
Advisory Professor: Clifton David Fuller, M.D., Ph.D.

The 1.5T hybrid MRI/linear accelerator (MR-linac) has recently been introduced into
clinical practice and used for the treatment of head and neck cancers (HNC). This device
enables on-line adaptive radiation therapy (ART) based on anatomical changes throughout
treatment and variations in patient position. This novel technology also has the potential for
advanced ART strategies such as dose-optimized ART, in which the treatment plan is
optimized based on the accumulated dose over previous fractions, or biological imageguided ART, in which the plan is adapted based on individual tumor response as measured
through quantitative imaging techniques such as diffusion-weighted imaging (DWI). The
aims of this dissertation are to validate the existing adaptive workflows for HNC on the MRlinac and perform technological validation of preliminary steps for these advanced ART
strategies.
First, we measured the dose distribution caused by the electron return effect at the
interface of high- and low-density materials using gel dosimetry. The second project focused
on validating our clinical workflow for the first ten HNC patients treated on the MR-linac. We
demonstrated that we could create quality adaptive treatment plans for HNC but that the
poor autosegmentation performance is a major bottleneck of the on-line Adapt to Shape
workflow.
Next, with the ultimate goal of creating a dose accumulation tool for MR-linac
treatments, we developed a method for reconstructing the delivered dose from Adapt to
vii

Position plans. Because these doses are calculated on the reference image rather than the
setup image to save time in the on-line workflow, doses can be recalculated on the setup
image off-line after tumor and OAR segmentation to determine the true delivered dose. We
evaluated the performance of various autosegmentation algorithms on the MR-linac setup
images and investigated how the segmentation accuracy impacts the dose calculation.
The last component of this project was optimization and technical validation of DWI
sequences on the MR-linac. We optimized turbo spin echo (TSE) and split acquisition of fast
spin echo signals (SPLICE) using both quantitative and qualitative metrics. Finally, we
compared these sequences to echo planar imaging (EPI) on the MR-linac and three DWI
sequences on a 1.5T MR simulator by measuring in vivo repeatability, ADC bias, and signalto-noise ratio.
In conclusion, these projects validate the clinical feasibility of treating HNC on the
MR-linac and pave the way for advanced adaptive strategies such as dose accumulation
and biological image-guided ART to personalize radiation therapy for HNC patients.
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Chapter 1: Introduction
1.1 Background
Patients undergoing radiation therapy (RT) for head and neck cancers (HNC)
experience debilitating side effects including oral mucositis, xerostomia, osteoradionecrosis,
and dysphagia [1–6] due to the high radiosensitivity of several organs at risk (OARs) in the
head and neck. Although some sequelae resolve shortly after the conclusion of RT, many
last for several years and significantly degrade patients’ oral health and quality of life.
Despite the prevalence and persistence of these side effects, RT remains the standard of
care for most HNC, including the most common oral cancer, human papillomavirus-positive
oropharyngeal cancer (HPV+ OPC). The incidence of HPV+ OPC is rising rapidly in the
United States, with an estimated 20,000-30,000 new diagnoses annually [7]. While RT is
highly curative for HPV+ OPC [8, 9], the high long-term survival rates imply that most HPV+
OPC patients will experience lingering side effects from treatment for decades of
survivorship.
RT-induced normal tissue injuries in the head and neck region remain prevalent
despite significant progress over the past few decades to make RT more conformal to the
tumor. Linear accelerators (linacs) are now standardly equipped with multi-leaf collimators
(MLC), which allow for the dynamic shaping of the radiation fields to reduce radiation
exposure to healthy tissues. Most linacs also contain an on-board imaging system such as
planar x-ray or cone beam computed tomography (CT) to verify patient positioning and to
ensure that the radiation is aimed directly at the tumor. However, despite these
technological advances, complete tumor conformality has not yet been achieved due to the
poor image quality of these on-board imaging systems and the uncertainties associated with
the treatment planning and delivery processes. In a typical course of RT, a treatment plan is
created at the beginning of treatment based on a CT simulation image, and then that same
1

treatment plan is delivered to the patient each day over a two-month course of RT. This
process relies on the unrealistic assumption that the anatomy does not change throughout
RT, thus resulting in the delivery of high radiation doses to adjacent healthy tissues as the
tumor shrinks.
To spare dose to normal tissues without compromising tumor control, a new
treatment approach called adaptive RT (ART) has been proposed, in which a new treatment
plan is created periodically throughout the course of RT to account for changes in tumor
volume, normal tissue deformation, weight loss, and variations in patient position from day
to day [10–15]. Adaptive replanning has been used with some success, but its widespread
clinical implementation has been limited by the necessity of acquiring a new CT simulation
image, creating a new treatment plan, performing quality assurance on the treatment plan,
and receiving physician and physics approval for each adaptive plan. For this reason,
adaptive replanning is not typically performed more than once or twice during the course of
RT. Furthermore, adaptive replanning is difficult for HNC because tumor borders and OARs
cannot be well-delineated on CT without the use of exogenous contrast [16]. However, the
integration of magnetic resonance imaging (MRI) simulation into ART workflows can
enhance the visualization of head and neck target volumes and OARs throughout the
course of RT due to the superior soft tissue contrast of MRI compared to CT [17, 18]. The
recent development of hybrid magnetic resonance imaging-linear accelerator (MR-linac)
devices has made daily on-board ART clinically feasible [19–21]. With these systems,
patients are imaged daily with the on-board MRI, and a new treatment plan is created at
each fraction while the patient is on the treatment table. Currently, two commercial MR-linac
systems are available: the 1.5T Elekta Unity and the 0.35T Viewray. While the capabilities
and workflows of the two systems are similar, the work in this dissertation will focus on (and
the term “MR-linac” will refer to) the 1.5T Unity system.
The MR-linac has afforded clinicians the abilities to visualize target volumes and
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OARs during every RT fraction, track treatment response based on changes in tumor size,
and personalize RT for each individual patient without requiring additional imaging
appointments for patients. However, this major technological advancement has presented
new challenges in terms of dosimetry, clinical workflows, and quality assurance. First, RT in
the presence of a magnetic field causes a phenomenon called the electron return effect
(ERE), in which the magnetic field causes secondary electrons to loop around and deposit
higher doses at boundaries of high- and low-density materials such as the skin surface and
nasal cavities. While the MR-linac’s Monte Carlo-based treatment planning system can
account for the ERE, dose distributions for MR-linac treatment plans may have perceptible
differences compared to conventional linac treatment plans. Second, the MR-linac is
currently only capable of step-and-shoot intensity-modulated RT (IMRT) delivery, not
volumetric modulated arc therapy (VMAT), which is currently the standard delivery method
on most modern linacs. The MR-linac also enables tracking of target volume motion in realtime during treatment but lacks gating capabilities, which means that clinicians cannot
respond to target volume motion to modify treatments effectively.
In terms of on-line adaptive replanning workflows, autosegmentation of daily setup
images for treatment plan reoptimization remains a challenge. The treatment planning
system currently only allows deformable contour propagation between a previously
contoured image and the setup image, and the results generally require manual editing to
produce clinically acceptable contours [22–24]. Furthermore, while on-line treatment plan
reoptimization eliminates the need for additional imaging appointments and expedites the
adaptive replanning process compared to off-line ART, MR-linac treatments take longer than
treatments on conventional linacs. Segmentation and plan reoptimization are major
bottlenecks in the on-line workflow, especially for HNC, which often requires complex
treatment plans due to the large number of OARs and target volumes/dose levels treated
[25]. Another new challenge arises now that multiple treatment plans are delivered
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throughout the course of RT: how to sum treatment plans to accurately quantify delivered
dose and how to interpret delivered dose when RT planning constraints and response
metrics have historically been based on planned dose on a static, pre-treatment
representation of the anatomy. The work in this dissertation seeks to address some of these
challenges with the MR-linac system to improve MR-guided ART for head and neck cancers.
Furthermore, the current MR-guided ART process on the MR-linac accounts for
anatomical changes throughout the course of RT, but anatomical variations are merely one
aspect of monitoring patient response using MRI. Recent studies have demonstrated the
utility of a quantitative MRI technique, diffusion-weighted imaging (DWI), in predicting head
and neck tumor response to RT [26–35] and normal tissue damage during RT [36–40]. DWI
measures the diffusion of water molecules through tissue and displays this information as a
spatial map of the apparent diffusion coefficient (ADC) value of each imaging voxel.
Consequently, functional changes during RT, such as the breakdown of cellular membranes
via radiation-induced apoptosis, are reflected as changes in ADC values within an imaging
volume. By obtaining DWIs serially throughout RT on the MR-linac, we have the capacity to
monitor tumor response and normal tissue injury and adapt treatments according to this
physiological information to deliver truly personalized RT. However, there is currently a gap
in knowledge about how DWI can be directly integrated into the RT treatment planning
process and how it can inform clinical decisions about RT plan adaptation. For any DWI
sequence, the variation in ADC over repeated scans must be determined using “test-retest”
studies to quantify the threshold change in ADC that reflects true biological response rather
than imaging noise [41]. Questions also remain regarding target volume and sub-volume
segmentation using DWI [42, 43] and how to modify dose based on response [44–46].
Further, there currently does not exist a single platform in which quantitative MR imaging
data can be tracked serially during RT and used in conjunction with anatomical data for
treatment planning and response assessment. Also, due to differences in hardware between
4

the MR-linac MRI components and conventional diagnostic MRI scanners, DWI sequences
must be optimized specifically for the MR-linac.
The objective of this project is to fulfill several of the workflow challenges and gaps in
knowledge to improve MR-guided ART for HNC on the MR-linac and to move us closer to
our ultimate goal of delivering personalized response-adapted RT. The goal of specific Aim
1 is to evaluate existing MR-linac clinical workflows for HNC and identify key areas for
further development, with particular focus on the ERE and an analysis of treatment
workflows and treatment plan variability in the first few months of treating HNC on the MRlinac. Specific Aim 2 is focused on improving autosegmentation of head and neck OARs and
moving toward an end-to-end dose accumulation workflow. Specific Aim 3 covers DWI,
including optimization of DWI sequences on the MR-linac for HNC and an in vivo test-retest
and phantom study to compare MR-linac DWI sequences to those from a diagnostic quality
MRI simulator (MR sim) scanner. From the MR-linac being installed at MD Anderson in 2014
to treating our first patient in 2019 to the start of our first MR-linac HNC randomized control
trial [47] in 2021, this technology and its clinical use has evolved rapidly during my time as a
graduate student (2016-2022). The work in this dissertation reflects this evolution, with the
projects in Specific Aim 1 occurring during the pre-clinical and early clinical stages and the
projects in Specific Aims 2 and 3 aiming towards developing a dose accumulation
framework and advanced imaging protocols for use in our clinical trial.

1.2 MR-Linac
1.2.1 Technical Design
The Elekta Unity MR-linac combines a modified 1.5T Philips wide-bore MRI system
with a 7 MV flattening filter-free Elekta linac [48–50]. The unique design of this system
addresses the following key issues: 1) magnetic field interference with the electronic
components of the linac, 2) radiofrequency interference from linac electronics with MRI
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components, and 3) transmission of the radiation field through the MRI components. The
MRI and linac form two concentric circles, with the MRI components in the center and the
linac beam-generating components and MLC housed within a ring-shaped gantry
surrounding the MRI. The MRI components are housed within a Faraday cage that protects
the MRI electronics from radiofrequency (RF) interference from the linac electronics.
Additional electromagnetic coils provide active magnetic field shielding to protect linac
components from the influence of the magnetic field. There is a small opening in the
Faraday cage to allow the radiation beam to pass through. The gradient and shim coils also
contain openings in the center for radiation beam passage. This design results in a
maximum radiation field size of 57 cm (right-left) by 22 cm (superior-inferior) [51]. The
receive coil system contains two radiolucent 4-channel array coils [52]. The posterior coil is
integrated into the linac couch, and the anterior coil is suspended over the patient after the
patient is positioned for treatment. The anterior coil is composed of a rigid plastic shell filled
with an expandable plastic foam, with all beam-attenuating and radiosensitive electronic
components on the outer edges to create a radiolucent window. Because the receive coil is
directly in the beam path, this coil design minimizes attenuation of the beam and radiation
damage to the electronics. The rigid curved shape does not alter the body contour of the
patient, helping to enable consistent positioning for RT.
Although this design accomplishes the goal of integrating an MRI and a linac with
minimal interference between the two systems, there are several limitations that may impact
image quality. First, the 2x4 channel array coil system has lower signal-to-noise ratio (SNR)
compared to receive coils commonly used in diagnostic quality MRIs. In general, SNR is
maximized when the receive coils are as close as possible to the imaging volume.
Diagnostic MRIs typically use a head and neck coil for HNC imaging, while our department’s
MR sim workflow for HNC uses flex coils to conform as tightly as possible around the RT
immobilization mask. On the MR-linac, the rigid anterior coil design prevents the coil from
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being flush against the body surface, which is advantageous for RT because it does not
alter the body shape but is disadvantageous from an imaging perspective because it
reduces SNR compared to head and neck or flex coils. Also, the number of channels in the
receive coil system is somewhat low compared to state-of-the-art receive coils that are often
used in diagnostic quality scanners, which limits parallel imaging capabilities. The gradient
coils on the MR-linac also have lower maximum gradient strength and slew rate (15 mT/m
and 65 T/m/s, respectively) compared to comparable 1.5T diagnostic scanners such as the
Philips Achieva (66 mT/m and 180 T/m/s) or Philips Ingenia (45 mT/m and 200 T/m/s).
Stronger gradients and faster slew rates enable faster imaging because gradients do not
need to be applied as long to have the same effect on spins compared to weaker
gradients/slower slew rates, allowing for shorter echo and repetition times. The gradient
performance is especially important for DWI, particularly in echo-planar imaging (EPI)
sequences that require the gradients to rapidly switch polarity several times during a single
spin echo excitation cycle. Finally, the split coil design that allows the radiation beam to pass
through the MRI coils may cause magnetic field inhomogeneities if the shim coils are not
properly tuned [53, 54].

1.2.2 Treatment Planning System and On-Line Adaptive Workflows
With the Unity MR-linac system, treatment plan adaptation occurs at each fraction of
RT using either the ‘Adapt to Position’ (ATP) or ‘Adapt to Shape’ (ATS) on-line workflow
(described below). The MR-linac uses the Monaco treatment planning system, which
employs a Monte Carlo dose calculation engine to account for the effects of the magnetic
field. The successful clinical implementation of on-line ART is made possible by novel
computational tools integrated into Monaco, allowing for automation of several steps of the
on-line workflow. In most cases, the entire treatment process for a single fraction, including
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patient setup, imaging, treatment plan re-optimization, plan review, and beam delivery, can
be completed within an hour [22, 55, 56].
At our institution, the clinical workflow for the MR-linac begins much like conventional
RT, with the patient undergoing simulation imaging in the treatment position. Each patient
receives both a CT simulation and an MR simulation on the same day with the same
immobilization setup, which ensures that the two images may be fused with high anatomical
accuracy via rigid image registration [57]. In our clinic, we use the CT simulation as the
reference image for the initial treatment plan, as is done in a conventional RT workflow. The
OARs are contoured on the CT using atlas-based auto-segmentation. The MRI is used for
manual delineation of the primary and nodal gross target volume (GTV) contours, which are
then rigidly propagated to the CT. The clinical target volume(s) (CTV) and planning target
volume(s) (PTV) are generated using margin expansions within the treatment planning
system, according to the treating physician’s orders. The treatment plan is then generated
on the CT and reviewed by the physicist and physician. This initial plan is known as the
“reference plan,” which serves as the starting point for the adaptive plans created at each
fraction.
For each fraction, the patient is set up on the MR-linac treatment table and imaged
with the daily setup imaging protocol (a T2-weighted scan for head and neck). The daily
setup image is imported into Monaco and rigidly registered with the reference (i.e.
simulation) image, aligning to the tumor or an MR-visible anatomical reference landmark.
The isocenter is updated in Monaco according to any positional shifts in the x, y, and zdirections. Unlike a regular linac, the table cannot be shifted with six degrees of freedom
because it is encompassed within the MR bore. Consequently, the MLC leaf positions must
be modified at each fraction to account for the position of the tumor. As such, the MR-linac
requires a “virtual couch shift” that shifts the radiation beams rather than the patient.
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At this point in the workflow, depending on the clinical indication and the variations in
anatomy that are visible on the setup imaging, the user may choose to proceed with either
ATP or ATS as the adaptation paradigm [58] (Figure 1.1). ATP accounts for the virtual
couch shift and re-optimizes the treatment plan based on the reference image anatomy. As
such, ATP is more appropriate when anatomical changes between fractions are minimal,
whereas the ATS workflow is indicated when anatomical variations are more significant. In
ATS, the treatment plan is re-optimized based on the anatomy captured on the daily setup
image. In clinical practice, a combination of the two workflows may be used throughout the
course of RT. For HNC patients in our clinic, we perform ATS periodically throughout the
treatment course when significant anatomical variation has occurred. Patients are indicated
for ATS using the same criteria that we use in our off-line workflow to identify patients who
require a mid-therapy verification simulation (i.e. ill-fitting mask, weight loss, tumor growth).
The new ATS plan then serves as the new reference plan for subsequent ATP fractions.
In the ATP workflow, the image, contours, and electron density values for the
adaptive plan come from the reference plan. ATP does not require the daily setup MRI to be
contoured, and the optimized plan dose is calculated on the reference image rather than the
daily image. In the ATS workflow, deformable image registration (DIR) is used to propagate
OAR contours from the reference image to the daily setup image, which are manually edited
if necessary. If the GTV is modified from the reference plan contour, Monaco will recreate
the CTV and PTV based on the margin expansions defined previously during the creation of
the reference plan. Since MRI does not contain quantitative electron density information
required for dose calculation, Monaco assigns electron densities for each structure in a
process called the “bulk density assignment” whereby the average electron density value for
each structure is measured on CT and applied to each voxel in the structure on the MRI. (In
ATP, the electron densities from the reference plan are used.)
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Figure 1.1: Representation of the Elekta Unity MR-linac Adapt to Position (ATP) and Adapt
to Shape (ATS) on-line workflows. In ATP, a rigid registration is performed between the
reference image (the pre-treatment CT in this example) and the daily MRI. The isocenter is
updated, and the adaptive plan is optimized on the reference image with the reference
image contours. In ATS, a deformable image registration is performed between the
reference image and daily MRI, and contours are deformed onto the daily MRI. The adaptive
plan is optimized on the daily MRI with the new contours. Image courtesy of Winkel et al.
[58], reproduced under Open Access License CC-BY-NC-ND.

The final step of the workflow is to create the adaptive treatment plan. The dose is
calculated on the reference image anatomy for ATP and on the daily MRI anatomy for ATS.
Rather than creating a new plan from scratch (i.e. specifying the isocenter, beam angles,
prescription dose, IMRT constraints, etc. again at each fraction), the treatment planning
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system uses a warm start optimization algorithm with the reference plan as a prior [20, 58].
The first step, known as “segment aperture morphing,” is to move the MLC leaves at each
control point of the reference plan to reflect the updated isocenter and any changes to the
shape of the target contour. Next, the user chooses between two primary plan
reoptimization methods: 1) Optimize Weights and 2) Optimize Weights & Shapes. In
Optimize Weights, the number of monitor units per segment is optimized to satisfy the IMRT
constraints specified in the reference plan. In Optimize Weights & Shapes, both the shapes
of the MLC leaves and the monitor units per segment are optimized to meet the IMRT
constraints. If the plan does not satisfy the IMRT constraints or other quality checks, the
IMRT constraints may be modified and the adaptive plan re-optimized until a satisfactory
plan is finalized. Finally, the plan is reviewed and subsequently approved and delivered.

1.2.3 Electron Return Effect
RT in the presence of a magnetic field changes the way that the radiation dose is
deposited in the body. The magnetic field does not act on the primary x-ray radiation beam
because photons are not charged particles. However, the magnetic field does influence the
secondary electrons that are produced when x-rays interact with matter in the body.
Because the secondary electrons are moving charged particles, they experience Lorentz
forces perpendicular to their velocity and the magnetic field, causing curved trajectories. The
impact of Lorentz forces on dose deposition is most prominent at air-tissue interfaces or
interfaces of low- and high-density regions. When electrons exit a high-density material and
enter a low-density material (with lower stopping power), many of these electrons will have
sufficient range in the low-density material to loop back around toward the high-density
material and deposit their dose in the high-density material. This phenomenon is known as
the electron return effect (ERE). At air-tissue interfaces, an increase in deposited dose (i.e.
“hot spot”) is observed at the skin/tissue surface; similarly, at interfaces of high- and low11

density tissues, a “hot spot” is observed in the high-density material, while a “cold spot” is
observed in the low-density material. The ERE is particularly important in the head and neck
region due to the plethora of air-tissue interfaces including the skin surface and nasal
cavities, as well as the interfaces between small OARs with varying densities.
The magnitude of the ERE depends on a number of factors including the magnetic
field strength, radiation field size, orientation of the body surface/tissue interfaces relative to
the magnetic field and radiation beam, and the densities/stopping powers of materials. To
compensate for the ERE, it must be considered in the beam arrangements for treatment
planning and must be adequately modeled in the treatment planning system. For simple
geometries, parallel opposed beam arrangements and multi-beam IMRT plans can cancel
out the increase in deposited dose in the high-density material [59, 60]. However, in
clinically realistic scenarios with irregular geometries, it may not always be possible to
completely eliminate hot spots [61]. Therefore, the impact of the magnetic field on charged
particles must be properly modeled by the treatment planning system to account for the
ERE, as is done in the Monte Carlo-based Monaco treatment planning system used for the
Unity MR-linac.

1.3 Gel Dosimetry
Gel dosimetry is a method for measuring 3-dimensional (3-D) radiation dose
distributions by irradiating a volume of a gelatin-based solution and measuring the radiationinduced changes using an imaging modality such as MRI or optical CT. In this dissertation,
we will focus on Fricke gel dosimeter formulations, which contain iron (Fe) ions that exhibit a
dose-dependent conversion of ferrous (Fe2+) ions to ferric (Fe3+) ions [62–64]. Ferrous and
ferric ions have different paramagnetic characteristics, so the conversion of one to the other
can be detected by measuring the change in the spin-lattice relaxation time (T1) of the
nearby spins using an MRI T1-mapping sequence. Depending on the specific formulation
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and concentration of the iron-containing agent, the radiation dose is inversely proportional to
T1, or proportional to the spin-lattice relaxation rate (R1=1/T1), over a range of
approximately 0.1–30 Gy [65, 66]. Dose response curves that relate the change in R1 to
dose can be constructed for any particular gel formulation by irradiating samples to known
doses and measuring the change in R1 between MRI acquisitions taken before and after
irradiation.
Fricke gel dosimeters have gained renewed interest in recent years with the
increased utilization of MRI in RT applications. They are particularly easy to use with MRlinacs, which allow the pre-irradiation baseline MRI scan, irradiation, and post-irradiation
MRI scan to occur in immediate succession without having to move the dosimeter (which
would introduce noise and potential measurement error). Unlike other types of 3-D
dosimeters such as cylindrical diode arrays where the measurement resolution is limited by
the spacing of detector elements, the measurement resolution is limited by the spatial
resolution of the MRI sequence used for dose readout. However, the dose response
calibration is heavily dependent on the specific gel formulation, MRI scan parameters, and
temperature and is sensitive to various sources of uncertainty such as inter- and intra-batch
variability and imaging noise [67, 68].
In Chapter 2 of this dissertation, gel dosimetry is used to measure the magnitude of
the ERE at the interface of high- and low-density materials.

1.4 Dose Accumulation
In Chapter 3 of this dissertation, we explore another topic relevant to MR-guided
ART: dose accumulation. “Dose accumulation” is a term that encompasses a range of
techniques for summing multiple RT dose distributions for a single patient [69, 70]. The goal
is to arrive at a better estimate of the delivered dose compared to standard RT practices, in
which a single plan is generated and the dose is calculated only on a static pre-treatment
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representation of the anatomy. Dose distributions in conventional RT are modeled on the
often-flawed assumption that the tumor and surrounding anatomy remain static throughout
the course of RT; in reality, these dose distributions represent the planned or predicted dose
rather than the delivered dose [70]. Dose accumulation can help us arrive at a more realistic
depiction of the delivered dose, but uncertainties in the dose accumulation process make
the calculated dose distributions, at best, estimates of the delivered dose. Nonetheless,
dose accumulation remains a vital mechanism for quantifying delivered dose and evaluating
the benefit of various ART strategies used in clinical practice.
Dose accumulation is most often considered in the context of ART, where adaptive
plans are generated on either on-board setup images (i.e. on-line ART) or simulation images
acquired throughout RT (i.e. off-line ART). In a general dose accumulation pipeline, the
dose distribution for each plan is scaled to the number of fractions delivered, the planning
images are co-registered, and the dose distributions are then mapped according to the
estimated displacements and added voxel-by-voxel [12, 15, 71]. Dose accumulation most
often utilizes deformable image registration (DIR), which creates a spatial correspondence
between two images that accounts for anatomical deformations [72]. Doses may be mapped
backward onto the pre-treatment anatomy or forward to any time point during treatment,
depending on the intended use case for the accumulated dose.
Dose accumulation is valuable from a clinical standpoint for a number of reasons,
both during and after RT. MRgART allows physicians to set complex goals for treatment
personalized for each individual patient, and dose accumulation helps us determine whether
the intended goals are being met. These intentions may include sparing dose to specific
OARs, escalating dose to target structures, or modifying target volumes as the tumor shrinks
to spare tumor-adjacent OARs [73]. During a course of treatment, the ability to accumulate
dose informs clinicians as to whether or not the daily dose distributions are representative of
the cumulative dose. For example, if the dose to an OAR exceeds tolerance on one day, it is
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clinically relevant to know whether the cumulative dose is in excess, as this may inform the
optimization strategy for subsequent fractions [74–76]. Alternatively, if OAR doses are
sufficiently low after a certain number of fractions, the physician may choose to increase the
target dose or add an extra fraction based on individualized treatment response [77–79].
If dose accumulation can be automated and integrated into the MR-linac on-line
clinical workflow, it may radically change how we approach daily MRgART. If we could
accumulate the dose at each fraction in the frame of reference of the daily setup image, then
we could adapt the plan using modified and/or re-prioritized planning objectives based on
knowledge of the cumulative delivered dose. In other words, a dose constraint that is
routinely met may be de-prioritized in the set of IMRT planning objectives in favor of a dose
constraint that is routinely violated. This approach may also be useful if the clinical intent is
to escalate dose to the tumor because the physician can make an informed decision about
how much the tumor dose can be increased without exceeding the OAR constraints.
Dose accumulation may lead to opportunities to reevaluate normal tissue
complication probability (NTCP) and tumor control probability (TCP) models [80–84]. The
existing dose-response models are largely based on doses calculated on the pre-treatment
simulation anatomy, which is often assumed to be static. If we can more accurately quantify
the delivered dose after the conclusion of RT in a systematic way, there is an opportunity to
refine the current NTCP and TCP models and develop a novel set of planning constraints for
the era of ART and personalized medicine [69, 85].
In the context of the MR-linac workflows, a dose accumulation framework would
differ slightly for the ATP and ATS workflows. In ATS, the doses for each fraction are
calculated directly on the setup image, which reflects the anatomy during the time of
treatment. To accumulate the doses, all images would have to be registered to a common
time point and the doses mapped and summed in a single frame of reference. The major
difference with ATP, however, is that the setup images for each fraction are not contoured
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and the doses are calculated on the reference image (i.e. the image associated with the
reference plan used as a basis for plan optimization). This method saves time while the
patient is on the table because the setup images are not contoured. However, to accurately
accumulate dose after the plans have been delivered, it is essential to reconstruct the
delivered dose on the images representing the anatomy during treatment delivery. Figure
1.2 shows the general steps required to accomplish end-to-end dose accumulation for the
two MR-linac workflows.
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Figure 1.2: The proposed dose accumulation framework for the MR-linac ATP (virtual
isocenter shift) and ATS workflows. a) Step 1 (ATP workflow only): Because ATP calculates
dose on the reference image rather than the daily setup MRI, the daily images are not
contoured during the treatment and must be segmented off-line. b) Step 2 (ATP workflow
only): The doses for each fraction must be recalculated on the daily setup images off-line to
reconstruct the delivered dose at each fraction. c) Step 3 (ATP and ATS workflows): The
geometric correspondence between each daily image and the reference image set (i.e.
simulation or any other established time point) is created via DIR and represented by a
deformation vector field (DVF). d) Step 4 (ATP and ATS workflows): The DVFs are applied
to the corresponding dose distributions to map the doses onto the reference image set, then
the doses are summed to calculate the final accumulated dose.
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Chapters 3 and 4 both deal with dose accumulation for MR-linac head and neck
treatment plans. In Chapter 3, doses from ATP plans that were generated from the same
reference plan are already implicitly rigidly registered because the doses are calculated on
the same reference image. As a crude dose accumulation methodology, we summed these
implicitly registered doses to arrive at an estimate of the delivered dose. A DIR-based dose
accumulation strategy could not be performed because it would need to be developed and
fully validated prior to implementation. Chapter 4 focuses on an off-line workflow for
autosegmenting the structures on MR-linac setup images and reconstructing the doses of
ATP plans. This work moves us closer to an end-to-end dose accumulation workflow for
MR-linac head and neck treatment plans.

1.5 Diffusion-Weighted Imaging
This section is loosely based on a section that I wrote for the review article [86]:
Salzillo TC, Taku N, Wahid KA, McDonald BA, Wang J, van Dijk LV, Rigert JM, Mohamed
ASR, Wang J, Lai SY, Fuller CD. Advances in Imaging for HPV-Related Oropharyngeal
Cancer: Applications to Radiation Oncology. Semin Radiat Oncol 2021;31:371-388.
https://doi.org/10.1016/j.semradonc.2021.05.001
This article is published open-access under Open Access License CC-BY.

1.5.1 DWI in Head and Neck Cancers
Squamous cell carcinomas constitute the largest fraction of HNC worldwide, and
among the types of squamous cell carcinomas, oropharyngeal cancers (OPC) are the most
common [87]. OPC can be further classified into tumors related to HPV infection (HPV+) and
tumors not related to HPV infection (HPV-), which are typically associated with risk factors
such as tobacco and alcohol use. As tobacco use declines in the United States, the
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prevalence of HPV- cancers has decreased over the last few decades, while the incidence
of HPV+ cancers is on the rise [8]. HPV+ and HPV- OPCs demonstrate different histological
properties. HPV- tumors tend to be more heterogeneous, keratinized (i.e. producing large
amounts of the protein keratin), and marked by regions of intra-tumoral necrosis, while
HPV+ tumors tend to composed of undifferentiated, tightly packed, homogeneous cells [88].
These cellular-level differences lead to differences in patient prognosis, with HPV+ OPC
tumors demonstrating higher radiation sensitivity [89] and improved long-term survival
compared to HPV- cancers (median survival of 131 months and 20 months, respectively) [8].
Quantitative MRI techniques such as DWI can provide information about the
physiological properties and underlying structure of tissues. The quantitative parameters, or
quantitative imaging biomarkers, measured by these imaging techniques have been shown
to be correlated with HPV status and tumor response in head and neck cancers.
Furthermore, functional changes in tumors over the course of treatment, such as the
breakdown of tumor cell membranes, may be quantified by acquiring DWI scans throughout
therapy and measuring differences in the ADC values from pre-treatment scans.
DWI measures the random motion (diffusion) of water molecules within each imaging
voxel by acquiring a series of images with different gradient strengths and/or durations (bvalues) and reconstructing the images into a quantitative map of the apparent diffusion
coefficient (ADC) using a mono-exponential model of diffusion [90, 91]. Diffusion reveals
how tightly packed the cells are in a tissue; many tumors, including head and neck
squamous cell carcinomas, are characterized by densely packed cells compared to healthy
tissue, resulting in restricted diffusion which can be measured with DWI [92].
Several studies have investigated whether the HPV status of head and neck cancers
can be predicted by ADC. In 2014, Nakahira et al. [93] compared pre-treatment ADC values
of HPV+ and HPV- oropharyngeal tumors for 26 patients and found that both the mean and
minimum ADC were significantly lower in HPV+ tumors compared to HPV- tumors (mean:
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0.987 ± 0.156 vs. 1.218 ± 0.214x10-3 mm2/s; minimum: 0.627 ± 0.088 vs. 0.784 ± 0.174x10-3
mm2/s). A number of studies have since found similar results for cancers of the oropharynx,
oral cavity, hypopharynx, and larynx cancers [88, 94–97]. However, other researchers have
found that while the mean, median, and/or minimum ADC values of HPV+ tumors tend to be
lower than those of HPV- tumors, the differences were not significant in cohorts of
oropharyngeal, oral cavity, maxillary sinus, and other head and neck cancers [98–101].
de Perrot et al. [88] analyzed histogram parameters of the distributions of ADC
values in oropharynx and oral cavity tumors and compared them to the HPV status and
tumor microarchitecture from histopathological analysis. They found that HPV+ tumors had
significantly higher skewness and excess kurtosis compared to HPV- tumors, which are
measures of the symmetry and peakedness of a distribution, respectively. HPV+ tumors
generally had leptokurtic (i.e. narrow), right-skewed histograms, corresponding histologically
to “homogeneous tumors with back-to-back densely packed cells, scant stromal component,
and scattered comedonecrosis.” In contrast, the histograms for HPV- tumors were wider and
normally distributed, while the histology showed “heterogeneous tumors with variable
cellularity, high stromal component, keratin pearls, and necrosis.” The correlation between
ADC histogram parameters and tumor histological characteristics is both expected and
promising; it confirms the ability of DWI to discriminate between homogenous tumors with
tightly packed cells where diffusion is highly restricted (i.e. HPV+ squamous cell
carcinomas) and heterogeneous tumors with necrotic regions where diffusion is less
restricted (i.e. HPV- squamous cell carcinomas).
DWI may also be able to predict treatment response in HPV-related head and neck
cancers. Ravanelli et al. [102] compared pre-treatment ADC histogram parameters of
oropharyngeal tumors to progression-free survival and overall-survival at 2 years. In
univariate analysis, both HPV status and mean ADC were significant predictors of
progression-free survival, but only HPV status was significantly related to overall survival.
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None of these factors were significant in multivariate analysis, suggesting that ADC and
HPV status are too strongly associated with each other to be independent predictors of
survival. They also split the cohort into two groups based on HPV status and analyzed the
ADC histogram parameters skewedness, kurtosis, and entropy (a measure of image
heterogeneity) as well as mean and standard deviation ADC. Of all the ADC metrics, none
were significantly associated with progression-free survival in either the HPV+ or HPVgroup, and only entropy was associated with overall survival for the HPV- patients. Chawla
et al. [100] performed a similar analysis to determine whether pre-treatment ADC values
could predict if patients developed distant metastases during a 14-year follow-up period.
Median ADC was not found to significantly predict distant metastases. When the cohort was
split into HPV+ and HPV- sub-groups, there was no significant difference in median ADC
between the patients who did and did not develop distant metastases in either sub-group.
Ding et al. [103] and Paudyal et al. [104] both studied changes in ADC parameters
from baseline to mid-treatment during chemo-radiotherapy and tested whether they could
predict complete response (CR) at mid-therapy and at 3-6 months post-therapy,
respectively. In Ding et al.’s study, the normalized change in ADC (ΔADC) from pretreatment to week 3 of treatment were significantly greater in the CR group compared to
non-CR. Paudyal et al. performed DWI at pre-treatment and during treatment weeks 1, 2,
and 3. ΔADC from baseline to 3 weeks was found to significantly predict CR. Furthermore,
these cohorts were composed primarily of HPV+ patients (all HPV+ for Ding et al. and 88%
HPV+ for Paudyal et al.), so differences in the prognostic value of ΔADC between HPV+
and HPV- lesions could not be ascertained.
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1.5.2 Image Formation in DWI
1.5.2.1 DWI Pulse Sequences
There are several types of MRI pulse sequences that can be used for DWI, each with
distinct underlying contrast mechanisms and image quality features. However, the common
feature in most DWI pulse sequences is the application of two equal and opposite diffusionsensitizing gradients in a spin echo acquisition module, which causes the MRI signal to be
more sensitive to signal from diffusing spins. This method was first proposed in 1965 by
Stejskal and Tanner [90]. Although modern implementations often use sinusoidal or
trapezoidal pulses, the general theory is the same as Stejskal and Tanner’s initial
implementation using rectangular pulses, which will be discussed here for simplicity. As
illustrated in Figure 1.3, the first diffusion pulse is applied after the 90° RF pulse, and the
second diffusion pulse with equal magnitude and duration is applied after the 180° RF pulse.
Because the spins have been inverted with the 180° pulse, the second diffusion pulse acts
as an equal and opposite gradient from the first. Stationary spins will have no net phase at
the end of the two diffusion gradients because the phase accumulated from the first is
reversed by the second. However, gradient amplitudes vary linearly with position, so
diffusing (moving) spins will experience different gradient strengths in different locations.
Consequently, any phase accumulated from the first diffusion gradient will not be completely
reversed by the second gradient, resulting in a net accumulated phase and a net signal loss
from the de-phased diffusing spins.
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Figure 1.3: Pulse sequence diagram showing the Stejskal-Tanner diffusion-sensitizing
gradient (DG) pulses used for diffusion weighting in DWI. The first pulse is applied after the
90° RF pulse, and the second pulse with equal gradient amplitude and duration is applied
after the spins have been inverted with the 180° pulse. Stationary spins experience the
same amount of phase accumulation from the two diffusion pulses but in opposite
directions, so the net phase is zero by the end of the second diffusion pulse. However,
diffusing spins experience different gradient magnitudes as they move, so diffusing spins
accumulate a net phase at the end of the two diffusion pulses, allowing the diffusion signal
to be measured. After the diffusion gradients are applied, a number of different readout
methods can be applied to acquire the image signal. The b-value of the sequence is
determined by the gradient magnitude (G), duration (δ), and time interval (Δ) between
pulses. Image courtesy of Allen D. Elster, MRIquestions.com, reproduced with permission.

After the diffusion-sensitizing gradients, a number of readout methods can be applied
to acquire the image signal. The most common method is single-shot EPI (referred to as
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“EPI” throughout the dissertation unless otherwise specified), which acquires all of k-space
(i.e. all phase-encoding steps) through a zig-zag k-space trajectory in a single repetition time
(TR) period by rapidly switching the frequency-encoding gradients. EPI’s primary advantage
is its speed, which minimizes the impact of non-diffusion motion such as vessel pulsation or
gross patient motion. However, any phase errors are propagated through all of k-space
because the phases are not reset at any point during the k-space acquisition, in contrast to
most other sequences that use multiple TR periods and reset the phase at the end of each
period. As such, EPI is prone to severe geometric distortions and magnetic susceptibility
artifacts, especially at air-tissue interfaces, which are common in the head and neck. Phase
errors also lead to chemical shift artifacts along the phase-encoding direction in EPI, so fat
suppression techniques are necessary. Furthermore, EPI places significant physical
demand on the gradient coils and operates best on systems with high-performance gradient
coils that have high gradient amplitudes and slew rates.
A number of alternative readout methods have been proposed for DWI to overcome
the shortcomings of EPI, which are the major focus of Chapters 5 and 6 of this dissertation.
First, multi-shot (or readout-segmented) EPI also uses rapid gradient switching to acquire a
fast image, but it splits the k-space readout into a small number of TR periods. Phase errors
have less time to accumulate during each cycle, so distortions and artifacts are substantially
improved over single-shot EPI [105, 106]. However, multi-shot EPI is not as fast as singleshot EPI and is thus more sensitive to motion or vessel pulsation, especially if motion has
occurred between shots. To minimize the impact of motion, 2-D navigator pulses are
repeated to dynamically track motion and correct for non-linear phase differences. In
Chapter 6, we use a multi-shot EPI sequence called RESOLVE (readout segmentation of
long variable echo trains) on our Siemens MR sim.
Another class of low-distortion DWI sequences use turbo spin echo (TSE)-based
signal readout. TSE, also known as “fast spin echo,” is a variation of the conventional spin
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echo pulse sequence where a series of refocusing RF pulses are applied after the initial 90°
and 180° spin echo RF pulses. The result is a series of echoes, called an echo train, within
a single TR cycle (rather than just one echo as in conventional spin echo imaging), allowing
multiple lines of k-space to be acquired during each cycle. Like EPI, k-space can be
acquired in either a single shot or multiple shots, depending on the echo train length. While
single-shot TSE minimizes the effects of motion, longer echo trains result in lower SNR
because the magnitude of each echo decreases as they get further from the center of kspace. Longer echo trains are also more susceptible to T2 blurring. However, TSE
sequences are much less prone to susceptibility artifacts and geometric distortion compared
to EPI [107, 108], which is their primary advantage in RT applications. Susceptibility artifacts
are reduced because each refocusing pulse resets the phase, so phase errors caused by
local field inhomogeneities do not accumulate throughout each TR as they do in EPI.
Geometric distortion is improved because the frequency encoding gradients are not
switched on and off as rapidly and do not switch polarity, so eddy currents and magnetic
field inhomogeneities are not as significant.
Another feature of TSE sequences is the production of stimulated echoes, which
occur when spins rephase as a result of three or more RF pulses [109]. Under perfect
conditions (i.e. the Carr-Purcell-Meiboom-Gill (CPMG) conditions [110], which dictate the
timing and phase relations of the pulses and echoes), the exact timing of the stimulated
echoes can be predicted, so the readout gradients can be timed to collect only the spin echo
signals. However, the diffusion gradients cause the CPMG conditions to be violated when
motion occurs, leading to phase errors and destructive interference between the spin
echoes and stimulated echoes that reduces SNR. To solve this problem, a method
proposed by Alsop splits the signal into CPMG and non-CPMG components and acquires
only the CPMG component [111]. Another solution has been proposed called split
acquisition of fast spin echo signals (SPLICE), which acquires and reconstructs the signal
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from both the spin echoes and stimulated echoes separately to improve SNR [112]. While
Alsop-TSE collects both phase and magnitude information of only the CPMG spin echo
signals, SPLICE collects only magnitude information but for both spin echoes and stimulated
echoes. In Chapters 5 and 6, we use both an Alsop-based TSE and a SPLICE DWI
sequence on the MR-linac, both of which use single-shot acquisitions.
In addition to EPI and TSE, a hybrid method known as turbo spin and gradient echo
(TGSE), also called gradient and spin echo (GRASE), is another class of readout methods
in which a series of rapidly alternating gradients (like EPI) follows each TSE RF pulse [113].
Adding the gradient echo component to TSE increases the number of echoes without
increasing the number of RF pulses, which reduces specific absorption rate compared to
TSE-based methods. TGSE improves geometric accuracy and is less prone to susceptibility
artifacts compared to EPI because fewer gradient polarity reversals are used. Still, phase
errors can accumulate between each RF pulse during the gradient echo portion, although to
a smaller degree than in EPI, making distortion worse than in TSE sequences. In Chapter 6,
the BLADE sequence on the Siemens MR sim uses a TGSE readout method.
The last element of DWI pulse sequences that we will discuss is the k-space
trajectory. Most sequences use a Cartesian k-space trajectory in which k-space is filled in
line by line. Cartesian k-space has a frequency-encoding axis and a phase-encoding axis,
and errors or motion in the phase-encoding direction can propagate throughout the entire
image, causing significant artifacts. Radial k-space trajectories offer an alternative to
Cartesian, whereby a line (or group of parallel lines) is sequentially rotated around the
center of k-space at each TR interval. Radial trajectories do not have specific frequencyand phase-encoding directions, so motion appears more diffusely distributed throughout the
whole image, making this a promising technique for DWI. Although radial methods require
multiple TR cycles to sample a sufficient portion of k-space, the reduced sensitivity to motion
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Table 1.1: Summary of DWI sequences used in this dissertation.
Sequence

Image Acquisition Mechanism

Pros

Cons

EPI (MR-linac)

Single-shot EPI: All of k-space
is acquired in a single TR by
rapidly switching the
frequency-encoding gradient
polarity

- Fast acquisition → minimal motion
artifacts
- High SNR compared to TSE-based
sequences (when other factors
such as number of averages and
fat suppression are held constant)

- Severe geometric distortions
and susceptibility artifacts due
to accumulated phase errors
and eddy currents
- Low gradient amplitude (15
mT/m) and slew rate (65
T/m/s) on MR-linac lead to
longer imaging times →
increases risk of T2 blurring
and potential for motion
artifacts compared to EPI on
MR sim

TSE (MR-linac)

Single-shot TSE: All of k-space
is acquired in a single TR by
applying a series of refocusing
RF pulses and capturing the
signal (magnitude and phase)
from each spin echo

- Reduced geometric distortion and
susceptibility artifacts compared to
EPI

- Reduced SNR compared to
SPLICE due to destructive
interference of spin echoes
and stimulated echoes
- Reduced SNR compared to
EPI-based sequences (when
other factors such as number
of averages and fat
suppression are held constant)

SPLICE (MRlinac)

Single-shot TSE with split echo
acquisition: All of k-space is
acquired in a single TR by
applying a series of refocusing
RF pulses and capturing the
signal (magnitude only) from
each spin echo and stimulated
echo separately

- Reduced geometric distortion and
susceptibility artifacts compared to
EPI
- Increased SNR compared to TSE
because spin echoes and
stimulated echoes are acquired
separately

- Reduced SNR compared to
EPI-based sequences (when
other factors such as number
of averages and fat
suppression are held constant)

EPI (MR sim)

Single-shot EPI: All of k-space
is acquired in a single TR by
rapidly switching the
frequency-encoding gradient
polarity

- Severe geometric distortions
and susceptibility artifacts due
to accumulated phase errors
and eddy currents

RESOLVE (MR
sim)

Multi-shot EPI: segments of kspace are acquired during a
small number of TRs (5 in this
sequence) using EPI (rapid
gradient switching)

- Fast acquisition → minimal motion
artifacts
- Increased SNR compared to TSEbased sequences (when other
factors such as number of
averages and fat suppression are
held constant)
- High gradient amplitude (45 mT/m)
and slew rate (200 T/m/s) on MR
sim lead to shorter imaging times
compared to MR-linac → reduces
risk of T2 blurring and potential for
motion artifacts compared to MRlinac
- Less prone to phase error
accumulation and eddy currents
compared to single-shot EPI →
improved geometric accuracy and
less risk of susceptibility artifacts
compared to single-shot EPI (but
not compared to TSE-based
sequences)

BLADE (MR
sim)

Radial TGSE: k-space is
acquired through a series of
parallel lines rotating around
the center of k-space,
combined with a hybrid
TSE/gradient echo acquisition

- Less prone to motion artifacts
compared to other multi-shot
methods because the radial
acquisition diffuses motion
throughout the whole image
- Reduced specific absorption rate
compared to TSE and EPI

- Longer acquisition times
compared to single-shot
EPI/TSE

- Longer acquisition times
compared to single-shot
EPI/TSE and potential for
motion between shots →
increased risk of motion
artifacts (although this is
mitigated by the use of a 2-D
navigator)
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eliminates the need for navigator pulses to correct for motion between shots (as used in the
RESOLVE multi-shot EPI sequence). However, radial acquisitions are longer than singleshot EPI or TSE. Another advantage of radial acquisitions is that the center of k-space is
sampled during every TR, which improves SNR. Of the six DWI sequences used in the work
for this dissertation (summarized in Table 1.1), EPI (MR-linac), TSE, SPLICE, EPI (MR sim),
and RESOLVE all use Cartesian k-space trajectories, while BLADE uses a radial trajectory.

1.5.2.2 Generation of Diffusion-Weighted Images and ADC Maps
Although we have discussed the types of pulse sequences that can be used in DWI,
there are still more elements to consider to arrive at the final diffusion-weighted images and
ADC map. As previously described, two diffusion-sensitizing gradient pulses are applied at
the beginning of each TR interval along with a spin echo module, followed by any of the
aforementioned readout methods. In practice, diffusion gradients are applied separately in
three orthogonal directions to separately measure the diffusion in each direction. Each kspace readout is also repeated multiple times and averaged together to improve SNR. This
factor known as the number of averages. In most applications (including the applications
described in this dissertation), the magnitude of the diffusion in each direction is combined
into a single image called the trace image or isotropic image. (For the remainder of this
dissertation, when referring specifically to diffusion-weighted images, we are referring to
trace/isotropic images.)
Diffusion-weighted images are also acquired at multiple b-values, or diffusion
weightings. The b-value is calculated as a function of the amplitude (G), duration (δ), and
time interval (Δ) between the two diffusion-sensitizing gradients (Figure 1.3). In the original
Stejskal Stejskal-Tanner implementation with rectangular pulses, the b-value is calculated
using:
b = γ2 G2 δ2 (Δ – δ/3)
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where γ is the gyromagnetic ratio. The formulas for modern implementations with sinusoidal
or trapezoidal pulses can be found in various references [114, 115]. However, in practical
use, the user selects the desired b-values, and the MRI scanner will select the appropriate
parameters to achieve those b-values. b-Values typically range from 0 to 1000 s/mm2 in
most clinical applications but often go as high as 2000 s/mm2 for certain specialized use
cases. A b=0 image uses the same readout method as the diffusion-weighted images but
without applying the diffusion gradients to generate a baseline scan with no diffusion
weighting.
At least two b-values must be acquired to calculate an ADC map. The ADC
calculation is performed voxel-by-voxel using the signal of each b-value image. The signal
decreases exponentially with increasing b-value according to the following equation:
𝑆𝐷𝑊𝐼 = 𝑆0 𝑒 −𝑏∙𝐴𝐷𝐶
where SDWI is the signal of the diffusion-weighted image at a given b-value and S0 is the
signal in the b=0 image. This equation can be rearranged to give the formula for ADC:
1
𝑏

𝑆𝐷𝑊𝐼
).
𝑆0

𝐴𝐷𝐶 = − ln(

Similarly, this equation can also be rearranged to show the linear relationship between the
b-value and the natural logarithm of the signal intensities:
ln (

𝑆0
𝑆𝐷𝑊𝐼

) = 𝐴𝐷𝐶 ∙ 𝑏

where the ADC is the slope. Thus, when multiple b-values are used, the ADC can be
calculated using linear regression between the b-values and natural logarithm of signal
intensities. This ADC calculation is performed for each voxel, and the final ADC map is a
spatial representation of the ADC values in each voxel.
One important consideration in DWI is that the ADC not only measures diffusion but
also includes contributions from perfusion, which is the microcirculation of blood through
capillary networks [116]. This perfusion contribution is why the ADC is called the apparent
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diffusion coefficient. The effects of perfusion are more pronounced at low b-values and
quickly drop off as the b-value increases; depending on the tissue, “low b-values” are
considered less than approximately 100-200 s/mm2. An alternative model called intra-voxel
incoherent motion (IVIM) has been developed for reconstructing diffusion-weighted images
into separate diffusion and perfusion components. IVIM is beyond the scope of this
dissertation. However, to minimize the contributions of perfusion to the ADC, consensus
recommendations from the MR-Linac Consortium suggest excluding the b=0 image from
ADC calculation and instead using a minimum b-value of 150 s/mm2 [54]. The impact of
using a b=150 s/mm2 image instead of the b=0 image in the ADC calculation is explored in
Chapter 6.

1.6 Study Goal and Specific Aims
The goal of the work in this dissertation is to benchmark the quality of our initial
clinical workflows for treating HNC on the MR-linac and to address key opportunities for
technical advancement. Our ultimate goal is to move from ART based only on anatomical
changes to ART based on delivered dose and biological response measured through
quantitative imaging. The work presented here spans from the pre-clinical MR-linac era to
the early stages of in vivo treatments on the MR-linac to the era of routine clinical use in
HNC and our first randomized control trial for HNC on the MR-linac. The specific aims of this
dissertation are as follows:

1. Evaluate existing MR-linac clinical workflows for HNC and identify key areas for further
development.
1-1: Quantify the magnitude of the ERE using gel dosimetry.
1-2: Analyze treatment plan quality, setup errors, treatment times, and dosimetric
variability among adaptive plans for HNC patients on the MR-linac.
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2. Develop and validate a procedure for daily dose reconstruction for the MR-linac Adapt to
Position workflow.
2-1: Determine the optimal method for autosegmentation of OARs on T2-weighted
MRIs used for daily positioning on the MR-linac.
2-2: Evaluate the accuracy of off-line dose reconstruction using autosegmented
structures on MRIs.

3. Develop a robust DWI scanning protocol on the MR-linac for HNC.
3-1: Optimize DWI pulse sequences on the MR-linac for HNC using phantom and in
vivo measurements.
3-2: Benchmark DWI image quality through quantitative evaluation of ADC
estimation accuracy, signal-to-noise ratio, and ADC repeatability and
comparison to a diagnostic MRI scanner.

1.7 Dissertation Organization
The primary body of work in this dissertation is composed of five chapters (Chapters
2-6). Chapter 2 is entitled “Measurement of the Electron Return Effect Using Gel Dosimetry”
and addresses Specific Aim 1-1. Chapter 3, “Initial Feasibility and Clinical Implementation of
Treating Head and Neck Cancers on the 1.5T MR-Linac,” covers Specific Aim 1-2. Chapter
4 is called “Autosegmentation Methods for Off-line Dose Reconstruction on MR-Linac Head
and Neck Images” and addresses Specific Aims 2-1 and 2-2. Chapter 5, “DWI Pulse
Sequence Optimization for Head and Neck on the MR-Linac,” covers Specific Aim 3-1.
Finally, Chapter 6 addresses Specific Aim 3-2 and is called “In Vivo Test-Retest Evaluation
of DWI Sequences on the MR-Linac and MR Sim.” After the main body of work, a discussion
follows in Chapter 7, and appendices and references are included at the end.
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Chapter 2: Measurement of the Electron Return Effect Using Gel Dosimetry
This chapter is based on the following publications [117, 118]:

McDonald BA, Lee HJ, Ibbott GS. Low-density gel dosimeter for measurement of the
electron return effect in an MR-linac. Phys Med Biol 2019;364:205016.
https://doi.org/10.1016/10.1088/1361-6560/ab4321
© IOP Publishing. Reproduced with permission. All rights reserved.
(Physics in Medicine and Biology allows authors to reuse text and figures from the Accepted
Manuscript version of their article in a thesis or dissertation.)

McDonald BA, Lee HJ, Ibbott GS. Evaluation of a lung-equivalent gel dosimeter for MR
image-guided radiation therapy. J Phys Conf Ser 2019;1305:012012.
http://doi.org/10.1088/1742-6596/1305/1/012012
This article is published open-access under Open Access License CC-BY.

2.1 Introduction
In recent years, a 1.5 T magnetic resonance imaging (MRI) system has been
integrated with a 7 MV linear accelerator (linac) to produce an MR-guided adaptive radiation
therapy (ART) system known as the MR-linac (Elekta AB; Stockholm, Sweden) [48–50]. MRI
offers several advantages compared to conventional on-board imaging techniques for
image-guided radiation therapy (RT) such as orthogonal x-ray planar imaging and computed
tomography (CT). These advantages include superior soft tissue contrast, improved
verification of patient setup, reduced ionizing radiation dose to the patient, and the ability to
generate highly conformal treatment plans through adaptive replanning.
In the MR-linac, the strong magnetic field (B0-field) presents several dosimetric
challenges due to the Lorentz forces acting on the secondary electrons. At interfaces
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between high- and low-density regions, a phenomenon known as the electron return effect
(ERE) causes hot and cold spots in the dose distribution [59, 119]. Secondary electrons
entering a low-density region can be re-directed back toward the high-density region,
causing more dose to be deposited in the denser tissue. The ERE is of particular concern in
the thoracic region where there are interfaces between lung, airways, soft tissue, and bone.
As a result of the ERE and the highly conformal treatment plans that can be
delivered on the MR-linac, there is a demand for a dosimetry system that can measure
steep dose gradients in three dimensions. Conventional quality assurance (QA) tools can
provide, at best, discrete point measurements in a pseudo-3D array [120]. Gel dosimetry
has been used as an alternative QA method due to its ability to measure continuous
volumetric dose distributions. Fricke-based gels are particularly useful for the MR-linac
because the radiation-induced oxidation of Fe2+ to Fe3+ and the corresponding change in
spin-lattice relaxation rate (R1 = 1/T1) is linear with dose and can be measured using MRI
[62, 64, 121].
Conventional gel formulations are water-equivalent, so they are optimized for
measuring dose to soft tissue but not to lung tissue. Previous studies have explored the
development of lung-equivalent gels using two different methods to reduce the density of the
gel [122–127]. One technique involves beating the gel to a foam-like consistency before it
sets, and the second involves mixing gel with small polystyrene beads to simulate air
pockets. In this study, we used the latter method with two Fricke-type gels to optimize lungequivalent gels for use with MR-guided ART systems.
Two concerns with the low-density gel dosimeters are the reduced MRI signal
intensity and the heterogeneity caused by the presence of the polystyrene beads.
Polystyrene generates no MR signal [128], so the total MR signal in the low-density gel is
reduced compared to conventional gel. Further, the heterogeneous composition of the lowdensity gels may interfere with the resolution at which absorbed dose can be measured.
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This investigation was an effort to mitigate these issues by optimizing the composition of the
low-density gel and the MR imaging acquisition parameters for dose readout.

2.2 Materials and Methods
2.2.1 Gel Formulation
The two radiochromic gel formulations used in this study were Fricke xylenol orange
gelatin (FXG) and ferrous oxide xylenol orange (FOX) [129, 130]. FXG and FOX gels were
formulated in-house using the following chemical components and concentrations: ~96%
w/w deionized water, 4% w/w 300 bloom gelatin, 0.05 mM xylenol orange disodium salt, 50
mM sulfuric acid, and 1 mM ammonium iron(II) sulfate hexahydrate (FXG only) or 1 mM
iron(II) oxide (FOX only). All chemicals were obtained from Sigma-Aldrich (St. Louis, MO,
USA). For each batch, the gelatin was first mixed with water at 40˚C to ensure complete
dissolution, then cooled to 25˚C prior to the addition of other components. The gels were
refrigerated at 4˚C for about 24 hours as they solidified, then they were stored in the dark
and equilibrated to room temperature for at least 3 hours prior to irradiation.
Each low-density gel was created by adding the liquid gel formulation into a
cylindrical container (5.5 cm diameter, 11.5 cm height) filled with expanded polystyrene
foam beads. To ensure uniform mixing of the gel and polystyrene beads, each container
was filled completely with polystyrene beads prior to the addition of gel. The bead-filled
containers were covered with a thin plastic film, which was pierced with a small hole to allow
air to escape as the liquid gel was added via a syringe. Four different sized polystyrene
beads were used (<1 mm, 2-3 mm, 2-4 mm, and 6-10 mm) as shown in Figure 2.1, and the
conventional gel with no polystyrene beads (referred to as “gel-only”) was used for
comparison. Low-density dosimeters were created using both FXG and FOX.
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Figure 2.1: The FXG low-density dosimeters with bead sizes (from left to right) <1 mm, 2-3
mm, 2-4 mm, and 6-10 mm.

2.2.2 Characterization of Low-Density Gels
2.2.2.1 CT Number
The CT number in Hounsfield units (HU) of each dosimeter was measured to verify lung
tissue equivalence. The dosimeters were imaged using CT (Philips Brilliance CT Big Bore;
Best, Netherlands; 120 kVp, 300 mAs, 1 mm voxel size). The average CT number was
measured within a region of interest (ROI) of approximately 60 x 40 mm2 in a central slice.

2.2.2.2 MR Signal Intensity
Gels were imaged with a T1-weighted spin echo pulse sequence on the MR-linac
(Elekta Unity; Stockholm, Sweden; TR/TE = 500/20 ms, number of signal averages = 1) with
1 mm, 2 mm, 3 mm, and 5 mm voxel sizes. Signal intensity was measured within an ROI of
approximately 60 x 40 mm2 in a central slice. ROIs were spatially consistent between
images of different voxel sizes to ensure direct comparison of the parameters for each gel.
Signal intensity is reported as the average pixel value over the ROI.
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2.2.2.3 Uniformity
Uniformity was calculated using the Uniformity Normalized Absolute Average
Deviation (UNAAD) metric [131, 132], which is a pixel-wise measurement of the difference in
each signal intensity value from the average. This method defines uniformity 𝑈 as

𝑁

1
𝑈 = 100 (1 −
∑|𝑌𝑖 − 𝑌̅|)
𝑁 ∙ 𝑌̅
𝑖=1

where 𝑌̅ is the average pixel value within an ROI, each 𝑌𝑖 is the pixel value of a single pixel,
and 𝑁 is the number of pixels in the ROI. The maximum value of 100 corresponds to a
perfectly uniform image. Uniformity was measured over the same ROIs described above.

2.2.3 Dose Response Curves
The relationship between dose and change in R1 value (∆R1) was measured for the
FXG conventional gel and the low-density FXG gel with <1 mm polystyrene beads. Gels
were irradiated to known doses up to 30 Gy at a reference depth (5 cm) on the MR-linac.
Each sample was imaged at the reference depth using fifteen turbo spin echo inversion
recovery sequences (TR/TE = 2500/20 ms, pixel size = 0.833×0.833 mm2, slice thickness =
5 mm, number of signal averages = 1, and inversion times ranging from 150–1400 ms) on
the MR-linac both pre- and post-irradiation. T1 maps were generated by a pixel-wise
exponential fit of the inversion recovery images using in-house software. T1 maps were
converted to R1 maps (R1 = 1/T1), and the pre-irradiation R1 values were subtracted from
the post-irradiation R1 values to obtain ∆R1. Three samples were prepared for each dose
point, and the average ∆R1 value was reported. To quantify error, 95% confidence intervals
(CIs) for the T1 parameter estimation were calculated at each point by the T1 mapping
software. The CIs for T1 pre- and post-irradiation were converted to CIs for ∆R1 at each
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point using error propagation. Dose response curves were fit using linear regression
constrained such that the line crossed through the origin.

2.2.4 Measurement of ERE
Two identical heterogeneous phantoms containing low-density gel surrounded by
conventional gel were created to simulate the lung-soft tissue interface. The inner cylinder
(5.5 cm diameter) contained FXG with <1 mm polystyrene beads. The outer cylinder (14.3
cm diameter) contained conventional FXG gel. The gel in the inner cylinder was housed in a
plastic container 1.0 mm thick with a CT number of approximately 70 HU. One phantom was
irradiated with the MR-linac (Elekta Unity; Stockholm, Sweden; 7 MV flattening filter-free
(FFF) beam) and one in a conventional linac (Varian Truebeam; Palo Alto, CA, USA; 6 MV
FFF beam) to study the effects of the B0-field on the dose distribution.
The phantoms were irradiated with a 20×20 cm2 open field such that the beam
traversed the boundaries between the low-density and conventional gels. In the MR-linac,
the beam direction was perpendicular to the B0-field. Both phantoms were imaged with the
MR-linac pre- and post-irradiation. An inversion recovery pulse sequence was used to
produce a ∆R1 map as described in section 2.3. The ∆R1 maps were converted to dose
maps using the dose response relationship measured for each gel. The boundaries between
the conventional and low-density gels were difficult to discern on the ∆R1 maps, so the ROIs
containing each gel were drawn on the corresponding inversion recovery images and
propagated to the ∆R1 maps. A line profile (3 pixels thick to minimize small fluctuations due
to noise) was plotted across the dose map in the direction of the beam.
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2.3 Results
2.3.1 Characterization of Low-Density Gels
2.3.1.1 CT Number
The CT numbers of the low-density gels and conventional gels are shown in Table
2.1. The low-density gels all have CT numbers around -600 HU, which falls slightly above
the range typically measured for lung tissue (between -700 and -800) [133–136] but still
between the CT numbers of water/soft tissue (~0) and air (-1000). For our purposes of
developing a lung-equivalent dosimeter to measure the electron return effect, any of the lowdensity gel formulations can be considered lung-equivalent.

Table 2.1: CT numbers (HU) of the low-density and conventional gels. Values represent the
mean ± standard deviation of the CT numbers within an ROI.
FXG

FOX

<1 mm

-596 ± 23

-611 ± 31

2-3 mm

-603 ± 167

-655 ± 127

2-4 mm

-606 ± 228

-635 ± 184

6-10 mm

-559 ± 368

-591 ± 354

Gel-only

15 ± 5

13 ± 6

2.3.1.2 MR Signal Intensity
The MR signal intensity increased linearly with voxel size for all gels, but the slopes
of the signal intensities varied based on gel type and bead size (Figure 2.2). The addition of
polystyrene beads caused a decrease in signal intensity compared to the conventional gel
for both FXG and FOX because the polystyrene beads produce no visible MR signal (Figure
2.3). All FOX formulations had lower signal than the corresponding FXG formulation, with
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the FXG low-density gels and the FOX low-density gels forming two distinct clusters on the
graph of signal intensity vs. voxel size. The FOX gel-only curve (orange solid line) fell within
the low-density FXG cluster, indicating that the addition of polystyrene beads to FXG
reduced the signal intensities to levels comparable with the FOX conventional gel.

Figure 2.2: Average MR signal intensity (arbitrary units) over an ROI for each low-density
and conventional gel formulation as a function of imaging voxel size.

Figure 2.3: 40×40 mm2 ROIs (T1-weighted spin echo, 1 mm voxels) of each FXG dosimeter
are shown with the same window/level settings to illustrate differences in signal intensity and
uniformity between the gels with different bead sizes.
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2.3.1.3 Uniformity
Uniformity generally improved with smaller bead sizes and larger voxel sizes (Figure
2.4). For the three smallest bead sizes, uniformity increased most sharply between 1 mm
and 3 mm voxel sizes, with little change between 3 mm and 5 mm. The uniformity for gels
with 6-10 mm beads did not increase with voxel size, likely because the beads were larger
than all voxel sizes used for imaging. The gels containing the smallest beads (<1 mm)
performed the best, with uniformity values of FXG with <1 mm beads comparable to those of
FXG and FOX conventional gels at 2 mm voxel sizes and above. There was no consistent
trend between uniformity and gel type, suggesting that bead size is the primary factor
affecting uniformity. Based on the signal intensity and uniformity results, the optimal gel
formulation to use as the lung-equivalent gel was determined to be FXG with <1 mm
polystyrene beads.

Figure 2.4: Uniformity measured as UNAAD values for all low-density and conventional gel
formulations as a function of imaging voxel size. A UNAAD value of 100 corresponds to a
perfectly uniform image.

40

2.3.2 Dose Response Characteristics
∆R1 was linear with dose up to 30 Gy for both gels (Figure 2.5; conventional FXG:
slope=0.01671, r2=0.982; low-density FXG: slope=0.03139, r2=0.998). The addition of
polystyrene beads caused the slope of the dose response curve to increase by 88% but did
not affect the linearity of the curve.

Figure 2.5: Dose response curves for conventional FXG and low-density FXG (<1 mm
beads). ∆R1 values represent the change in R1 between the pre- and post-irradiation
images. Error bars represent 95% confidence intervals.

2.3.3 Measurement of ERE
Dose maps and intensity profiles for the phantoms irradiated in the linac and MRlinac are shown in Figure 2.6. For both phantoms, dose generally decreased as the beam
penetrated further into the phantom, with a region of low dose inside the low-density inner
cylinder. In the MR-linac dose map, there is a region of enhanced dose (increase of about
2.2 Gy or 8.7%) in the conventional gel just before the beam enters the low-density gel, then
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Figure 2.6: a) Dose map for linac (6 MV FFF beam), b) dose map for MR-linac (7 MV FFF
beam), c) line profile for linac, d) line profile for MR-linac. The black lines on the dose maps
indicate where the line profiles in c) and d) were acquired. The boundaries between the
inner and outer cylinders are marked with black circles. The directions of the magnetic field
and the beam path are denoted by B0 and γ, respectively.
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a region of reduced dose (decrease of about 2.2 Gy or 17.7%) in the low-density gel just
before the beam re-enters the conventional gel. There is also dose enhancement (increase
of about 2.1 Gy or 9.4%) as the beam exits the phantom toward the air. These hot and cold
spots are not observed in the linac dose distribution, which indicates that this difference is
due to the presence of the magnetic field and the ERE. Any additional differences in the
dose distributions are likely caused by the differing depth dose characteristics of the 6 MV
FFF linac beam and the 7 MV FFF MR-linac beam.
The linac dose map appears noisier than the MR-linac dose map because the linac
phantom had to be moved back and forth between the MR-linac for imaging and the linac for
irradiation. The setup for the pre-irradiation imaging was reproduced as closely as possible
during the post-irradiation imaging, but minute differences in position can introduce noise
during the subtraction of the pre- and post-irradiation images.

2.4 Discussion
The goals of this study were 1) to develop and characterize an optimal formulation of
a low-density, lung tissue-equivalent gel dosimeter and 2) to use the lung-equivalent
dosimeter to measure the magnitude of the ERE at the lung-soft tissue interface in an MRlinac. Based on our results, the optimal lung-equivalent gel formulation was determined to
be FXG with <1 mm beads. This low-density gel was then used in a phantom simulating the
lung-soft tissue interface. Regions of enhanced and reduced dose at the boundaries were
observed in the phantom irradiated in the MR-linac but not in the linac, consistent with the
ERE.
FXG was chosen over FOX due to the higher signal intensity values measured for
each bead size. Interestingly, the conventional FOX gel had similar signal intensity values
as all of the low-density FXG gels (Figure 2.2). Considering that conventional FOX gel has
been used successfully in dosimetry studies before [129, 130], the signal intensity of low43

density FXG is sufficient to produce acceptable quality images for dosimetric analysis.
However, the low-density FOX gels exhibited much lower signal intensities than the
conventional FOX gel and low-density FXG gels; signal intensities this low may cause
increased uncertainty in measured dose distributions.
The smallest bead size was selected for the optimal lung-equivalent gel due to the
high uniformity. Although lung tissue itself is heterogeneous, it is important for the lungequivalent dosimeter to be fairly homogeneous to reduce noise in dose maps, which in turn
reduces uncertainty in the measured dose. There are already multiple sources of noise
inherent to gel dosimetry, including variations in temperature and chemical concentration
throughout the gel volume, thermal noise from MRI readout, and subtraction of the preirradiation image from the post-irradiation image [67, 68]. Many of these sources of
uncertainty can be minimized by using an optimized MRI scanning protocol [68, 137, 138]
and/or by applying smoothing filters in post-processing [139, 140]. However, the
heterogeneity of the low-density gel introduces an additional source of noise in the dose
map and requires further sequence optimization.
In this study, we investigated the effects of imaging voxel size on signal intensity and
uniformity. Although both metrics improved with larger voxel sizes, there is a trade-off
between these metrics and spatial resolution when voxel size is increased. Interestingly, the
optimal low-density gel (FXG <1 mm) demonstrated a comparable uniformity value to both
conventional gels at 2 mm voxel sizes and above. To preserve spatial resolution in the dose
maps of the ERE phantoms without compromising the MR signal, we used small pixels
(0.833×0.833 mm2) in the imaging plane and a larger slice thickness (5 mm). The line
profiles drawn in the dose maps were 3 pixels (2.5 mm) thick to smooth out the small
fluctuations due to random noise. Further investigation into optimizing the MR acquisition
parameters and the potential use of smoothing filters is warranted.
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The linearity of the dose response curve for the low-density gel is an encouraging
result that suggests that this novel gel formulation demonstrates predictable dose response
behaviour and can be used reliably for dose measurements up to 30 Gy. However, previous
studies have demonstrated that the dose response curves of FXG, FOX, and similar Frickebased gel dosimeters begin to plateau above a particular saturation dose due to the
oxidation of the finite number of ferrous ions [63, 66, 141, 142]. Until the high-dose
behaviour of low-density FXG is determined, extrapolation of the dose response curve to
doses higher than 30 Gy is not recommended.
Another practical concern regarding the dose response curves is that different ∆R1to-dose factors must be applied to different regions of the ∆R1 map, depending on the
geometry of the phantom. In the present study, the exact boundary between the two gels
was difficult to discern on the ∆R1 map, particularly in the MR-linac phantom due to the hot
and cold spots from the ERE. To determine exactly which pixels contained each gel, ROIs
containing each gel were identified on the inversion recovery images from which the ∆R1
maps were reconstructed, which showed the boundary much more clearly. If the incorrect
factor is applied to even a few pixels on the border of the two gels, the accuracy of the dose
map may be compromised.
Previous phantom measurements of the ERE have used dosimeters composed of
soft tissue-equivalent materials containing air cavities [129, 143, 144], allowing only dose to
soft tissue to be measured. Another study used a lung-equivalent material inside a cavity but
used film and ion chambers to generate two-dimensional and point measurements,
respectively [145]. Similarly, in an MR-visible anthropomorphic phantom containing lungequivalent material, dose to lung tissue could only be measured using a film or TLD insert at
pre-determined depths prior to irradiation [128, 146]. Our phantom design allowed us to
measure the volumetric dose distribution to both normal tissue and lung tissue, which
presented a significant advantage for simulating clinically relevant scenarios.
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Our measured dose maps of the ERE are qualitatively consistent with previous
phantom measurements and Monte Carlo simulations [59, 119, 129, 147]. A region of
enhanced dose was observed in the higher density material just before the intersection with
the lower density material, and a region of reduced dose was observed in the lower density
material just before the boundary with the higher density material. However, the magnitudes
of the hot and cold spots measured in the present study differ from previously reported
measurements in phantoms with air cavities, which is to be expected. Lee et al. [129]
reported dose enhancement of up to 40% in FOX gel and 30% in a PRESAGE® dosimeter
at the air-tissue interface in a 1.5 T magnetic field. These values are greater than the
magnitude of the hot spot of 8.7% observed in the lung-soft tissue phantom in the current
study, which was anticipated because the density of the low-density gel falls roughly halfway
between that of air and conventional gel dosimeters. The exact dimensions of the phantoms
differ as well, which further contributes to this discrepancy.
Two Monte Carlo studies that specifically looked at the lung-soft tissue interface also
reported hot and cold spots of higher magnitude than measured in the current report.
Raaijmakers et al. [119] and Lee et al. [147] measured hot spots of 49% and 46.5%,
respectively, and cold spots of 36% and 39.4%, respectively, in Monte Carlo simulations
with a 1.5 T field. The discrepancy between these results and the current study may be
explained by the fact that the average CT numbers measured for the low-density gels are
slightly higher than mean values for healthy lung tissue reported in the literature (typically
around -700 to -800 HU) [133–136]. However, due to the heterogeneity of lung tissue and
the variations in volume fraction of air throughout the respiratory cycle, the CT number of
lung can range from -300 to -1000 [148]. Regardless, the low-density gel used in the ERE
phantom has a low enough CT number compared to conventional FXG gel to demonstrate
the dosimetric impact of the ERE when a radiation beam traverses a boundary between
materials of significantly different densities. Future studies include comparing the planned
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dose distribution from a treatment planning system to the measured dose from the lowdensity gel dosimeter to ensure that the effects of the magnetic field are accurately modeled
in the treatment planning system.
Although the results of this study demonstrated that the ERE causes a measureable
effect in the dose distribution in a phantom irradiated in a 1.5 T MR-linac, the influence of
the ERE at air-soft tissue and lung-soft tissue interfaces can be adequately managed in
clinical treatment plans. The effects of ERE are nulled across a symmetrical air cavity with
the use of opposing beams [59] and can be minimized across cavities with more complex
geometries by using multiple beams in intensity-modulated radiation therapy [60]. Several
studies have assessed the quality of treatment plans for breast [149, 150], lung [151, 152],
prostate [60], and head and neck [60] in a 1.5 T MR-linac and have all found that the most
prominent effect of the magnetic field is a slight increase in skin dose. In the two papers
specifically investigating treatment plans for lung, the careful selection of beam geometries
enabled the ERE to be reduced to potentially clinically insignificant dose effects at the tissue
interfaces. However, accurate modeling of the ERE in the treatment planning system is
required to account for the dosimetric effects of the ERE, and dosimetry tools such as the
low-density gel dosimeter in the present report are necessary for external validation of these
dosimetric properties.

2.5 Conclusion
In this study, an optimal low-density gel dosimeter was selected from several
candidate formulations and was characterized based on CT number, MR signal intensity,
uniformity, and dose response. This low-density gel was successfully used in a phantom
simulating the lung-soft tissue interface to measure the magnitudes of hot and cold spots in
the dose distribution due to the ERE in an MR-linac. Unlike previous gel dosimetry
measurements of the ERE, which have only been able to measure dose in gel at the gel-air
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interface, our novel low-density dosimeter allowed the measurement of dose within both the
low-density and high-density gels. This low-density gel is a promising new tool for dosimetry
applications for MR-guided radiation therapy, although further optimization of MR scanning
parameters and image post-processing is required.
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Chapter 3: Initial Feasibility and Clinical Implementation of Treating Head and Neck
Cancers on the 1.5T MR-Linac

This chapter is based on the following publication [22]:
McDonald BA, Vedam S, Yang J, Wang J, Castillo P, Lee B, Sobremonte A, Ahmed S, Ding
Y, Mohamed ASR, Balter P, Hughes N, Thorwarth D, Nachbar M, Philippens MEP, Terhaard
CHJ, Zips D, Böke S, Awan MJ, Christodouleas J, Fuller CD. Initial Feasibility and Clnical
Implementation of Daily MR-Guided Adaptive Head and Neck Cancer Radiation Therapy on
a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of
Technical Innovation. Int J Radiat Oncol Biol Phys 2021;109(5):1606-1618.
https://10.1016/j.ijrobp.2020.12.015
This article is published open-access under Open Access License CC-BY-NC-ND.

3.1 Introduction
High-field magnetic resonance imaging (MRI)-guided radiation therapy (RT) has
become a clinical reality with the commercial implementation and health-system
accreditation of a hybrid 1.5T/7MV MRI/linear accelerator (MR-linac) [48, 50, 58]. The
enhanced soft tissue contrast of the MR-linac allows visualization of non-bony target
volumes and organs at risk (OARs) during treatment setup, enabling daily on-line treatment
plan reoptimization for adaptive radiotherapy (ART) [58, 153, 154]. First clinical experiences
with the MR-linac have been previously reported for oligometastatic, pelvic, and breast
tumors[55, 155–157], but utilization of the device has since expanded to a number of other
tumor sites, including head and neck cancer (HNC).
Rather than ad hoc technology development and implementation via unstructured,
non-sequential processes, the MR-Linac Consortium [158] has developed the R-IDEAL
conceptual framework of systematic technical and clinical reporting processes for clinical
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radiotherapy applications [159]. Furthermore, to our knowledge, there are no reports of highfield MR-guided daily ART for HNC on a hybrid MR-linac system. Thus, pursuant to this
commitment, we sought to undertake an R-IDEAL Stage 2a (“technical optimization of the
innovation for treatment delivery”)/2b (“proof of early clinical effectiveness and safety of the
innovation”) study with the following aims:
1) Describe an adapt-to-position (ATP) workflow for daily ART using conventional
fractionation and ensuring preservation of pre-therapy dose constraints for target volumes
and OARs; 2) Demonstrate the capacity of the 1.5T MR-linac system to deliver safe and
clinically acceptable ART plans for HNC; 3) Characterize performance based on treatment
times, quality assurance (QA) results, setup corrections, cumulative doses, and dosimetric
variability between adaptive plans.

3.2 Methods
3.2.1 MR-Linac Clinical Workflow for Head and Neck
The clinical workflow described in this paper was developed as a multi-institutional
effort through the MR-Linac Consortium’s Head and Neck Tumor Site Group. Although initial
implementation at a single site (MD Anderson Cancer Center; Houston, TX) is described,
this workflow is based on guidelines iterated through the Tumor Site Group prior to largescale implementation.

3.2.1.1 Pre-treatment Workflow
3.2.1.1.1 Patient Selection
HNC patients are deemed eligible for treatment on the 1.5T/7MV MR-linac (Unity;
Elekta AB; Stockholm, Sweden) if the following criteria are met: Patients must have intact
tumor or an MR-visible reference OAR (e.g. skull base) and planning target volume (PTV)
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length <20 cm in the super-inferior direction (due to field size constraints [51]). Patients with
claustrophobia, contraindications to MRI (metal objects, pacemakers, etc.), and/or
compromised airway are excluded. Because the MR-linac is located in the out-patient
radiation treatment center at our institution, the patient must be ambulatory. If the patient is
admitted to the in-patient facilities at any time during treatment, he or she must be treated
with a back-up plan on a conventional linac at the in-patient center.

3.2.1.1.2 Simulation Protocol
All patients receive both CT and MR simulations on the same day and with the same
immobilization devices to ensure that the CT and MR images may be rigidly registered [57].
The CT simulation is used for planning for both the MR-linac treatment and the back-up plan
on a conventional linac. A tabletop overlay is used on the CT scanner to reproduce the
actual couch top in the MR-linac treatment room. Placement of the index bars along the
couch establishes the location of patient immobilization aids and the actual tumor volume
with respect to the isocenter on the MR-linac. The tabletop overlay is also equipped with a
hoop-shaped device representing the maximum clearance of the MR-linac bore to ensure
that the patient and all immobilization aids will be able to fit into the MR-linac. The patient is
immobilized with a custom thermoplastic immobilization mask and cushion (Klarity Medical
Products; Heath, OH) (Figure 3.1).
The MR simulation protocol includes two standard vendor-provided non-contrast T2weighted 3-D MRI sequences and may include additional specialized sequences (diffusionweighted imaging (DWI), 2-D balanced fast field echo (bFFE) in three orthogonal directions
for motion estimation, etc.). The physician determines at the time of MR simulation whether
the 2-minute T2-weighted scan is adequate for daily setup and plan reoptimization; if the
tumor or reference OAR is not clearly visible, the 6-minute scan is used for daily imaging.
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Figure 3.1: The MR-linac simulation and on-line adaptive replanning workflow. a) Custom
head & neck immobilization mask with the coil on the MR-linac; b) indexing bar on the CT
simulation MR-linac table overlay; c) CT sim hoop device used to test clearance in MR-linac
bore; d) planning CT with contours; e) reference treatment plan on planning CT; f) daily
setup MRI from MR-linac (2-minute T2 protocol); g) rigid registration of planning CT and
setup MRI; h) adaptive plan using ATP workflow; i) dose volume histogram (DVH) of
reference plan; j) DVH comparison between reference and adaptive plans.
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3.2.1.1.3 Treatment Planning and Pre-Treatment Preparation
The CT and T2-weighted MR simulation images are fused for contouring of the target
volume(s) and OARs by the physician and dosimetrist, respectively. Treatment planning is
done in Monaco (version 5.4; Elekta AB), which employs a Monte Carlo-based dose
calculation engine. All MR-linac plans use step-and-shoot intensity-modulated radiation
therapy (IMRT). An initial reference plan is created by a dosimetrist based on the target
prescription dose(s) and OAR constraints provided in the physician’s planning directive. The
optimized plan is reviewed by the physician and physicist. Upon approval, the treatment
plan is exported to the radiotherapy treatment data management system (Mosaiq; Elekta
AB), where a Plan of Care is created for the patient. The Plan of Care specifies the exact
MRI exam card(s) to be loaded during each treatment session.

3.2.1.2 Online Clinical Workflow
The Unity on-line adaptive workflow has been previously described by Winkel et al.
[58]. At our institution, a T2-weighted MRI is used for daily setup verification and plan
adaptation for HNC patients. The 6-minute scan was used for the first three patients to be
conservative, but the 2-minute scan was used for all subsequent patients because the target
or reference anatomy could be adequately visualized. The daily setup image is then fused
with the reference plan image.
Two on-line adaptive workflows are possible with the Unity system: adapt-to-position
(ATP) and adapt-to-shape (ATS). ATP is a virtual isocenter shift of the reference plan based
on rigid registration with either a dose recalculation or plan reoptimization. ATS involves
deformable image registration to propagate contours onto the daily setup image followed by
a full plan reoptimization on the current anatomy [58]. The ATP workflow was used for online plan adaptation for six patients, and a combination of on-line ATP and off-line ATS was
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used for four patients (maximum one ATS during treatment course) to account for soft tissue
deformation.
The following acceptance criteria are used for on-line plan review and to determine
when an ATS is required: After fusion of the setup and reference plan images, if the
isocenter shift is <5 mm in all directions and planning constraints are satisfied, the ATP
workflow can proceed. If all shifts are <5 mm but any one dosimetric criterion is not satisfied
for three consecutive fractions, the physician must be consulted prior to treatment and an
off-line ATS is considered. If any shift is >5 mm, the patient must be repositioned; if any shift
is still >5 mm (most likely due to patient weight loss), the physician must approve the plan
prior to treatment, and an off-line ATS will be performed.
On-line ATS is challenging for HNC due to the large number of structures used in
plan optimization. To improve the efficiency of the on-line workflow, ATS was only performed
off-line to create a new reference plan for use in the subsequent days’ on-line ATP. When
an ATS is performed, a 6-minute T2-weighted MRI is acquired during the previous fraction
as the reference image for the ATS plan because the 2-minute scan is not adequate for
target delineation. In the current study, the goal of treatment plan reoptimization was to
ensure the delivery of pre-therapy planned doses to target volumes and OARs, referred to
as an ARTex_aequo1 approach in the nomenclature defined by Heukelom and Fuller [73]. Thus,
in any off-line ATS’s, the target structures were registered rigidly rather than deformably and
were not modified in any capacity; only OAR contours were updated to reflect anatomical
changes.
Four methods are available for plan recalculation/reoptimization: “original segments,”
“adapt segments,” “optimize weights,” and “optimize weights and shapes” [58]. In our ATP

Definition of ARTex_aequo: “Serial plan verification to ensure pre-therapy plan parameters are stable…
The new plan has the same constraints for tumor and OAR dose as the original and only allows for
limited target volume adaptations and associated additional sparing of OAR, nor additional dose to
the tumor.” [73]
1
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workflow, we use “adapt segments” when the isocenter shift is <1 mm in all directions.
Otherwise, we use “optimize weights” first then “optimize weights and shapes” if the plan
does not satisfy dosimetric criteria. For ATS, we use “optimize weights and shapes.”
During on-line plan adaptation, motion monitoring with a bFFE sequence is turned on
to ensure that the patient has not deviated from the original position. Once the adaptive plan
is created, it must be approved by the physicist and physician. Next, a secondary monitor
unit (MU) calculation is performed using RadCalc (LAP/LifeLine Software, Inc; Austin, TX)
for beam-by-beam validation of the MUs in the adaptive plan. Upon final approval, the
treatment is delivered. IMRT QA is performed after the treatment using a cylindrical diode
array.

3.2.2 Patient Cohort and Informed Consent
This prospective study included the first ten HNC patients at our institution who
satisfied the following criteria: treated with multiple IMRT fractions on the MR-linac, enrolled
in the MOMENTUM observational clinical trial, and not enrolled in any other clinical trials
involving non-conventional dosing or fractionations schemes. These patients provided
written informed consent for their images, treatment plans, and clinical data to be used.

3.2.3 Treatment Times, IMRT Quality Assurance, and Setup Variability
Treatment times were calculated from the time stamps in the record & verify system
(Mosaiq). Three times are reported: 1) setup and plan reoptimization (the time between the
patient’s arrival at the MR-linac and the delivery of the first beam); 2) beam delivery (the
time between delivery of the first and last beam); and 3) total treatment time.
IMRT QA was performed for every adaptive plan following treatment. An MRcompatible cylindrical diode array (ArcCHECK MR; Sun Nuclear Corporation; Melbourne,
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FL) was used with 3% dose/3mm distance to agreement γ criteria [120, 160, 161]. We used
a tolerance limit of γ≥95% and an action limit of γ≥90%, per consensus recommendations
[162]: a γ value of 90% or more was considered passing, but γ values between 90% and
95% were visually inspected prior to passing QA.
Daily setup variability was quantified by recording the isocenter shifts along the x
(left/right), y (superior/inferior), and z (anterior/posterior) axes at each adaptive treatment
delivered on the MR-linac (253 fractions among 10 patients). Systematic and random errors
in each direction were calculated using Van Herk’s method [163], such that M represents the
mean systematic error of all isocenter shifts for all patients,  represents the standard
deviation of the systematic error, and  represents the standard deviation of the random
error.

3.2.4 Comparison of Reference Plan and Daily Adaptive Plans
In order to validate the daily plan quality generated by the daily ATP workflow, the
initial reference plan was compared to the accumulated dose of the daily adaptive plans
(summation plan) for each patient. In the Unity ATP workflow, all treatment plans generated
from the same reference plan have their dose distributions calculated on the reference
image set (i.e. the treatment plans and doses are already in the same frame of reference).
This enables rigid dose summation of the ATP plans, whereby all daily adaptive plan doses
are scaled to a single fraction then added voxel-by-voxel. In this study, daily adaptive plans
were summed using rigid dose summation on the reference image set to create the
summation plan. When ATS was performed, the ATS reference image was rigidly registered
to the initial reference image prior to plan summation.
Plans were evaluated using the actual values of the quantities used as dosimetric
constraints for each patient, such as maximum dose (Dmax) to the spinal cord or mean dose
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(Dmean) to the parotid glands. In cases where there were multiple prescription dose levels to
different target volumes, only the highest dose was considered for analysis. The summation
plan and reference plan for each patient were compared by calculating the percent
difference of each plan quality metric:
%difference = 

𝐷𝑠𝑢𝑚 −𝐷𝑟𝑒𝑓
𝐷𝑟𝑒𝑓

× 100%.

In cases where the backup plan was delivered on a conventional linac for one or more
fractions, only the MR-linac plans were considered for dosimetric analysis by scaling the
reference plan to the number of fractions delivered on the MR-linac prior to taking the
percent difference. The cumulative dose at each fraction was calculated for one
representative case and compared to the expected dose (the cumulative dose if the initial
reference plan had been delivered at each fraction). The number of times an adaptive plan
violated a dosimetric constraint was also tracked for each patient.

3.2.5 Accuracy of Deformable Image Registration in Adapt-to-Shape Workflow
To evaluate whether an on-line ATS workflow would be feasible for future patient
treatments, we performed a post-hoc analysis of the quality of contours propagated via the
“adapt anatomy” deformable image registration tool available through Monaco’s ATS
workflow. For each case, select OAR contours (bilateral parotid glands, bilateral
submandibular glands, spinal cord, brainstem, and mandible) from the CT simulation were
deformed onto the daily setup MRI for fractions 1, 10, 20, and 30. The OAR contours were
also rigidly propagated from the CT simulation to the MR simulation, and the contours were
deformed from the MR simulation to the same daily setup MRIs to test the quality of MR-toMR registration. For ground truth comparison, the MRIs were manually segmented by a
physician. The deformed contours were compared to the physician-segmented contours
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using the Dice similarity coefficient (DSC) and mean surface distance (MSD). This analysis
was performed on all cases that had at least 30 fractions.

3.3 Results
3.3.1 Patient Cohort
The patient cohort included eight males and two females with median age 62 (range:
39–80). The most common treatment sites were larynx (n=3) and oropharynx (n=3). A total
of 253 adaptive treatments were delivered on the MR-linac among the ten patients. Seven
patients received at least one treatment with their backup plan on a conventional linac due
to machine downtime and/or admittance to in-patient facilities. All patients were treated with
the ATP on-line workflow, with four patients receiving a mid-treatment off-line ATS re-plan
due to anatomical changes. Full treatment information is provided in Table 3.1. Dosimetric
constraints used for each patient’s plans are provided in Table 3.2.

Table 3.1: Patient treatment information for the 10 cases.
Case

1
2
3
4
5
6
7
8
9
10

Treatment
site
Larynx (true
vocal cord)
Larynx (true
vocal cord)
Oropharynx
(base of
tongue)
Orbit
Hypopharynx
(pyriform
sinus)
Oropharynx
(tonsil)
Nasosinus
Larynx (true
vocal cord)
Oral cavity
(oral tongue)
Oropharynx
(tonsil)

Total
prescription dose
(cGy)

Total no.
of
fractions

No. of
fractions
treated
on MRlinac

6300

28

24

6300

28

6996

Concurrent
systemic
treatment?

Intent of
treatment

Adaptation
method

T1 N0 M0

No

Curative

ATP

24

T1a N0 M0

No

Curative

ATP

33

26

T4 N2 M0

Yes

Curative

ATP

1400

4

4

Recurrent

No

Palliative

ATP

6996

33

25

T1 N0 M0

Yes

Curative

ATP

6996

33

29

T2 N1 M0

Yes

Curative

ATP/ATS

6000

30

28

T2 N0 M0

Yes

Curative

ATP

6525

29

27

T1b N0 M0

No

Curative

ATP/ATS

Fx 6

6996

33

33

Recurrent

Yes

Curative

ATP/ATS

Fx 26

6996

33

33

T2 N1 M0

No

Curative

ATP/ATS

Fx 8

Tumor
stage

Time
point of
ATS

Fx 24

58

59

constraint was used for that OAR.

specified. “Ipsilateral” and “contralateral” are abbreviated “ipsi” and “contra,” respectively. A • symbol means that no dosimetric

Table 3.2: Dosimetric constraints/plan quality metrics used for all patient plans. All numerical values are in cGy unless otherwise

3.3.2 Treatment Times, IMRT Quality Assurance, and Setup Variability
The minimum, lower quartile, median, upper quartile, and maximum treatment times
(minutes) were 20, 27, 31, 38, 71 for setup and plan reoptimization; 7, 13, 13, 16, 28 for
beam delivery; and 31, 41, 46, 53, 85 for total treatment time, respectively. 91% of total
treatment times were under 60 minutes.
All adaptive plans in this study passed IMRT QA with a γ value greater than 90%
(Figure 3.2). The minimum, lower quartile, median, upper quartile, and maximum γ values
were 90.9%, 99.4%, 99.9%, 100.0%, and 100.0%, respectively. 98% of all adaptive plans
had a γ value ≥ 95%, indicating excellent agreement between the expected and delivered
dose distributions overall. The outliers below 95% all occurred for a single patient, the first
oropharynx patient. The absolute value mean systematic error of the isocenter shifts was ≤
0.7 mm in all 3 orthogonal directions, and the systematic and random errors were ≤ 3.3 mm
(Table 3.3). The maximum absolute value isocenter shifts in any single fraction were 8.0,
19.7, and 7.3 mm in the x, y, and z directions, respectively. In the y-direction, the shift
exceeded 1 cm only four times (Figure 3.3).

Figure 3.2: Frequency distribution of IMRT QA results for daily adaptive treatment plans.
Minimum, lower quartile, median, upper quartile, and maximum are 90.9%, 99.4%, 99.9%,
100.0%, and 100.0%, respectively.
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Table 3.3: Average systematic error (M), standard deviation of the systematic error (), and
standard deviation of the random error () of the x, y, and z isocenter shifts during daily
setup of 10 patients (253 adaptive fractions on the MR-linac).
Axis
x (left/right)
y (sup/inf)
z (ant/post)

M (mm)
-0.3
0.7
0.1

 (mm)
3.3
2.6
1.4

 (mm)
1.7
2.9
2.0

Figure 3.3: Isocenter shifts in the x (left/right), y (superior/inferior), and z (anterior/posterior)
directions over 253 adaptive fractions.

3.3.3 Comparison of Reference Plan and Daily Adaptive Plans
The summed dose to the clinical target volume (CTV) was within [-0.61%, 1.78%] of
the reference plan dose in all cases, with the summed dose falling below the reference plan
dose in only 2/10 cases (Figure 3.4). For the contralateral carotid artery, ipsilateral parotid
gland, contralateral parotid gland, contralateral cochlea, and brainstem, the summation plan
dose was lower than the reference plan dose in all cases. The dose to the ipsilateral cochlea
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Figure 3.4: Percent differences between the summation plan and reference plan doses for
each plan quality metric specified in Table 3.2. Positive values mean that the dose in the
summation plan exceeded the dose in the reference plan. The number of treatments
delivered on the MR-linac (n) for each case is provided in the legends. In cases where no
dosimetric criterion was used for an OAR, that case was omitted from the legend of the
graph. “Ipsilateral” and “contralateral” are abbreviated “ipsi” and “contra,” respectively.
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was higher in the summation plan for 3/7 cases, but all cases fell within a maximum dose
deviation of 4.3%. Doses to the spinal cord exceeded those in the reference plans for cases
1 and 2 by 8.1% and 2.1%, respectively. However, the total summed doses were between
10 and 11 Gy in these two cases, and these small absolute deviations in dose resulted in
higher percent deviations despite the doses falling far below the constraint of 45 Gy.
Similarly, dose sparing of 5%–12% was seen for five OARs in case 4, which was the largest
dose sparing benefit seen for any case. Case 4 only had four fractions delivered, so the
percent differences are larger than measured in most other cases.
All cases had at least two fractions where one or more planning constraint was not
met in the adaptive plan (Table 3.4). However, in most cases where a constraint was

Table 3.4: Number of times a constraint was violated in an adaptive plan.

Treatment
site
Total
number of
MR-linac
fractions
CTV (high
dose)
PTV (high
dose)
Parotid
(ipsi)
Parotid
(contra)
Cochlea
(ipsi)
Cochlea
(contra)
Brainstem
Spinal cord
Carotid
(contra)
Brachial
plexus
(ipsi)
Brachial
plexus
(contra)

Case 1
Larynx
(true
vocal
cord)

Case 2
Larynx
(true
vocal
cord)

Case 3
Oropharynx
(base of
tongue)

Case 4

24

24

26

4

0

2

2

0

Orbit

Case 5
Hypopharynx
(pyriform
sinus)

Case 6

Case 7

Oropharynx
(tonsil)

Case 8
Larynx
(true
vocal
cord)

Case 9
Oral
cavity
(oral
tongue)

Nasosinus

25

29

0

2

28

27

33

33

1

2

3

2

1

Case 10
Oropharynx
(tonsil)

6
*†

*†

•

•

26

0

0

29

0

•

31*†

7

•

•

26*†

0

0

0

0

•

2

0

•

•

0

0

0

15

0

•

14†

2

•

•

0

0

0

0

4

•

0

0

•
0

•
0

0
1

0
0

0
0

0
0

0
0

•
0

0
0

0
0

0

0

•

•

•

•

•

0

•

•

•

•

1

•

•

•

•

•

2

0

•

•

7

•

•

•

•

•

0

0

• constraint was not used for optimization
* constraint was not met in initial reference plan
† constraint was not met in summation plan
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violated in at least one fraction, that constraint was still met in the summation plan. For the
ipsilateral parotid glands in cases 3, 6, and 9 and the contralateral parotid gland in case 3,
the constraints were not met in the initial reference plan and therefore were violated at
nearly every fraction and also in the summation plan. There was only one instance
(ipsilateral cochlea in case 9) where the constraint was met in the reference plan but not in
the summation plan.
Case 9 was chosen as a representative case to illustrate the dosimetric differences
between the expected cumulative dose (if the reference plan had been delivered daily) and
the actual cumulative dose delivered to the OARs and CTV (Figure 3.5). Despite the
fluctuations in dose between adaptive treatments, minimal deviation was observed between
the delivered and expected doses from fraction to fraction (within [-122.7 cGy, 152.4 cGy]
over all cumulative fractions). The largest deviation occurred for the ipsilateral cochlea,
which had a total of 14 constraint violations out of 33 fractions, resulting in a total dose
deviation of 141.8 cGy (4.3%) at the end of treatment. Overall, doses to all OARs were
highly consistent between the reference plan and summation plan in all cases, despite
constraint violations and variations in daily dose distributions due to on-line plan adaptation.

3.3.4 Accuracy of Deformable Image Registration in Adapt-to-Shape Workflow
Figure 3.6 shows the performance of CT-to-MR and MR-to-MR deformable image
registration from the CT or MR simulation image to the daily setup MRIs at fractions 1, 10,
20, and 30. The median DSC value fell below the threshold value of 0.8 recommended by
the AAPM Task Group 132 [164] for CT-to-MR in all cases. The median DSC met this
threshold for MR-to-MR in most cases except for the mandible at fractions 10, 20, and 30.
However, the MR-to-MR contour quality was highly variable, with minimum values
consistently below 0.6 for all OARs except the brainstem. The median MSD fell within the
recommended threshold of 3 mm for all MR-to-MR contours and for the brainstem,
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submandibular glands, and mandible for CT-to-MR. High variability in MSD was observed
for the parotid glands and spinal cord, especially for MR-to-MR. The performance of the
deformable image registration did not appear to degrade at later time points for either CT-toMR or MR-to-MR.

Figure 3.5: The absolute difference between the cumulative delivered dose and the
expected delivered dose if the reference plan had been delivered at each fraction for case 9
(treatment site: oral tongue). Positive values mean that the cumulative delivered dose
exceeded the reference plan expected dose. An off-line ATS was performed between
fractions 25 and 26 (dotted line). This case was chosen as a representative case because
all fractions were delivered on the MR-linac.
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Figure 3.6: a) Dice similarity coefficient (DSC) and b) mean surface distance (MSD)
between physician-drawn contours and contours propagated via deformable image
registration from the CT and MR simulation images to the setup MRIs at fractions 1, 10, 20,
and 30.
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3.4 Discussion
ART has begun to play an increasingly prominent role in the treatment of HNC for
two primary reasons: 1) significant tumor shrinkage, weight loss, and large anatomical
deformations of OARs are often observed for HNC patients during RT [165–167]; and 2)
treatment-related side effects from conventional RT can be particularly debilitating for HNC
and often persist for years after treatment [4, 168]. Several studies have demonstrated
clinically significant reductions in doses to the parotid glands [10, 12, 169], spinal cord [169,
170], and swallowing-related structures [15, 71] with one or more off-line plan adaptations
over the course of radiotherapy. Because off-line adaptive re-planning is time- and resourceintensive, many studies have focused on identifying anatomical and dosimetric guidelines to
determine when plan adaptation would be optimally effective [71, 170, 171]. However, the
clinical introduction of the 1.5T MR-linac has made daily ART for HNC a feasible clinical
reality.
In this study, we present our initial experience with daily MR-guided ART for HNC on
a 1.5T MR-linac. We employed an ARTex_aequo approach [73] intended to deliver prescription
and OAR doses defined prior to therapy. Target volumes were not modified, and OAR
contours were updated only when a new reference plan was created via an off-line ATS plan
adaptation. We used this conservative approach for our first HNC case series on the MRlinac to test safety and feasibility and to iteratively improve our clinical workflow. However,
following the present R-IDEAL stage 2a/2b systematic evaluation, we plan to transition to
ART approaches intended to spare OAR doses and/or handle shrinking tumor volumes in
the near future [47]. The technological innovations with the MR-linac platform, including
enhanced visualization of soft tissue and the on-line ATP and ATS workflows, have the
potential to overcome many of the time and resource limitations associated with OARsparing and target volume-modifying ART approaches.
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Total treatment times ranged from 31-85 minutes, with 91% completed within 60
minutes. Most of the upper outliers were due to isocenter shifts being too large or the on-line
adaptive plan not meeting acceptance criteria. In these cases, the patient was repositioned
and may have been given a short break out of the mask. Although these treatment durations
are longer than HNC treatments on conventional linacs, they are comparable to other
specialized image-guided procedures in our clinic.
One common concern with on-line adaptive re-planning is that a plan must be
delivered before patient-specific IMRT QA is performed, in significant contrast to
conventional QA workflows. However, all adaptive treatment plans in this study passed
IMRT QA (γ>90%), with 98% of plans scoring 95% or higher. These high pass rates may be
attributed to the comprehensive series of safety checks that are implemented at various
stages of the clinical workflow, including annual, monthly, and daily linac and MRI QA as
well as the secondary MU check during on-line plan adaptation. This workflow enables any
dosimetric issues to be caught long before the patient is treated and ensures that on-line
adaptive treatments are safe for all patients. The outliers with pass rates between 90% and
95% all occurred for the same patient, the first oropharyngeal cancer case. Of all treatment
sites in this study, the oropharynx cases had the most complex plans. However, all adaptive
plans for the next two oropharynx cases had pass rates above 99%, suggesting that plan
quality improved with experience.
The setup variability results indicate that immobilization in a custom thermoplastic
head and neck mask resulted in highly reproducible patient positioning with setup errors
consistent with values previously reported in the literature [172–174]. In both the ATP and
ATS workflows of the Unity system, an adaptive plan cannot be created if the isocenter shift
exceeds 5 cm in any one direction because the table can only be moved longitudinally along
the y (superior/inferior) axis. All isocenter shifts fell far below this threshold, with maximum
shifts of 0.80, 1.97, and 0.73 cm in the x, y, and z directions over all 253 adaptive plans.
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Although shifts greater than 1 cm seem quite large with a mask, this occurred only four
times and only in the y direction, which can be attributed to errors in positioning the mask
along the index bar. In these cases, a decision was made not to reposition the patient
because an acceptable ATP plan could still be generated. However, while on-line plan
reoptimization directly accounts for inter-fraction positional variations, minimizing these
variations can help the optimization algorithms achieve “better plans” that meet all
dosimetric constraints.
One advantage of treating with the MR-linac is the ability to observe motion during
the treatment with the motion monitoring cine imaging. Although not directly quantified in this
paper, the intra-fraction motion was observed during each treatment and appeared minimal
with our immobilization setup and consistent with previous findings [175, 176]. The current
version of the MR-linac does not allow for intra-fraction motion correction, but the beam can
be manually stopped if the target has moved substantially. Large target motion does not
appear to be a major issue in the head and neck given that the patients are masked. The
only motion observed was due to respiration and swallowing, which, as demonstrated by
Bruijnen et al. [175], do not typically cause net tumor displacement over time.
Differences between the reference plan doses and summed doses were minimal,
with the largest percent deviations occurring when the absolute doses were small (as in
case 4 when only 4 fractions were delivered or cases 1 and 2 when the spinal cord doses
were around 10 Gy). It is important to note that the ATP workflow was used for the majority
of fractions, with only a single ATS fraction for cases 6, 8, 9 and 10. There was no
modification of the CTV or intentional dosimetric sparing to any OARs for these cases. Any
dosimetric sparing to the OARs is likely caused by small changes in the locations of “hot
spots” in the dose distribution within each OAR, which is a result of both daily plan
adaptation and the inherent randomness of the Monte Carlo dose calculation. Instead of the
“hot spot” being located in the same voxel at each fraction, the “hot spot” is smeared around
69

a larger volume over all fractions, effectively reducing the maximum or mean cumulative
dose to any OAR compared to the reference plan. Overall, the consistency between the
reference and summation plan doses demonstrate that our conservative initial clinical
implementation of the ATP workflow on the MR-linac for HNC is safe for patients and
performs at least as well as the standard of care from a dosimetric perspective.
One drawback of this dosimetric analysis was that the adaptive plans were summed
using rigid plan summation on the anatomy of the reference plan in the ATP workflow. This
dose summation approach was necessary because there are currently no validated
deformable dose accumulation tools for the Unity system. In the absence of such a tool and
with only ten cases in this initial feasibility study, it is difficult to draw conclusions about the
dose sparing benefit of this MR-guided ARTex_aequo approach. However, the current standard
of care in RT is to plan multi-fraction treatments based on the obviously erroneous
assumption that the anatomy remains constant throughout all treatment fractions. Thus, all
dose estimates in conventional RT are based on the simulation image, which is analogous
to the reference plan anatomy in MR-guided daily adaptive RT. Because all doses were
summed on the reference plan anatomy, we may conservatively conclude that the
dosimetric variability between daily adaptive plans results in minimal variation from the
reference plan over the course of RT.
Another major goal of this study was to characterize the frequency of plan constraint
failure for standard head and neck radiation plans and to determine reasonable criteria to
accept or reject an on-line adaptive plan based on the pattern of these constraint violations
throughout a treatment course. We have shown in this manuscript that most constraint
violations are random and do not have a major impact on the cumulative delivered dose. We
have also shown that when constraint violations are systematic (i.e. the same constraint is
violated in multiple consecutive fractions), our off-line ATS approach allows us to modify the
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cumulative dose to ensure that the same plan parameters are met without having to keep
the patient on the treatment table and in the mask for a time-consuming on-line ATS.
Ultimately, the results presented in this manuscript have enabled our clinic to move
toward a protocol with “soft” constraints rather than “hard” constraints, whereby each
constraint has a 3% tolerance when creating on-line adaptive plans. Values above 3%
overdose for OARs or below 3% underdose for targets are rejected and require modification
of IMRT constraints and plan reoptimization. Values that violate the stated constraint but fall
within the 3% tolerance are accepted for a single fraction but flagged; multiple consecutive
values within this range trigger an off-line ATS. This method allows us to differentiate
between random violations that are unlikely to affect the cumulative dose and systematic
violations that require off-line plan modification.
In this initial feasibility study, our conservative implementation was to use an on-line
ATP/off-line ATS workflow to limit the patient time in mask during each fraction. The greatest
bottleneck in the ATS workflow is the time spent manually correcting contours propagated
via the “adapt anatomy” deformable image registration tool within Monaco, which is a “onesize-fits-all” tool with no allowable parameter optimization. To test the feasibility of
performing on-line ATS in the future, we measured the performance of contours propagated
from the simulation images to the daily setup images at fractions 1, 10, 20, and 30. We
tested both CT-to-MR and MR-to-MR because we routinely use CT for our reference plans
but were interested in seeing whether using MR for the reference plans would improve the
deformable image registration for ATS plans. While the median DSC and MSD values were
marginally better for MR-to-MR compared to CT-to-MR, the variability in performance across
all cases indicates that the image registration is not reliable enough to routinely perform ATS
on-line without extensive manual correction. We also tested the image registration quality at
four time points to investigate whether the performance decreased as anatomical changes
became more significant over time, and if so, whether we could determine a maximum time
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interval between ATS fractions. No clear trends were observed with time, and DSC and
MSD consistently failed to meet the recommended tolerances even at the first fraction.
Furthermore, due to the large number of OAR contours and the poor performance of the
DIR, our dosimetrists report spending 1.5-2 hours on average for each off-line ATS plan,
with the majority of that time spent on editing OAR contours after the image registration.
Based on these results, we will continue to implement ATS off-line until a more robust
deformable image registration tool can be implemented into the on-line clinical workflow.
Despite these limitations, this effort represents the first report of 1.5T MR-guided
daily ART for HNC and the first prospective series of dosimetric analyses of HNC treatment
on a hybrid MR-linac system. Consistent with R-IDEAL, in this planned “prospective small
uninterrupted case series,” we have demonstrated “technical improvements, feasibility, and
safety” [159] of 1.5T daily ARTex_aequo treatment for HNC. The continued R-IDEAL
programmatic integration of this data with extant efforts across the MR-Linac Consortium is
designed to ensure that rather than ad hoc reportage, iterative technical developments on a
new technology are reported systematically. Future prospective analyses combining HNC
data from other MR-Linac Consortium sites using the same workflow are currently being
planned. Furthermore, first technical studies have shown that MR imaging using the 1.5 T
Unity system not only provides excellent anatomical image data [53, 177] but also allows for
robust and reproducible quantitative imaging techniques, such as DWI [177]. Consequently,
functional MR data acquired sequentially during MR-guided RT needs to be investigated
systematically in order to pave the way towards future biologically individualized RT of HNC.
Next steps include an R-IDEAL Stage 2a evaluation of functional imaging integration and
feasibility with DWI, and Stage 2a implementation using an ARTreduco [73] approach within
the prospective Phase II randomized MR-ADAPTOR trial [47].
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3.5 Conclusion
The aim of this article was to describe our institution’s clinical workflow for treating
HNC on a 1.5T MR-linac and to demonstrate safety and feasibility through a prospective
analysis of ten cases treated with an on-line ATP workflow. Treatment times remained under
one hour in 91% of cases. All treatment plans passed IMRT QA, and patient immobilization
in a custom head and neck mask resulted in highly reproducible patient setups. The daily
adaptive plans were very consistent with the reference plans with minimal dosimetric
differences. In summary, daily MR-guided adaptive RT for HNC is safe and clinically feasible
with the MR-linac, although further studies with more advanced dose accumulation
strategies are required to investigate the true dosimetric impact of this treatment approach.
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Chapter 4: Autosegmentation Methods for Off-line Dose Reconstruction on MR-Linac
Head and Neck Images

This chapter is based off the following paper, which is currently available as a preprint on MedRXiv:
McDonald BA, Cardenas C, O’Connell N, Ahmed S, Naser MA, Wahid KA, Xu J, Thill D,
Zuhour R, Mesko S, Augustyn A, Buszek SM, Grant S, Chapman BV, Bagley A, He R,
Mohamed A, Christodouleas JP, Brock KK, Fuller CD. Investigation of Autosegmentation
Techniques on T2-Weighted MRI for Off-line Dose Reconstruction in MR-Linac Adapt to
Position Workflow for Head and Neck Cancers. MedRXiv 2021.
https://doi.org/10.1101/2021.09.30.21264327
Supplementary data for this chapter is provided in Appendix B.

4.1 Introduction
Novel magnetic resonance imaging (MRI)-linear accelerator (MR-linac) devices have
enabled the clinical adoption of on-board adaptive radiation therapy (ART) [22, 50, 155, 178]
for head and neck cancers (HNC). While MR-linac systems improve soft tissue visualization
and allow a new radiation therapy (RT) treatment plan to be created during every treatment
fraction to better target the tumor and avoid healthy tissues, current systems do not have
mechanisms for accumulating delivered dose over the entire course of RT.
Furthermore, on the 1.5T MR-linac system, the Adapt to Position (ATP) workflow
(virtual isocenter shift) is used for the majority of fractions in standard-fractionation head and
neck RT [22], which minimizes treatment times compared to the Adapt to Shape (ATS) (full
adaptive replan) workflow and is appropriate when day-to-day anatomical variations are
small [58]. However, this workflow reduces the time required for adaptive replanning by
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estimating dose on the previously segmented reference image rather than calculating dose
directly on the setup image, which reflects the anatomy at the time of beam delivery. Thus,
there remains an unmet need for a method to not only accumulate dose across multiple
fractions but also to accurately reconstruct the delivered dose on the anatomy at the time of
treatment for ATP plans.
Our approach for dose accumulation for head and neck ART on the MR-linac
involves 1) autosegmenting the structures on each fraction’s setup image, 2) recalculating
the delivered dose on the setup image, 3) deformably registering each setup image to a
common time point (i.e. the pre-RT or post-RT anatomy), 4) deformably mapping doses to
that same common time point, and 5) summing the mapped doses. In this paper, we are
focusing on the first two steps to determine the optimal method for automatically segmenting
the T2-weighted setup images used in our head and neck workflow [22] and to evaluate the
impact of autosegmentation on dose calculation accuracy.
Various autosegmentation methods that have historically been applied to computed
tomography (CT) images have shown promise on MRI [179], including deformable image
registration (DIR)-based structure propagation [22, 23], atlas-based autosegmentation [180–
182], and deep learning [183–185]. While several studies have shown that deep learning
can improve organ-at-risk (OAR) segmentation accuracy compared to atlas-based
autosegmentation on CT for head and neck [186–188] and other treatment sites [189–192],
to our knowledge, only a single study thus far has directly compared these methods on MRI
for any treatment site [193]. As MR-guided ART becomes more accessible, evaluating these
autosegmentation methods on MRI is crucial. We are also interested in leveraging images
from previous MR-linac fractions to contour future fraction images for the same patient.
Images from multiple prior fractions can be used as atlases in an individualized patient prior
atlas-based autosegmentation approach, which has been shown to improve segmentation
accuracy over deformable structure propagation from a single prior image [194].
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Our aim in this paper is to evaluate the geometric accuracy of these
autosegmentation methods for head and neck OARs and to test permutations with various
sets of parameters, including different label fusion methods and numbers of atlases. We will
also explore the feasibility of recalculating daily fraction doses on autosegmented setup
images from the MR-linac and understand how differences in geometric accuracy affect the
recalculated dose.

4.2 Materials and Methods
4.2.1 Patients and Informed Consent
18 head and neck cancer patients and 3 healthy volunteers were included in this
study. For patients, the disease sites included 9 oropharynx (8 human papilloma virus
(HPV)+ and 1 HPV-), 3 larynx, 2 nasopharynx/nasal cavity/orbit, 2 oral cavity, and 1
hypopharynx. The age range for all subjects was 22 to 81 (median: 60). All patients were
consented to the MOMENTUM observational clinical trial [195], and all healthy volunteers
were consented to an internal institutional review board-approved volunteer imaging study.

4.2.2 Images and Manual Segmentation
A total of 41 T2-weighted MRI scans were used as the primary data set in this study
(5 each for 5 patients and 1 each for the remaining 16 patients/volunteers, as explained
below), and an additional 45 image sets from the same patients were added for the deep
learning model. All images were acquired on a 1.5 T MR-linac (Unity; Elekta AB; Stockholm,
Sweden). The T2-weighted sequence is a low-resolution 2-minute scan used for setup and
treatment plan reoptimization in the Unity ATP workflow, as described previously [22, 58],
with the following scan parameters: 3-D spin echo acquisition, 1535 ms repetition time, 278
ms echo time, 0.83 mm in-plane resolution, 2 mm slice thickness, 1 mm slice gap, 400 x 400
mm2 field of view, 300 slices; 117 second acquisition time.
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Each image in the primary data set was manually segmented by 7 individual
observers (postgraduate year 4 radiation oncology residents who were specifically trained
on head and neck anatomy and MRI by an experienced HNC radiation oncologist). The
following OARs were segmented: brainstem, mandible, left and right parotid glands, left and
right submandibular glands, and spinal cord. Ground truth contours were generated from the
7 observer contours using a multi-label simultaneous truth and performance level estimation
(STAPLE) algorithm [196] constrained to prevent overlapping contours (ADMIRE software
v3.26, Elekta AB, Stockholm, Sweden). All STAPLE contours were reviewed by two
additional observers (one radiologist and one radiation oncologist with at least 5 years of
experience) for quality, and all were considered sufficient for further use as ground truth.
These ground truth contours from this primary cohort were used as atlases/training data for
the atlas-based and deep learning autosegmentation methods as well as the ground truth
contours used to evaluate the autosegmentation methods. The 45 additional image sets that
were added to the deep learning model were contoured by a single observer (radiologist).

4.2.3 Autosegmentation Methods
A total of 20 autosegmentation methods in ADMIRE were evaluated, divided into
three primary categories: 1) population atlas library (PAL), 2) individualized patient prior
(IPP), and 3) deep learning (DL).

4.2.3.1 Population Atlas Library (PAL)
PAL is conventional multi-atlas-based autosegmentation where all the atlases (i.e.
image and structure set pairs) are from different patients so that the atlas library is
representative of a wide range of anatomies and can be generalized to other patients. In
multi-atlas-based autosegmentation, each atlas is deformably registered to the image to be
segmented, resulting in one intermediate structure set per atlas. Next, a label fusion step is
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performed to generate a final consensus contour from all of the intermediate contours.
Three label fusion methods were used: STAPLE, patch fusion (PF), and random forest (RF)
(described below). For each label fusion method, the autosegmentation was run using 5, 10,
and 15 atlases, resulting in 9 total PAL-based autosegmentation methods for evaluation.
The naming convention used for PAL methods is PAL appended with the label fusion
method (ST, PF, or RF) and number of atlases, for example PAL_ST_5 for PAL with
STAPLE and 5 atlases.
STAPLE estimates the sensitivity and specificity of each intermediate segmentation
as compared to the remaining segmentations (on a structure-by-structure basis), then it
weights each segmentation based on its relative performance and generates a consensus
segmentation based on the weighted average [196, 197]. Unlike STAPLE, which uses only
the label data, PF uses the intensity values of the image to create the weights for the
weighted average. Specifically, the similarity between each atlas and the image to be
segmented is estimated by computing the local cross-correlation coefficient (LCC) for every
voxel, and the atlas weights are determined on a voxel-by-voxel basis based on the LCC
[198, 199]. Finally, the RF autosegmentation method uses the atlases to train a RF model—
a supervised machine learning algorithm based on decision trees—to create a binary
classifier to determine whether or not each voxel in an image belongs to a given structure
[200]. The RF classifier is applied only to the voxels where the intermediate segmentations
mapped from each atlas do not fully agree.

4.2.3.2 Individualized Patient Prior (IPP)
IPP is atlas-based autosegmentation using images from the same patient as atlases.
With the MR-linac, an image is acquired at every fraction, so if a small number of image sets
from the first few fractions are contoured, we can leverage that data to segment images from
the remaining fractions. In this study, IPP was evaluated using 1, 2, 3, and 4 prior fractions.
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Images from the patient’s 5th fraction were used for evaluation, and the fraction(s)
immediately prior were used as atlases (i.e. the 4th fraction was used for 1 prior fraction, the
3rd and 4th were used for 2 prior fractions, etc.). When one prior fraction is used, IPP is
simply a DIR-based structure propagation and requires no label fusion. When multiple prior
fractions are used, IPP works similarly to PAL with the same three label fusion methods
(STAPLE, PF, RF). A total of 10 IPP-based autosegmentation methods were evaluated: IPP
with 1 prior fraction and IPP with 2, 3, and 4 prior fractions each using STAPLE, PF, and RF.
The naming convention for IPP methods follows the same convention as described
previously for PAL methods, e.g. IPP_PF_2 for IPP with patch fusion and 2 prior fractions,
or IPP_1 for IPP with 1 prior fraction.

4.2.3.3 Deep Learning (DL)
The DL model used a 3-D ResUNet framework [201] trained on 86 image sets (41
with ground truth STAPLE consensus contours from the 7 observers plus 45 contoured by a
single observer to maximize available training data). The network structure consisted of an
encoder and decoder plus five long-skip connections for a total of five levels between the
encoder and decoder. A residual block was used in each level of the encoder and decoder,
and down-sampling and up-sampling layers (i.e. max-pooling and up-pooling operators)
were used to connect each block. The MR images were pre-processed by thresholding the
lower and upper 0.25% pixel values to eliminate potential outliers, normalizing pixel values
using Z-score normalization, and scaling all image values into the range of [-1, 1] using a
linear transform. All algorithm modules were developed using the TensorFlow DL library with
a Python and C++ interface, and the final deep learning autosegmentation model was
implemented into ADMIRE. An approach similar to leave-one-out cross validation was used;
since multiple image sets per patient were included for some patients, all image sets from a
given patient were left out for the model evaluated on that patient.
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4.2.4 Geometric Evaluation and Statistical Analysis
The results of each autosegmentation method were compared against the ground
truth contours using the Dice similarity coefficient (DSC) [202], mean surface distance
(MSD), Hausdorff distance (HD), and Jaccard Index (JI) calculated in ADMIRE. The interobserver variability of the seven observers was measured using pair-wise comparison of
each observer’s segmentations (i.e. observer 1 vs. 2, 1 vs. 3, … , 6 vs. 7) on each image set
in the primary cohort. The same four geometric indices were measured for each pair of interobserver contours. For the spinal cord contours, since some observers did not contour the
spinal cord in the entire field of view, the remainder of the spinal cord contours were
cropped at the inferior-most slice for each image prior to measuring the inter-observer
variability metrics. However, the consensus contours were generated from the non-cropped
contours, and they were all visually inspected to ensure that the consensus contours
extended through the entire field of view, which they did in every case.
The results of each autosegmentation method were compared to the inter-observer
variability using Dunn’s test with control [203, 204] using the inter-observer variability
distribution as the control. Dunn’s test with control is a non-parametric test to compare
multiple distributions to a single control distribution. Reported p-values are Bonferroni
corrected p-values. The test was performed separately for each structure. Each
autosegmentation method was also compared pair-wise using the Steel-Dwass test for
multiple comparisons [205]. The Steel-Dwass test for multiple comparisons is a nonparametric equivalent to the Tukey all-pairs comparison with cumulative experimental error
correction. The comparisons were performed pooled over all structures. All statistical
analyses were performed in JMP Pro (v15.0.0, SAS Institute Inc., Cary, NC). The execution
time per case of each autosegmentation method was also recorded, and the mean and
standard deviation execution time were calculated.
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4.2.5 Dosimetric Analysis
To evaluate the impact of the differences in autosegmentation performance on the
reconstructed dose, the dose from the 5th ATP fraction was recalculated on the T2-weighted
image for 5 patients using the contours from 4 select autosegmentation methods and the
STAPLE ground truth contours (5 total plans per patient). Four autosegmentation methods
were selected for further evaluation based on their geometric performance and execution
time: IPP with RF and 4 prior fractions (IPP_RF_4), DL, IPP with one prior fraction (IPP_1),
and PAL with STAPLE and 5 atlases (PAL_ST_5). IPP_RF_4 performed best overall for all
four geometric metrics, while DL and IPP_1 demonstrated the best tradeoff between
geometric performance and execution time. PAL_ST_5 was the worst performing method
across all four geometric metrics and was included to demonstrate the degree to which poor
autosegmentation can affect the calculated dose.
The doses from the 5th fraction (all ATP plans) were reconstructed in Monaco
(Research v5.59.13; Elekta AB; Stockholm, Sweden) on the setup image set for the 5th
fraction using the following methodology: First, a duplicate copy of the setup image was
imported for each patient with contours for the seven OARs (parotid glands, submandibular
glands, mandible, spinal cord, brainstem) from each of the four autosegmentation methods
and the ground truth contours. The setup image was then aligned to the reference image for
the ATP plan (i.e. the planning CT) using the same isocenter shift used clinically. Next, all
contours that were not included in this autosegmentation study were propagated from the
reference image to the setup image using the Adapt Anatomy function in Monaco, with OAR
contours registered deformably and any target volumes registered rigidly. It was verified that
these contours were identical across all copies of the same image so that the only difference
in the structure sets would be the seven autosegmented OARs. Bulk electron densities were
assigned to each structure based on the average electron density value of each structure
from the CT. Next, the beams and segments were transferred from the clinically delivered
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ATP plan onto the setup image by creating an ATS plan. However, instead of reoptimizing
the segments and/or fluence, the dose was recalculated directly without any modification to
the original beams and segments. This workflow was repeated for each of the
autosegmentation results, resulting in a unique dose distribution for each autosegmentation
method and the ground truth contours per patient.
To compare the dosimetric performance of each autosegmentation method, the
mean dose (Dmean) for and maximum dose (Dmax) were calculated for each of the seven
structures on each recalculated dose distribution. For both Dmean and Dmax, the difference
between the ground truth contours and each of the four autosegmentation method contours
was calculated (ΔDmean and ΔDmax).
Next, we investigated whether any of the geometric metrics (DSC, HD, MSD, JI)
between each autosegmented contour and the ground truth contours are correlated with the
absolute value dosimetric differences (|ΔDmean| and |ΔDmax|) between the autosegmented
and ground truth contours. Linear regression was performed between |ΔDmean| and each of
the four metrics and between |ΔDmax| and each of the four metrics. The correlation
coefficient (R2) of each linear fit was measured, and an F-test of overall significance was
performed for each fit (α=0.05).

4.3 Results
4.3.1 Execution Time and Autosegmentation Failures
The mean execution time per case is shown in Figure 4.1. DL was the fastest
method with an execution time of 33 ± 0 s (mean ± standard deviation). For all IPP and PAL
cases, execution time increased with the number of prior fractions/atlases for the same
autosegmentation type and label fusion method. No clear trends were observed for the
execution times of the STAPLE, RF, and PF label fusion methods when the
autosegmentation type and number of prior fractions/atlases were held constant.
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PF methods often failed in the spinal cord, meaning that no spinal cord contour could
be generated despite repeated attempts. It failed in all cases for IPP_PF_2, IPP_PF_3, and
IPP_PF_4. Only 4, 3, and 2 cases were successful in PAL_PF_5, PAL_PF_10, and
PAL_PF_15, respectively. There were no autosegmentation failures for any other structures.

Figure 4.1: Execution time per case for each autosegmentation method. Data is
represented as mean and standard deviation (error bars). Figure courtesy of Carlos
Cardenas, PhD, used with permission. (Analysis performed by me, figure created by Dr.
Cardenas.)

83

Figure 4.2: DSC, MSD (mm), HD (mm), and JI for the autosegmentation methods compared
to ground truth contours and the pair-wise comparison of inter-observer variability.
Distributions are shown as box plots, with the five horizontal bars in each distribution
representing the minimum, first quartile, median, third quartile, and maximum. Figure
courtesy of Carlos Cardenas, PhD, used with permission. (Analysis performed jointly by me
and Dr. Cardenas, figure created by Dr. Cardenas.)
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4.3.2 Geometric Evaluation and Statistical Analysis
DSC, MSD, HD, and JI values for each autosegmentation method and the pair-wise
inter-observer variability analysis are shown in Figure 4.2. In general, all IPP methods had a
greater median DSC and JI and lower median MSD and HD compared to all PAL methods
for all structures (except the DSC and JI for the mandible). PAL methods generally showed
greater variability in performance among the test cases compared to IPP methods. For IPP
and PAL, for a given autosegmentation type and label fusion method, no clear trends in
performance were observed as the number of prior fractions or atlases increased. For PAL,
PF and RF appeared to have comparable performance, but ST had poorer performance. No
clear trends were observed among the label fusion methods for IPP. For most structures, DL
had similar median DSC and MSD values compared to all IPP methods but had much
greater variability across test cases. All IPP methods and DL had higher median DSC
values, lower median MSD values, and less variability compared to the inter-observer
variability for all structures. Differences between each PAL method and the inter-observer
variability were less pronounced. The highest performing method overall was IPP_RF_4,
which had the highest median DSC and JI and lowest median MSD and HD for all
structures. The worst performing was PAL_ST_5, which demonstrated the poorest median
values for nearly every metric and structure. Segmentation results for all 20
autosegmentation methods are shown on an example patient in Figure 4.3.
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Figure 4.3: Segmentations for six of the seven OARs (excluding the brainstem since it
cannot be visualized in the same plane as all the other segmentations) for one example
patient. Ground truth segmentations are in green, and each set of autosegmented contours
is in red. The spinal cord contour is missing in the IPP_PF methods because the
segmentation failed. Figure courtesy of Kareem Wahid, B.S., used with permission.
(Analysis performed by me, figure created by Kareem Wahid.)
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Results of Dunn’s test to compare each method to the inter-observer variability are
shown in Figure 4.4. Most IPP methods performed significantly better than the interobserver variability for the DSC, JI, and MSD. Exceptions included the DSC and JI of IPP_1
for the mandible and MSD of all IPP_PF and IPP_RF iterations for the right submandibular
gland. PAL methods were not significantly different than the inter-observer variability in most
cases. There were several exceptions, mainly including the DSC and JI of the brainstem
and mandible for several PAL methods with 10 and 15 atlases. Most PAL methods differed
significantly from the inter-observer variability in the HD for the parotid glands. DL was
significantly different than the inter-observer variability in the DSC and JI for all structures
except the left submandibular gland, but it was not significantly different in the HD or MSD
for all structures except the brainstem and right parotid gland.

Figure 4.4: Heat map of p-values for Dunn’s test with the inter-observer variability as a
control. Reported values are Bonferroni adjusted p-values. Red boxes indicate nonsignificant results (p>0.05), and blue boxes indicate significant results (p<0.05). White
represents missing values (IPP_PF methods failed for the spinal cord for every test case).
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Results of the Steel-Dwass test for pair-wise comparison between each method are
shown in Figure 4.5. None of the IPP methods or DL were significantly different from each
other in any of the four metrics. Most PAL methods were not significantly different from each
other with a few exceptions. Notably, PAL_ST_5 (the worst performing method overall)
significantly underperformed PAL_PF_10, PAL_RF_10, PAL_PF_15, and PAL_RF_15 in
most metrics. PAL_RF_15 (the best performing method overall) performed significantly
better than PAL_ST_5, PAL_PF_5, and PAL_ST_10 in all metrics but HD. Most PAL
methods were significantly different than all other IPP methods and DL except for
PAL_RF_10 and PAL_RF_15.

Figure 4.5: Heat map of p-values for the Steel-Dwass test for pair-wise comparison
between autosegmentation methods pooled over all ROIs. Red boxes indicate nonsignificant results (p>0.05), and blue boxes indicate significant results (p<0.05).
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Figure 4.6: Differences (cGy) in dosimetric performance criteria (ΔDmean and ΔDmax)
between plans based on ground truth contours and select autosegmentation methods for 5
patient cases. Positive/negative values mean that the dose was higher/lower in the
autosegmented structure than in the ground truth structure, respectively. Treatment sites for
the five patient cases are: case 1: larynx – left supraglottis; case 2: left hypopharynx; case 3:
larynx – left glottis; case 4: oropharynx – right tonsil; case 5: oropharynx – right tonsil.

4.3.3 Dosimetric Analysis
The dose differences (ΔDmean and ΔDmax) between plans recalculated with the ground
truth contours vs. plans recalculated with the various autosegmented contours (IPP_RF_4,
DL, IPP_1, and PAL_ST_5) are shown in Figure 4.6. For IPP_RF_4, DL, and IPP_1 (the
high-performing methods geometrically), the majority (95%) of ΔDmean and ΔDmax values
across all ROIs fell within ±250 cGy. However, a few outlier dose differences occurred even
for these three high-performing methods, with maximum |ΔDmean| and |ΔDmax| as high as 617
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cGy and 785 cGy, respectively. For these three methods, dosimetric differences greater
than ±250 cGy occurred in all ROIs except the spinal cord and mandible and occurred most
often in the parotid glands. Among the five cases, they occurred most often in cases 1 and 3
(treatment sites: left supraglottis and left glottis, respectively). Of the three autosegmentation
methods, they occurred most often for DL. For PAL_ST_5 (the poorest performing
geometrically), dosimetric differences were higher overall compared to the three highperforming methods, with maximum |ΔDmean| and |ΔDmax| as high as 1112 cGy and 1919
cGy, respectively. Dosimetric differences greater than ±250 cGy occurred in all ROIs except
the right submandibular gland, and differences greater than ±500 cGy occurred for all ROIs
except the spinal cord and right submandibular gland. The causes of major outlier
dosimetric differences (greater than ±500 cGy) in all four autosegmentation methods are
explored further in Appendix A. In short, they tend to occur when the superior and/or
inferior boundary of an ROI falls within a steep dose gradient and is placed in the wrong
slice by the autosegmentation method.
The results of the correlation between each dosimetric difference (ΔDmean and ΔDmax)
and each of the four geometric metrics (DSC, MSD, HD, JI) are shown in Figure 4.7 and
Figure 4.8. Although the F-test was significant in all cases (p<0.05), correlation coefficients
were poor (maximum R2 value 0.314). Correlations were slightly stronger for ΔDmean than for
ΔDmax (R2 between 0.128 and 0.314 for ΔDmean and R2 between 0.030 and 0.096 for ΔDmax).
Of all geometric metrics, HD demonstrated the best correlation with both ΔDmean and ΔDmax.

90

Figure 4.7: Correlation between |ΔDmean| and each geometric metric. The light blue region
around the line of fit shows the 95% confidence region of the fit. The correlation coefficient
(R2) and p-value of the F-test are shown in the upper left corner of each plot.
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0.0422

Figure 4.8: Correlation between the absolute value of |ΔDmax| and each geometric metric.
The light blue region around the line of fit shows the 95% confidence region of the fit. The
correlation coefficient (R2) and p-value of the F-test are shown in the upper left corner of
each plot.

92

4.4 Discussion
In this study, we evaluated the geometric and dosimetric performance of several
autosegmentation methods for the low-resolution T2-weighted MR images used for
treatment positioning in the ATP workflow for HNC on the 1.5 T MR-linac [22]. In ATP, the
reference plan image is aligned with the daily setup image to create a virtual isocenter shift,
but the dose for the daily adaptive plan is calculated on the reference image rather than the
daily setup image [58]. This workflow allows for quick plan adaptations to account for small
changes in the position of the tumor at each fraction without having to segment the setup
image while the patient is on the treatment table. However, if one wants to accurately
accumulate the dose delivered over a patient’s entire RT course, then the delivered dose at
each ATP fraction must be reconstructed on the daily setup images, which represent the
anatomy at the time of beam delivery. To calculate doses on MR images, the electron
density values of each imaging voxel must be estimated, which is routinely accomplished by
assigning each structure on the MR a uniform electron density value, as measured either
from that patient’s CT simulation image or from population reference values [154, 206–208].
This method, commonly called bulk density assignment, requires the MR to be segmented.
Thus, our goal in this study was to determine the optimal autosegmentation method for
these daily setup MRIs and evaluate their impact on the calculation of the delivered dose.
Two recent studies have detailed a framework for daily dose reconstruction for
prostate cancer RT on the MR-linac using MRI cine imaging and treatment log files [209,
210]. This approach accounts for intra-fraction motion by synchronizing the motion trajectory
and small units of delivered fluence based on the time stamps. While intra-fraction motion is
a major consideration for many treatment sites including prostate, intra-fraction motion is
minimized in HNC treatment with the use of an immobilization mask [175]. As such, we have
elected to take a computationally simpler approach where we reconstruct the dose based on
the static anatomy represented in the daily setup image. Our workflow is more closely
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aligned with previously reported studies where dose is reconstructed based on on-board
setup imaging using cone beam CT [171, 211] or CT-on-rails [71], with the key difference
from these studies being that a unique ATP treatment plan is delivered each day rather than
delivering the same plan at each fraction.
In this study, both the geometric performance and execution time of each
autosegmentation method were considered in selecting the most favorable method.
IPP_RF_4 (IPP with RF label fusion and four prior atlases) had the highest median DSC and
JI and lowest median MSD and HD of all methods. However, it did not perform significantly
differently than DL or any other IPP method in the Steel-Dwass test for any of the four
metrics, and its mean execution time of 6.8 minutes per case is 12, 4, and 2 times longer
than DL, IPP_1, and IPP_RF_2, respectively. DL was also not significantly different than any
of the IPP methods in terms of geometric performance but was the fastest method, with an
execution time of 33 seconds per case. However, the downside of DL is that it requires
many more ground truth image sets for training data compared to IPP or PAL. As such,
expanding our current model to include all OARs for HNC treatment planning would require
many more manual segmentations, which would be an extremely time-intensive process.
IPP_1 would be a favorable alternative to DL as long as one MR image per patient is
manually segmented, although any error in the initial segmentation is propagated to the next
image with IPP_1. As our results have shown, increasing the number of prior fractions with
IPP does not significantly improve performance but increases execution time by roughly 1.52 minutes for every added fraction. This study has also shown that nearly all PAL methods
perform significantly worse than DL and all IPP methods and have much longer execution
times. Despite these performance limitations, PAL may be a useful method for segmenting
the first image for a new patient, as long as the contours are manually reviewed and edited if
necessary.
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To our knowledge, the present manuscript is the first to compare multi-atlas-based
autosegmentation with a population atlas library (i.e. PAL), multi-atlas-based
autosegmentation using individualized patient prior images (i.e. IPP), and DL-based
autosegmentation. Several recent studies have investigated at least one of these methods,
and many have focused on parameter optimization, as we did in this study. Van de Velde et
al. [212] studied the optimal number of atlases using the PAL STAPLE and PF algorithms in
ADMIRE (the same autosegmentation software used in the present study) to contour the
brachial plexus on CT images. Looking at a range of 2-12 atlases, they found 9 to be the
optimal number of atlases for both STAPLE and PF based solely on geometric metrics. Lee
et al. [213] also tested the optimal number of atlases in head and neck CT images using
MIM software, but their approach involves using a large population atlas library and
selecting a small number of atlases that most closely match the patient being segmented,
followed by DIR and label fusion of the intermediate results. They looked at 20, 40, 60, 80,
and 100 atlases in the library and found that geometric performance generally peaked
around 60 atlases, with more atlases either not improving segmentation accuracy and even
degrading performance in some cases.
Schipaanboord et al. [214] and Van de Velde et al. [215] both showed that when
atlas selection strategies are used to select atlases most similar to the anatomy of the
patient being segmented, performance is significantly improved over using a random
selection of atlases. This concept can logically be extended to support the IPP atlas-based
autosegmentation method used in the current paper; using prior images from the same
patient as atlases achieves the maximal similarity between the atlases and the image being
segmented. Our results support this idea, with all nearly IPP methods performing
significantly better than PAL methods. Zhang et al. [194] investigated the IPP approach with
STAPLE in ADMIRE using MR-linac images of the abdomen. They demonstrated that IPP
with 7 prior images, both with and without an MRI pre-processing step, improved
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autosegmentation quality over both rigid registration and DIR from the pre-RT MR sim. They
also found that the mean DSC increased as the number of prior fractions increased for all
OARs, in contrast to our results, which did not show a significant improvement with
increasing the number of prior fractions in IPP. This discrepancy may be due to the fact that
there is more deformation from day to day in the abdomen compared to head and neck, so
the benefit of adding more prior fractions may depend on the treatment site.
In our study, we also performed further dosimetric evaluation on contours from
IPP_RF_4 (the top performing method overall geometrically), DL (the fastest method and
one of the high-performing methods), IPP_1 (the second fastest method and one of the
high-performing methods), and PAL_ST_5 (the worst performing method overall) to better
understand how contour geometry affects the dose volume histogram parameters of the
recalculated doses. Large dosimetric discrepancies between ground truth and PAL_ST_5
were observed, which was expected because the geometric performance was quite poor.
While dosimetric differences were smaller overall for the three high-performing methods,
roughly 5% of the all measured ΔDmean or ΔDmax data points were greater than 250 cGy and
2% were greater than 500 cGy. Appendix A provides a closer examination of outlier ΔDmean
or ΔDmax values greater than 500 cGy for the three high-performing methods and greater
than 1000 cGy for PAL_ST_5. In all cases but one, the large dosimetric discrepancy was
caused by disagreement between the ground truth and autosegmented contours about the
slice in which the superior and/or inferior aspect of the contour begins. When the OAR
boundary occurs in a high dose region, the dose differences can be substantial. Even a
difference as small as 3 slices (with 1 mm slice spacing) in one example led to a ΔDmax
value of nearly 800 cGy.
Our results correlating the geometric and dosimetric metrics in Figures 4.7 and 4.8
showed a significant but weak correlation for all metrics (maximum R2 of 0.314).
Correlations were stronger for |ΔDmax| than for |ΔDmean| for each corresponding geometric
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metric, and they were slightly stronger for the distance-based metrics (HD and MSD) than
for the volume-based metrics (DSC and JI). These results are in accordance with similar
studies that have shown that geometric indices are not strongly correlated with various
measures of dosimetric plan quality [216–219], highlighting the need for autosegmentation
methods to be evaluated on dosimetric criteria in addition to geometric criteria [220].
There are a few limitations involved in this study. First, we acknowledge our relatively
small sample size but employed cross-validation strategies where appropriate to maximize
robustness of our results. Also, the physicians who manually contoured the images were
postgraduate year 4 radiation oncology residents. While the inter-observer variability among
this group may be greater than fully board-certified radiation oncologists, the STAPLE
consensus contours used as ground truth in this study were reviewed and approved by two
more experienced observers. Finally, although a variety of DL architectures and parameters
could have been tested, only one DL model was used in this study due to the number of
cross-validation models that had to be created and the long training time for each model.
Thus, the comparison between DL and the various PAL and IPP iterations served as a pilot
study of DL for this particular clinical application, and we anticipate that further refinement of
our DL model and including additional data may improve performance.
In the era of ART, there is still a critical need to develop accurate, fully automated
dose accumulation strategies. Our results demonstrate that several autosegmentation
methods in the ADMIRE platform, particularly DL and IPP_1, are fast and highly accurate on
the low-resolution T2-weighted images used for daily positioning on the MR-linac for head
and neck cancers and can be used to reconstruct daily fraction doses on the anatomy at the
time of treatment. Still, dosimetric accuracy may be compromised if autosegmentation errors
occur in areas with high dose gradients, resulting in dosimetric discrepancies as high as 800
cGy even with these geometrically high-performing autosegmentation methods. As such,
visual inspection and manual contour editing are recommended prior to dose recalculation.
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Alternatively, more efficient solutions have been proposed to automatically detect potential
autosegmentation failures using machine learning models [221–224]. While these tools have
shown promise for detecting autosegmentation errors and minimizing user intervention,
more work is needed at this time to support a fully automated dose accumulation workflow.
Furthermore, next steps to realize an end-to-end dose accumulation solution include
autosegmentation of target volumes [225–228] and validation of methods for deformable
image registration and dose mapping and summation [70, 72], which were beyond the
scope of this paper.

4.5 Conclusion
Our study has demonstrated the feasibility of implementing autosegmentation for
daily dose reconstruction in an off-line dose accumulation workflow for MR-guided RT for
HNC. In the comparison of autosegmentation methods, DL was the fastest and did not
perform significantly differently from IPP methods. While DL was subject to a few geometric
and dosimetric outliers, further optimization of the algorithm and adding more cases may
improve performance. IPP methods performed highly as well with no significant difference in
geometric performance between any methods. Thus, the IPP method with the shortest
execution time, IPP_1, is preferred since adding more fractions did not significantly improve
performance. PAL methods performed the worst in terms of geometric accuracy, dosimetric
accuracy, and execution time and are thus not preferred unless a DL model or prior fractions
from the same patient are not available. Dosimetric analysis revealed that small
autosegmentation error within steep dose gradients may cause large dosimetric
discrepancies, so segmentations should be visually inspected and edited if necessary prior
to dose reconstruction.
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Chapter 5: DWI Pulse Sequence Optimization for Head and Neck on the MR-Linac

The work in this chapter was done in collaboration with Lin Zhu, MD, PhD. I designed
the experimental approach for all aspects of this work, but Dr. Zhu performed the data
collection and analysis for the qualitative image scoring. Data used with permission.

5.1 Introduction
As hybrid MRI-linear accelerator (MR-linac) devices become increasingly prevalent,
there is widespread interest in using quantitative MRI techniques such as DWI to monitor
treatment response and adapt treatment plans [54, 229]. Already, diffusion-weighted
magnetic resonance imaging (DWI) of head and neck cancers (HNC) has been used to
predict response to radiotherapy, identify radioresistant tumor sub-volumes, and guide dose
escalation for adaptive replanning. Integration of DWI into treatment planning has the
potential to allow patients to receive truly personalized radiation therapy that increases dose
to selective areas of disease while sparing normal tissue.
While field strengths of current commercial MR-linac systems are as high as 1.5T,
several challenges exist in acquiring DWIs for head and neck cancer on the 1.5T MR-linac,
including low signal-to-noise ratio (SNR) due to the lack of a dedicated head and neck coil
as well as the reduced gradient strength and slew rate compared to comparable diagnostic
MRI scanners [54]. Thus, DWI sequences need to be optimized specifically for the MR-linac
to account for these design differences and the accompanying loss of SNR.
Single-shot echo planar imaging (EPI) is the fastest and most common DWI readout
method but suffers from geometric distortions and magnetic susceptibility artifacts,
particularly at air-tissue interfaces within the head and neck. Non-echo planar imaging (EPI)
DWI techniques such as turbo spin echo (TSE) can improve spatial accuracy [107, 108,
230] and are thus of particular interest for radiation therapy applications due to requirements
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for geometric accuracy in treatment planning. However, TSE-based DWI sequences
generally exhibit low SNR compared to EPI caused by destructive interference between the
spin echoes and stimulated echoes. An alternative TSE-based sequence called split
acquisition of fast spin-echo signals (SPLICE) acquires and reconstructs the spin echo and
stimulated echo components separately to improve SNR [112, 230]. In this paper, we
optimize TSE and SPLICE DWI sequences on the 1.5T MR-linac.
With the increased prevalence of MR-linac devices, there exists a need to optimize
and standardize pulse sequences for their use. While quantitative metrics such as SNR and
ADC accuracy can be used to compare pulse sequences, these markers often do not tell the
whole story as they rely on voxel-wise calculations. Individual observers can often
distinguish between “good” and “bad” sequences using a holistic approach that takes into
account many different criteria—for example, an optimal sequence may combine relatively
high contrast with few artifacts and less blur. However, visual interpretation alone does not
allow us to identify the parameters that contribute to the quality of various sequences in a
manner that allows us to generalize to future sequence development. In this paper, we
examine how a combination of quantitative and qualitative measures can be used to
thoroughly evaluate pulse sequences to identify the ones that are optimal for use.

5.2 Methods
5.2.1 Imaging Subjects and Informed Consent
This prospective study was performed on two healthy volunteers (both male, ages 22
and 43) who provided written informed consent to participate in this study under a sequence
optimization protocol approved by the MD Anderson Cancer Center Institutional Review
Board.
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5.2.2 Imaging Protocols
Volunteers were imaged on a 1.5T MR-linac (Elekta Unity; Stockholm, Sweden)
equipped with a radiolucent 8-channel body array coil [52]. Volunteers were immobilized in
custom thermoplastic radiotherapy masks to minimize motion. SPLICE and TSE DWI
sequences were optimized systematically in this study by acquiring repetitions of each
sequence with a single parameter changed during each acquisition.
For SPLICE, the TSE refocusing pulse flip angle (hereby referred to as “flip angle”)
was varied between 60° and 100° in increments of 10°. For TSE, the half scan factor
(fraction of k-space acquired) was varied between 0.6 and 0.9 in increments of 0.1. For both
TSE and SPLICE, various fat suppression methods were used: spectral presaturation with
inversion recovery (SPIR), spectral adiabatic inversion recovery (SPAIR), short inversion
time inversion recovery (STIR), and no fat suppression (noFS) [231]. The default fat
suppression method for the SPLICE variable flip angle and TSE variable half scan factor
series was SPIR. For the variable fat suppression series, the default SPLICE flip angle was
90° and the default TSE half scan factor was 0.8. The shorthand naming convention for
sequences is “SPLICE flip 60,” etc. for SPLICE with variable flip angles; “SPLICE SPAIR,”
etc. for SPLICE with variable fat suppression; “TSE half scan 0.6,” etc. for TSE with variable
half scan factors; and “TSE SPAIR,” etc. for TSE with variable fat suppression. The same
SPLICE sequence with a 90° flip angle and SPIR fat suppression was used in both the
variable flip angle and fat suppression series, so it is denoted “SPLICE flip 90 (SPIR)” when
all sequences are listed together. The same convention applies for “TSE half scan 0.8
(SPIR).” Scan parameters for each sequence are in Table 5.1, excluding parameters that
were constant for all sequences. All sequences used a 2-D multi-slice acquisition, 5 mm
slice thickness, 0 mm slice gap, 3 mm acquisition pixel size, 1.5 mm reconstruction pixel
size, 288 (right-left) x 252 (anterior-posterior) x 140 mm (foot-head) field of view, anterior-
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posterior phase encode direction, sensitivity encoding (SENSE) acceleration factor of 2, and
b-values (number of averages) 0 s/mm2 (4) and 500 s/mm2 (12). ADC maps were
reconstructed on the scanner using the b=0 and b=500 images.

5.2.3 In Vivo Quantitative Analysis
Contrast-to-noise ratio (CNR) was quantified by subtracting the mean pixel value of a
region of interest (ROI) in a low-contrast region (posterior neck muscles) from a highcontrast region (parotid glands) and dividing by the standard deviation of pixel values in the
low-contrast region. The parotid gland ROIs encompassed the entire gland on both the left
and right, and the ROIs were combined into a single ROI to measure the mean and
standard deviation. ROIs were drawn on a T2-weighted image acquired during the same
scan session and rigidly copied onto the b=500 images of SPLICE flip 90 (SPIR) and TSE
half scan 0.8 (SPIR). ROIs were manually edited on the SPLICE and TSE to account for
minor geometric distortions, then the SPLICE ROIs were rigidly copied onto the b=0 and
b=500 images of the remaining SPLICE sequences and the TSE ROIs copied onto the
remaining TSE sequences. Because muscle structure boundaries could not be visualized on
DWI, the muscle ROIs drawn on the T2 avoided the edges of the muscles by at least 0.5 cm
to ensure that the ROIs would fall entirely within muscle tissue when transferred to the DWIs
to account for minor distortion.
To quantify differences in ADC estimation among pulse sequences, the parotid gland
ROIs for each sequence were rigidly copied onto the corresponding ADC map. The mean
ADC values were measured for each volunteer.
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Table 5.1: Sequence parameters for all SPLICE and TSE iterations. Abbreviations: TR =
repetition time; TE = echo time; WFS = water-fat shift; BW = bandwidth; TSE = turbo spin
echo; SPLICE = split acquisition of fast spin echo signals; SPIR = spectral presaturation with
inversion recovery; SPAIR = spectral adiabatic inversion recovery; STIR = short inversion
time inversion recovery; IR = inversion recovery; noFS = no fat suppression.
Initial
flip
angle (°)

Refocusing
flip angle
(°)

Half
scan
factor

Fat
suppression

TR (ms)

TE (ms)

Bandwidth:
WFS (pix) /
BW
(Hz/pix)

TSE
factor

Total
scan
duration
(min:sec)

SPLICE
flip 60

90

60

1

SPIR

5338

81

0.424/512.6

42

7:07

SPLICE
flip 70

90

70

1

SPIR

5338

81

0.424/512.6

42

7:07

SPLICE
flip 80

90

80

1

SPIR

5338

81

0.424/512.6

42

7:07

SPLICE
flip 90
(SPIR)

90

90

1

SPIR

5340

81

0.424/512.6

42

7:07

SPLICE
flip 100

90

100

1

SPIR

5340

81

0.424/512.6

42

7:07

SPLICE
SPAIR

90

90

1

SPAIR

7189

81

0.423/513.6

42

9:35

SPLICE
STIR

90

90

1

STIR (IR
delay:
160 ms)

7245

81

0.423/513.6

42

9:40

SPLICE
noFS

90

90

1

none

5099

81

0.423/513.7

42

6:48

TSE half
scan 0.6

90

100

0.6

SPIR

2959

71

0.320/678.2

25

3:57

TSE half
scan 0.7

90

100

0.7

SPIR

3211

71

0.320/678.2

29

4:17

TSE half
scan 0.8
(SPIR)

90

100

0.8

SPIR

3526

71

0.320/678.2

34

4:42

TSE half
scan 0.9

90

100

0.9

SPIR

3778

71

0.320/678.2

38

5:02

TSE
SPAIR

90

100

0.8

SPAIR

5055

71

0.320/678.2

34

6:44

TSE STIR

90

100

0.8

STIR (IR
delay:
160 ms)

5436

71

0.320/678.2

34

7:15

TSE noFS

90

100

0.8

none

3289

71

0.320/678.2

34

4:23
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5.2.4 In Vivo Qualitative Analysis
Using Matlab 2017b (Natick, MA), we developed a graphical user interface via which
expert observers could qualitatively assess the various pulse sequences. Six expert
observers (two radiologists, two radiation oncologists, and two MRI physicists) participated.
First, each participant was asked to score each pulse sequence according to six criteria:
SNR, CNR, peripheral blurring, central blurring, degree of fat suppression, and homogeneity
of fat suppression. Scores ranged from 1 (worst) to 4 (best). Observers were then shown all
fifteen pulse sequences simultaneously and asked to rank them from 1 (best) to 15 (worst).
Participants were asked to score sets of scans obtained from two volunteers and were
blinded to the acquisition parameters for all qualitative assessments. For both the criterion
scoring and pulse sequence ranking tasks, scans were presented to each participant in a
randomized order.

5.2.4.1 Analysis of Ranking Task
We first examined whether expert observers ranked the pulse sequences similarly
across the two sets of volunteer scans. For each set of scans, we calculated a mean rank
for each of the 15 pulse sequences. We then performed a Pearson correlation to compare
the mean ranks across the two sets of volunteer scans.
Next, we looked to see if any sequences were consistently ranked as good or bad by
the expert observers. Under the null hypothesis of no consistency, the rank of each stimulus
should fall within a range centered on the mean rank of 8. Using a bootstrap analysis with
10,000 simulations, we calculated the expected range of rank averages for p<0.01. We
identified good sequences as those whose mean ranks fell below the lower limit of the
calculated rank range, and bad sequences as those whose mean ranks fell above the upper
limit of the calculated rank range.
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5.2.4.2 Analysis of Criterion Scoring Task
For each sequence, we calculated the mean score across expert observers for each
of the six criteria. We then examined whether the best ranked sequences also have the best
criterion scores by calculating the Pearson correlation between mean criterion scores and
average ranks. Pearson correlations were also performed between the quantitative values
and qualitative ranks for both CNR and SNR.

5.2.5 Phantom Analysis
Two replicate scans of each sequence were acquired on a Quantitative Imaging
Biomarker Alliance (QIBA) diffusion phantom (Qalibre MD; Boulder, CO) containing vials
with known ADC values at 0°C. SNR was calculated on the b=0 and b=500 images for each
sequence using the “altSNRnDyn” method from QIBA recommendations [232]: the two
replicate scans were averaged pixel-wise to create the “signal image” and subtracted pixelwise to create the “difference image.” A 1 cm circular ROI was placed in the central phantom
vial in the central image slice for both the signal and difference images. The SNR is
calculated as:
𝑎𝑙𝑡𝑆𝑁𝑅𝑛𝐷𝑦𝑛 = √𝑛

𝑚𝑒𝑎𝑛𝑝𝑖𝑥𝑒𝑙𝑣𝑎𝑙𝑢𝑒𝑜𝑛𝑠𝑖𝑔𝑛𝑎𝑙𝑖𝑚𝑎𝑔𝑒
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛𝑝𝑖𝑥𝑒𝑙𝑣𝑎𝑙𝑢𝑒𝑜𝑛𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑖𝑚𝑎𝑔𝑒

where n is the number of replicate scans used (n=2). 95% confidence intervals for SNR
were calculated as:
1.96

𝑎𝑙𝑡𝑆𝑁𝑅𝑛𝐷𝑦𝑛 √𝑠𝐶𝑉 2 + 𝑛𝐶𝑉 2
√𝑁

where sCV and nCV are the coefficients of variation (standard deviation divided by mean)
within the ROIs placed in the signal and difference images, respectively.
ADC bias was calculated for the central vial (pure water) by calculating the percent
difference between the known ADC value (1127x10-6 mm2/s) and the mean measured value
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within a 1 cm ROI in the central slice. Because QIBA recommendations give a tolerance of
±40x10-6 mm2/s for the central vial, an equivalence test [233] was performed in JMP Pro
(v15.0.0, SAS Institute Inc., Cary, NC) for each scan to compare the distribution of ADC
values in the ROI in the central vial to the known value.
Percent coefficient of variation (%CV), within-subject coefficient of variation (wCV),
and repeatability coefficient (RC) were calculated using an ROI in the central vial. %CV is
the standard deviation of ADC values in the ROI divided by the mean (calculated separately
for each replicate image). wCV is calculated using:
𝑤𝐶𝑉 = 100%

𝜎𝑤
𝜇

where μ is the mean of mean ADC values across replicate scans and σw is the standard
deviation of mean ADC values across replicate scans. RC is calculated using:
𝑅𝐶 = 2.77 ∙ 𝜎𝑤 .

5.3 Results
5.3.1 In Vivo Quantitative Analysis
Representative b=500 images of each pulse sequence are shown in Figure 5.1.
CNR values of each sequence are shown in Figure 5.2. CNR values were similar for the
b=0 and b=500 images of each sequence for TSE, but the b=500 CNR was slightly lower
than the b=0 for most SPLICE sequences. Fat suppression had a greater effect overall on
CNR than flip angle for SPLICE or half scan factor for TSE. noFS had the greatest CNR of
the fat suppression methods for both SPLICE and TSE, while STIR had the second greatest
CNR for SPLICE but the lowest CNR for TSE. For the SPLICE flip angle series, CNR
peaked at a flip angle of 80°. Half scan factor did not impact CNR for TSE.
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Figure 5.1: In vivo b=500 s/mm2 images of each pulse sequence displayed in the same
slice and with the same window/level settings.
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Figure 5.2: CNR values (unitless) for b=0 and b=500 images for the various pulse sequence
series. Dots represent CNR values measured in each volunteer, and bars represent the
mean CNR.
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In vivo parotid gland ADC values are shown in Figure 5.3. In the absence of a
known ground truth value, population mean and standard deviation parotid gland ADC
values from the literature [40, 234–239] are included in the graph for comparison. SPLICE
had higher ADC values overall compared to TSE. For the SPLICE flip angle series, ADC
increased with flip angle for one volunteer but did not show any trends for the other or for
the mean. For TSE, ADC consistently increased with half scan factor. ADC was lowest
without fat suppression in both SPLICE and TSE and was highest with SPIR for SPLICE
and SPAIR for TSE. The parotid gland ADC values from the literature show substantial
variation among sequences; studies that used different pulse sequence parameters on the
same cohort demonstrated that different sequence parameters resulted in significantly
different ADC values [235, 237]. All mean ADC values measured in this study fell within the
range of ADC values reported in the literature.
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Figure 5.3: ADC values measured for parotid glands in this study (blue) and in the literature
(green) [40, 234–239]. For sequences in this study, bars represent the mean ADC value
among the two volunteers, and dots represent the mean ADC of the left and right parotid
glands for each volunteer. In all pulse sequences, the same volunteer had the higher mean
ADC value. For results from the literature, bars and error bars represent population mean
and standard deviation ADC values of the parotid glands, respectively.

110

5.3.2 In Vivo Qualitative Analysis
5.3.2.1 Ranks Across Volunteers
First, we compared mean ranks across the two sets of volunteer scans. Pearson’s
correlation showed that across the two sets of scans, mean ranks were highly correlated
with r = 0.85.

5.3.2.2 Best and Worst Ranks
Next, we examined the ranks of the videos across expert observers to see if any
pulse sequences were consistently ranked “good” or “bad.” Under the null hypothesis of no
consistency, the rank of each stimulus should fall within a range centered on the expected
mean. A bootstrap analysis with 10000 simulated distributions of rank averages showed this
expected range to fall between 5.17 and 10.9 (p<0.01).
Across expert observers, mean ranks for the pulse sequences ranged from 3.17 to
14.17 for volunteer 1 and 5.0 to 12.3 for volunteer 2. Averaging across volunteers, mean
ranks ranged from 4.5 to 13.25. Three pulse sequences, SPLICE flip 90 (SPIR), SPLICE flip
80, and SPLICE flip 60, were observed to have rankings that were significantly lower than
expected (Figure 5.4); the ranks for these “best” pulse sequences ranged from 4.5 to 5.17.
In addition, three pulse sequences, TSE half scan 0.6, TSE half scan 0.7, and TSE STIR,
were observed to have rankings that were significantly higher than expected; the ranks for
these “worst” pulse sequences ranged from 11.0 to 13.25.

5.3.2.3 Criterion Scores
Criterion scores for each sequence are shown in Table 5.2. We examined whether
the best ranked sequences also have the best criterion scores. For each pulse sequence,
we first calculated the mean score across all six criteria. Next, we performed a Pearson test
to examine the relationship between mean criterion scores and average ranks. Our analysis
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showed that the pulse sequences that received the lowest average ranks from the expert
observers (the “best” pulse sequences) also had the highest (best) criterion scores with r =
–0.96. We also performed Pearson correlations between the quantitative CNR values and
qualitative CNR scores and between the quantitative SNR values and qualitative SNR
scores. CNR had a weak correlation with r = 0.39, and SNR had a moderate correlation with
r = 0.70.

Figure 5.4: Bootstrap analysis showing that the expected range of mean ranks falls
between 5.17 and 10.9 (p<0.01). Three sequences had ranks below 5.17 (“best” pulse
sequences) and three sequences had ranks above 10.9 (“worst” pulse sequences). Figure
courtesy of Lin Zhu, MD, PhD, used with permission. (Dr. Zhu analyzed the data and
created the figure.)

112

Table 5.2: Mean criterion scores and ranks for each sequence.

SPLICE
flip 90
(SPIR)
SPLICE
flip 80
SPLICE
flip 60
SPLICE
SPAIR
SPLICE
flip 70
SPLICE
noFS
SPLICE
flip 100
SPLICE
STIR
TSE half
scan 0.9
TSE noFS
TSE
SPAIR
TSE half
scan 0.8
(SPIR)
TSE half
scan 0.6
TSE half
scan 0.7
TSE STIR

SNR

CNR

Degree of
Fat
Suppression

Fat
Suppression
Homogeneity

Peripheral
Blur

Central
Blur

Mean
Score

Average
Rank

2.58

2.58

3.08

2.75

2.58

2.75

2.72

4.50

2.67

2.58

2.83

2.58

2.83

2.83

2.72

5.00

2.67

2.67

2.92

2.92

2.67

2.67

2.75

5.17

2.58

2.75

3.08

2.83

2.83

2.67

2.79

5.75

2.42

2.33

3.08

2.83

2.83

2.58

2.68

6.00

3.25

2.83

1.17

3.17

2.50

2.67

2.60

6.17

2.50

2.83

3.00

2.58

2.50

2.75

2.69

6.25

2.42

2.42

3.25

3.33

2.50

2.67

2.76

6.33

1.92

2.25

3.00

2.42

2.00

2.33

2.32

9.33

2.58

2.42

1.17

2.67

2.25

2.17

2.21

9.33

1.75

2.08

2.83

2.25

2.17

2.00

2.18

9.50

1.83

2.25

2.75

2.50

2.00

1.92

2.21

10.58

1.50

1.75

2.67

2.33

2.00

2.00

2.04

11.00

1.75

1.83

2.83

2.42

2.08

1.83

2.13

11.83

1.33

1.83

3.08

2.83

1.42

1.50

2.00

13.25

5.3.3 Phantom Analysis
SNR values of each sequence are shown in Figure 5.5. For all sequences, SNR was
higher for the b=500 images than for b=0 and higher for SPLICE overall than for TSE. In the
SPLICE variable flip angle series, SNR was highest for 100° and 80° for b=0 and highest for
90° and 100° but lowest for 80° for b=500. For SPLICE fat suppression, STIR had the
highest SNR for both b=0 and b=500, and SPIR had the second highest for b=500 but the
lowest for b=0. In the TSE half scan factor series, SNR of half scan 0.8 was highest for b=0
but lowest for b=500, while SNR of half scan 0.9 was highest for b=500 and second highest
for b=0. SNR of b=0 TSE images did not vary substantially with fat suppression but was
highest marginally for SPIR; for b=500, SNR was highest for SPAIR and lowest for SPIR.
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ADC bias values in the central phantom vial and the results of the equivalence test
are shown in Figure 5.6. All sequences had mean ADC biases within ±40x10-6 mm2/s
(±3.55%) and were not statistically significantly different from the known value (1127x10-6
mm2/s) except SPLICE flip 100 (both scans) and TSE half scan 0.6 (first scan). The lowest
ADC biases (within ±1%) occurred for SPLICE flip 60, SPLICE flip 70, and SPLICE flip 80
(SPIR).
Repeatability metrics are shown in Table 5.3. %CV values were lower overall for
SPLICE sequences than for TSE. All sequences exceeded the 2% QIBA threshold except
for SPLICE flip 90, SPLICE flip 100, and SPLICE STIR. No trends were observed between
SPLICE and TSE for wCV and RC. The ranking of sequences from lowest to highest was
the same for wCV and RC. All RC values met the 15x10-6 mm2/s threshold except SPLICE
flip 70, TSE noFS, and TSE half scan 0.6. Among the four sequence parameters being
optimized (flip angle and FS for SPLICE, half scan factor and FS for TSE), no consistent
trends in the %CV, wCV, or RC values were observed except for TSE half scan factor,
where values generally increased as half scan factor decreased.
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Figure 5.5: SNR values (unitless) for the b=0 and b=500 images for the various pulse
sequence series. Error bars represent 95% confidence intervals.
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Figure 5.6: Mean percent ADC bias for the central phantom vial (pure water) in two replicate
scans. Error bars represent 95% confidence intervals. The dotted lines represent the
tolerance value of ±40x10-6 mm2/s (±3.55%) from the QIBA recommendations. Bars are
marked with * if the distribution of ADC values within the ROI was statistically significantly
different from the known value and tolerance in the equivalence test.
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Table 5.3: Repeatability metrics for phantom acquisitions. %CV values are the mean %CV
values of two replicate acquisitions. QIBA recommended tolerance values are included in
the last row for reference.
SPLICE flip 60
SPLICE flip 70
SPLICE flip 80
SPLICE flip 90 (SPIR)
SPLICE flip 100
SPLICE SPAIR
SPLICE STIR
SPLICE noFS
TSE half scan 0.6
TSE half scan 0.7
TSE half scan 0.8 (SPIR)
TSE half scan 0.9
TSE SPAIR
TSE STIR
TSE noFS

%CV (%)
2.96
2.79
2.66
1.87
1.91
2.27
1.56
2.16
3.06
2.70
2.69
2.84
2.94
3.86
3.31

wCV (%)
0.12
0.72
0.18
0.28
0.26
0.05
0.37
0.23
1.25
0.37
0.29
0.23
0.03
0.08
0.79

RC (x10-6 mm2/s)
3.61
22.51
5.50
8.40
7.69
1.46
11.39
7.14
39.82
11.68
9.09
7.19
0.98
2.46
24.98

5.4 Discussion
As the clinical utilization of MR-linac devices increases, there exists an increased
need to develop high quality pulse sequences that can be standardized across clinical sites.
Pulse sequence optimization can be performed using quantitative analysis of phantom
scans, or with quantitative or qualitative analysis of in vivo scans. While quantitative
assessment of pulse sequences has its advantages—it is easier to directly compare various
sequences using recognized metrics such as SNR or ADC accuracy—these parameters do
not fully capture the advantages or disadvantages of particular scans. In contrast, while
qualitative assessment allows for a more holistic view of a scan’s pros and cons, it becomes
more difficult to identify the exact parameters that make a scan “good” or “bad”.
Furthermore, qualitative assessment depends heavily on the person performing the
assessment: for example, a radiation oncologist may value different criteria compared with a
radiologist or a medical physicist. Our study addresses this issue by examining all three
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types of analyses. We propose that a combination of phantom quantitative assessment as
well as in vivo quantitative and qualitative assessment provides a well-rounded approach to
sequence optimization that can be duplicated for future sequence optimization studies.
Our results demonstrate that the various metrics used for pulse sequence evaluation
in this study did not always agree, which further highlights the need for a well-rounded
assessment of sequences. For example, only a weak correlation was found between the
qualitative CNR scores and the quantitative CNR values in vivo (r = 0.39). Comparing the
SNR measured in the phantoms with the qualitative in vivo SNR rankings, the correlation
was moderate (r = 0.70). In a similar study by An et al. [106] that used both quantitative and
qualitative metrics to compare single-shot EPI vs. multi-shot EPI sequences, the quantitative
and qualitative metrics resulted in opposite conclusions: the observers scored the multi-shot
EPI higher than single-shot EPI across all qualitative criteria, but single-shot EPI had
significantly higher SNR and CNR when measured quantitatively. The authors weighted the
human observer rankings higher than the quantitative measurements when selecting the
sequence with superior image quality.
In this study, no sequence consistently scored best across all metrics in either the
SPLICE flip angle series or the TSE half scan factor series. In the in vivo SPLICE images,
flip angles of 90° and 80° were ranked highest by the observers. The CNR was highest for
80, but differences across flip angles were small. For the phantom metrics, SNR of b=0
images was highest for 100° and 80°, while SNR of b=500 images was highest for 90° and
100°. For ADC accuracy, 60°, 70°, and 80° were all within ±1%, but 90° and 100°
underestimated ADC by roughly 3% and 5%, respectively. For phantom repeatability, 90°
and 100° had the lowest %CV, and 60° and 80° had the lowest wCV and RC. Considering
all of these factors, flip angles of 80° and 90° performed the best. For TSE half scan factors,
the in vivo images with half scan factors of 0.8 and 0.9 were the highest ranked. There were
no substantial differences between half scan factors for CNR. Half scan factors of 0.8 and
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0.9 had the highest phantom SNR values for the b=0 and b=500 images, respectively. There
were no substantial differences in ADC accuracy between half scan factors 0.7, 0.8, and 0.9
(all within 1-2% bias), while 0.6 had a bias of 3% for one of the two scans. In the phantom
repeatability metrics, 0.8 and 0.7 had the lowest %CV, and 0.9 and 0.8 had the lowest wCV
and RC. Overall, half scan factors of 0.8 and 0.9 performed the best.
Fat suppression is an essential component of any DWI sequence because
unsuppressed fat can cause chemical shift artifacts, inaccurate ADC measurements, and
reduced lesion conspicuity [240]. In this study, we investigated three fat suppression
methods–STIR, SPIR, and SPAIR–and included sequences with no fat suppression for
comparative purposes. STIR uses inversion recovery to null signal from fat by using an
inversion time corresponding to the time at which fat has zero net longitudinal magnetization
[241]. However, because the inversion recovery signal from each tissue at the inversion time
depends on their T1 values, STIR nulls signal not only from fat but also from any tissue with
the same T1 value as fat. On the other hand, SPIR and SPAIR selectively null signal only
from fat by using an inversion pulse and spoiler gradient before using an inversion delay
(like STIR) to nullify any remaining fat signal [231]. The difference between SPIR and SPAIR
is that SPIR uses a conventional radiofrequency pulse for the initial inversion pulse, while
SPAIR uses an adiabatic pulse, which can invert spins over a range of frequencies and is
less sensitive to magnetic field inhomogeneities compared to conventional pulses. However,
adiabatic pulses are comprised of complex waveforms and take much longer to apply,
adding a significant time penalty to SPAIR sequences compared to SPIR.
To select an optimal fat suppression method for SPLICE and TSE, we primarily
considered the quantitative and qualitative results from the in vivo images. Because the
diffusion phantom does not contain fat, phantom images alone are not adequate to ascertain
differences in SNR between the sequences. The phantom SNR values can provide
information as to the degree of water signal loss, but they cannot capture the nuances of
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imaging heterogeneous biological systems containing both water and fat with a range of
proton resonant frequencies. For the same reasons, the phantom ADC values did not show
substantial differences between fat suppression methods with the exception of TSE STIR,
but the in vivo ADC measurements had much larger differences in ADC (which were more
substantial than differences due to flip angle or half scan factor). Among the SPLICE fat
suppression methods, STIR had the highest phantom SNR and in vivo CNR but was ranked
the lowest of all SPLICE sequences in qualitative scoring. In contrast, the observers ranked
SPLICE with SPIR (flip angle 90) as the best sequence overall and SPLICE with SPAIR as
the second best of the fat suppression methods (fourth best overall), but SPIR and SPAIR
had the lowest in vivo CNR values of the fat suppression methods. For TSE, SPAIR and
SPIR were ranked the highest among the fat suppression methods by the observers and
also had slightly better in vivo CNR compared to STIR. Despite the discrepancies in
qualitative and quantitative results, we consider SPIR and SPAIR to be the optimal fat
suppression methods in terms of image quality, and we favor SPIR due to the increased
image acquisition time (~2 minutes) with SPAIR.
There were a few limitations to this study. First, our sample size of two volunteers is
very small, and we were only able to include healthy volunteers in our study. However, the
total scan time for all sequences was approximately two hours, and our plans to recruit more
volunteers and patients was interrupted by institutional constraints on clinical research due
to covid-19 protocols. For the qualitative analysis, the sample size was too small to calculate
inter- or intra-observer variability in a statistically significant manner. However, as a
surrogate metric, we correlated the mean ranks of each sequence between the two sets of
volunteer images and found that they were highly correlated (r=0.85). While these limitations
make it difficult to definitively select the optimal sequence parameters, the primary goal of
this paper is to present a framework for sequence optimization that encompasses a wide
variety of factors and may be used in future studies with larger sample sizes. Now that we
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have narrowed down our search space to flip angles of 80 and 90, half scan factors of 0.8
and 0.9, and fat suppression method SPIR as the most favorable sequence parameters,
next steps include acquiring a series of these images on a larger cohort of patients and
using our evaluation framework to select the optimal SPLICE and TSE sequences.

5.5 Conclusion
In this paper, we have presented a pulse sequence optimization framework that
utilizes a combination of quantitative and qualitative metrics using both in vivo and phantom
images. For our use case of SPLICE and TSE DWI pulse sequences, we have found the
optimal sequence parameters to be a flip angle of 80° or 90° for SPLICE, a half scan factor
of 0.8 or 0.9 for TSE, and the SPIR fat suppression method for both SPLICE and TSE when
considering how each sequence iteration performed across all quantitative and qualitative
metrics. Further investigation of these sequences in a larger patient cohort is necessary to
definitively select the optimal sequence parameters.
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Chapter 6: In Vivo Test-Retest Evaluation of DWI Sequences on the
MR-Linac and MR Sim

Supplementary data for this chapter is provided in Appendix B.

6.1 Introduction
Diffusion-weighted imaging (DWI) is a quantitative magnetic resonance imaging
(MRI) technique that measures the diffusion of water through tissues, a surrogate of tissue
cellularity. DWI has many existing and emerging applications for head and neck cancer
(HNC) imaging, including lesion characterization and prediction and assessment of
treatment response [86, 242–245]. In recent years, several studies have focused on
understanding how serial DWI of HNC throughout chemotherapy and/or radiation therapy
(RT) can be used to monitor treatment response and adapt treatments based on individual
response [31, 34, 35, 42–45, 245]. However, longitudinal imaging is burdensome to patients
and clinical staff and is generally not feasible outside of specialized research studies.
The recent clinical adoption of hybrid MRI/linear accelerator (MR-linac) devices has
made it possible to image patients with both anatomical and quantitative MRI sequences
during every RT treatment fraction [177, 246–249]. Furthermore, current MR-linac systems
enable on-line treatment plan adaptation based on daily changes in the size and shape of
the tumor and deformation of surrounding anatomy. With further software development and
extensive validation of quantitative MRI sequences, biological image-guided adaptive RT on
MR-linac systems may become a clinical reality in the near future [229, 250].
Still, hardware modifications of current MR-linac systems to accommodate linear
accelerator integration introduce additional challenges for acquiring robust quantitative MRI
information. The 1.5T MR-linac used in this study employs a split gradient coil design to
allow radiation beam passage, which may contribute to non-linearities of the magnetic field
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gradient closer to isocenter than typically seen in conventional MRI scanners [53, 54]. The
maximum gradient strength (15 mT/m) and slew rate (65 T/m/s) of this system are lower
than conventional MRIs, which necessitates longer diffusion times to achieve the same level
of diffusion weighting (b-value) and reduces the signal-to-noise ratio (SNR) [54]. The
radiolucent 2x4 channel body coil array also reduces SNR compared to other types of
commonly used coils [251]. In light of these challenges, the MR-Linac Consortium has
released guidelines for acquiring DWI on this system [54], which has informed the selection
of sequence parameters used in this study.
Furthermore, in RT, spatial accuracy of images is crucial to ensure the precise
targeted delivery of radiation to the tumor. Single-shot echo planar imaging (EPI), the most
commonly used readout method for DWI, is prone to severe geometric distortions and
susceptibility artifacts, especially in the head and neck [108]. Turbo spin echo (TSE)-based
DWI sequences have been shown to improve spatial fidelity [107, 108] and are thus of great
interest for biological image-guided adaptive RT applications. However, destructive
interference between spin echoes and stimulated echoes can reduce SNR in TSE-DWI. An
alternative TSE-based method, “split acquisition of fast spin echo signals” (SPLICE),
acquires the spin echo and stimulated echo contributions separately to preserve SNR while
maintaining the spatial accuracy of TSE [230].
In this study, we investigate the performance of single-shot EPI, TSE, and SPLICE
DWI sequences on the 1.5T MR-linac and compare them to three DWI sequences on a 1.5T
diagnostic quality MR simulation (MR sim) scanner. The MR sim sequences include singleshot EPI and two additional low-distortion sequences: “BLADE,” which uses a radial blade kspace acquisition, and “readout segmentation of long variable echo trains” (RESOLVE), a
multi-shot EPI sequence. We characterize the repeatability, apparent diffusion coefficient
(ADC) bias, and SNR of these six DWI sequences using data from human papillomaviruspositive (HPV+) oropharyngeal cancer patients, healthy volunteers, and a diffusion phantom.
123

6.2 Methods
6.2.1 Participants and Imaging
Ten HPV+ oropharyngeal cancer patients and ten healthy volunteers were included
in this study. All participants provided written informed consent; patients were consented to
the MOMENTUM observational clinical trial [195] and volunteers to an internal volunteer
imaging protocol, both approved by the institutional review board at MD Anderson Cancer
Center. Inclusion criteria for patients included non-recurrent, histologically confirmed HPV+
oropharyngeal cancer with no prior history of cancer therapy. All imaging occurred between
diagnosis and the start of treatment. Clinical demographics are shown in Table 6.1.
Patients and volunteers were imaged on a 1.5T MR-linac (Elekta Unity; Stockholm,
Sweden) with a 3-D fat-suppressed T2-weighted MRI sequence and three DWI sequences:
EPI, SPLICE, and TSE. Volunteers were also imaged on a 1.5T MR sim (Siemens Aera;
Erlangen, Germany) with a multi-slice fat-suppressed T2-weighted MRI sequence and three
DWI sequences: EPI, BLADE, and RESOLVE. Full sequence parameters are shown in
Table 6.2. The MR-linac acquisitions used a rigid radiolucent 2x4 channel array coil [252],
and the MR sim acquisitions used two 4-channel flex coils. Acquisition times (minutes) were
3.07, 7.38, 4.90, 2.93, 7.13, and 6.75 for EPI (MR-linac), SPLICE, TSE, EPI (MR sim),
BLADE, and RESOLVE, respectively.
The diffusion b-values used were 0, 150, 500 s/mm2 for the MR-linac, 0, 500 s/mm2
for EPI on the MR sim, and 0, 800 s/mm2 for BLADE and RESOLVE. The choice of b-values
for the MR sim was based on scan protocols used in clinical trials at our institution, which
were used in this study without modification. MR-linac b-values were chosen based on the
MR-Linac Consortium’s recommendations [54]: a high b-value of 500 s/mm2 (to keep the
diffusion time similar to the diffusion time on diagnostic systems to preserve SNR) and a low
b-value of 150 s/mm2 (to minimize perfusion contributions to ADC). However, because only
two b-values were used for the MR sim images, ADC maps for the MR-linac images were
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reconstructed only with the 0 and 500 s/mm2 images for direct comparison to the MR sim.
ADC maps were reconstructed using the built-in software on each scanner. A secondary
analysis in Appendix B explores differences in ADC values and repeatability metrics
between ADC maps reconstructed with the 0 and 500 s/mm2 images and the 150 and 500
s/mm2 images.
Each study participant underwent two scan sessions per device (2 total scan
sessions for patients, 4 for volunteers). The first and second time points occurred at least
one day apart, depending on clinical scheduling availability; mean (range) number of days
between scans was 8 (1-15) for patients and 6 (1-21) for volunteers. All participants were
imaged in a custom radiotherapy immobilization mask to minimize motion and ensure setup
repeatability. During each scan session, participants were scanned twice with each DWI
sequence, with a short “coffee break” out of the mask between each set to test short-term
repeatability. One patient did not undergo the second scan session. One patient did not
have SPLICE images acquired during one scan session. One volunteer completed only part
of both second scan sessions (one EPI, SPLICE, and TSE acquired at the MR-linac and one
BLADE acquired at the MR sim).
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Table 6.1: Clinical demographics for patients and healthy volunteers. All patients had nonrecurrent, histologically confirmed HPV+ oropharyngeal cancer.
Characteristic
Sex
Male
Female
Age (years)
Median (range)
Disease sub-site
Tonsil
Base of tongue
T stage
T1
T2
T3
N stage
N1
N2
M stage
M0
Clinical AJCC Stage
I
II

Patients

Healthy
Volunteers

10 (100%)
0 (0%)

7 (70%)
3 (30%)

61 (58-74)

30 (24-43)

4 (40%)
6 (60%)
5 (50%)
2 (20%)
3 (30%)
7 (70%)
3 (30%)
10 (100%)
6 (60%)
4 (40%)
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Table 6.2: Sequence parameters for the six DWI sequences. Abbreviations: EPI = echo
planar imaging; SPLICE = split acquisition of fast spin echo signals; TSE = turbo spin echo;
RESOLVE = readout segmentation of long variable echo trains; SE = spin echo; TGSE =
turbo gradient spin echo; TR = repetition time; TE = echo time; STIR = short inversion time
inversion recovery; SPIR = spectral presaturation with inversion recovery; FS = fat
saturation; WFS = water-fat shift; BW = bandwidth; pix = pixel; SENSE = sensitivity
encoding; GRAPPA = generalized autocalibrating partial parallel acquisition; AP = anteriorposterior; RL = right-left; FH = foot-head; min = minutes; sec = seconds.
*Philips and Siemens report bandwidth differently. We report the vendor-specified values for
easy reproducibility of sequences. **Double refocused, so two TE's
EPI (MRlinac)

Scan type

Single-shot
SE EPI

SPLICE
(MR-linac)
Single-shot
TSE with
split
acquisition
of spin echo
and
stimulated
echo

TSE (MRlinac)

EPI (MR
sim)

BLADE (MR
sim)

RESOLVE
(MR sim)

Single-shot
TSE

Single-shot
SE EPI

Multi-shot
radial TGSE

Multi-shot
SE EPI

TR (ms)

3613

3823

2530

6000

5400

9380

TE (ms)

75

82

72

80

55

63/104*

Refocusing flip angle
(degrees)
b-values (number of
averages)
Half scan/partial Fourier
factor
Fat suppression
Bandwidth**
Philips: WFS (pix)/BW
(Hz/pix)
Siemens: BW (Hz)

N/A

80

100

N/A

120

180

0 (2), 150
(4), 500 (12)

0 (4),150
(6), 500 (12)

0 (4),150
(6), 500 (12)

0 (2), 500
(8)

0 (2), 800
(8)

0.88

1

0.8

0.75

0 (2), 800
(8)
1.5 (BLADE
150%)

STIR

SPIR

SPIR

Spectral FS

Spectral FS

Spectral FS

6.082/35.7

0.722/300.7

0.320/678.2
1132

1220

888

EPI/TSE factor

39 (EPI)

42 (TSE)

34 (TSE)

130 (EPI)

15 (TSE)

Acceleration type (factor)

SENSE
(2.2)

SENSE (2)

SENSE (2)

GRAPPA
(2)

None

Phase encode direction

0.875

96 (EPI - 5
segments)
GRAPPA
(2)

AP

AP

AP

AP

N/A (radial)

AP

300 x 300 x
100

288 x 252 x
100

288 x 252 x
100

256 x 256 x
96

256 x 256 x
96

256 x 256 x
192

Acquisition pixel size (mm)

3.5

3

3

1.97

2

2

Reconstruction pixel size
(mm)

1.6

1.5

1.5

1

1

2

Slice thickness/gap (mm)

4/0

5/0

5/0

4/0

4/0

4/0

Total scan duration
(min:sec)

3:04

7:23

4:54

2:56

7:08

6:45

Field of view (RL x AP x FH)
(mm)
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6.2.2 In Vivo Data Analysis
A radiologist with 5 years of experience segmented the primary tumor and
pathological lymph nodes for patients and parotid glands for volunteers. One patient did not
have an MR-visible primary tumor. A total of 9 primary tumors, 30 lymph nodes, and 20
parotid glands were analyzed. Segmentations were done on the T2 and rigidly copied to the
high-b-value image of each DWI then manually edited to account for any distortion.
Segmentations were rigidly copied to each corresponding ADC map.
Repeatability metrics (short-term and long-term within-subject coefficient of variation
(wCV)) of mean ADC were calculated for each DWI sequence and structure type according
to the Quantitative Imaging Biomarker Alliance (QIBA) consensus recommendations [41,
232]. First, mean ADC values within each structure were extracted for each image. Second,
for each pair of replicate images, the mean and variance were calculated. Next, wCV2 was
calculated for each pair of replicate images by dividing the variance by the square of the
mean. Finally, wCV was calculated by taking the square root of the mean of the wCV2
values. For the short-term wCV calculation, there were two pairs of replicate measurements
per patient/volunteer (two replicate images from the first scan session and two replicate
images from the second scan session). For the long-term wCV calculation, there were also
two pairs of replicate measurements per patient/volunteer (the first image from the first scan
session was paired with the first image from the second scan session, and the second
images from the first and second scan sessions were paired). 95% confidence intervals for
wCV were calculated using a chi-square statistic with n(K-1) degrees of freedom, where n is
the number of sets of replicate measurements and K is the number of repeats [253]. In this
study, K is 2 and n is twice the number of patients/volunteers because two sets of replicate
data points were used per participant.
Bland-Altman analysis was performed between all pairs of DWI sequences to
measure differences in calculated ADC values. For pairs of MR-linac DWI sequences, data
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from both patients (primary tumors and lymph nodes) and volunteers (parotid glands) were
combined. For pairs including at least one MR sim DWI sequence, only data from volunteers
was used because patients were not imaged on the MR sim. Mean difference (bias) values,
95% confidence intervals for the mean differences, and 95% Bland-Altman limits of
agreement were calculated in JMP (v15.0.0; SAS Institute Inc.; Cary, NC, USA) using the
Method Comparison add-in. Bland-Altman analysis was also performed to assess
differences in ADC values between ADC maps reconstructed with b=0,500 s/mm2 and
b=150,500 s/mm2 (Appendix B).

6.2.3 Phantom Data Acquisition and Analysis
ADC bias, wCV, repeatability coefficient (RC), and SNR were calculated for each
sequence using methods described in the QIBA guidelines [41, 232]. Four sequential
repeats of each DWI sequence were acquired of the QIBA diffusion phantom (Diffusion
Phantom Model 128; CaliberMRI; Boulder, CO), which was held at 0° in an ice water bath.
Scans of each sequence were split into different scanning sessions to prevent overheating
of the phantom and loss of thermal equilibrium. A single repeat of each sequence was also
acquired at a separate time point for long-term repeatability measurements.
ADC bias, repeatability metrics, and signal-to-noise ratio (SNR) were calculated
using methods described in the QIBA guidelines [41, 232]. All regions of interest (ROIs)
were circles 1-2 cm in diameter placed in each vial in the central slice of the phantom. ADC
bias was calculated for each vial by measuring the mean ADC value in each ROI and
subtracting the manufacturer-provided known ADC. The within-ROI percent coefficient of
variation (%CV) was calculated using an ROI in the central vial and dividing the standard
deviation within the ROI by the mean and converting to a percentage. This quantity was
calculated for each of the four repeats, and the average value and standard deviation are
reported for each DWI sequence. The within-subject coefficient of variation (wCV) was
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calculated using an ROI in the central vial in each of the four repeats and measuring the
mean ADC value within each ROI. wCV is equal to the standard deviation of the mean ADC
values divided by the mean of mean ADC values and converted to a percentage. The
repeatability coefficient (RC) is equal to 2.77 multiplied by the standard deviation of the
means.
SNR was calculated for each b-value by creating a “signal image,” where each voxel
value is the average voxel value of the four replicate DWIs, and a “temporal noise image,”
where the voxel values are the standard deviation values of the four repeats. Next, an ROI
was placed in the location of the central vial. The SNR is equal to the mean value in the ROI
for the “signal image” divided by the mean value in the ROI for the “temporal noise image.”

6.3 Results
6.3.1 In Vivo ADC Repeatability and Bias
Representative images of the six DWI sequences of a patient and volunteer are
shown in Figure 6.1. In vivo mean ADC values and short-term and long-term wCV values
are shown in Table 6.3. Long-term wCV values were higher than short-term wCV values for
all sequences and structure types. For the MR-linac sequences with which both patients and
volunteers were imaged, both short-term and long-term wCV values were consistently
higher for primary tumors and lymph nodes than for parotid glands. In parotid glands, wCV
values were slightly higher overall for the MR-linac sequences compared to the MR sim
sequences.
Differences in ADC repeatability metrics between ADC maps calculated with b=0,500
and b=150,500 s/mm2 are shown in Table B.1. Mean ADC values were consistently higher
for the b=0,500 ADC maps than for the b=150,500 ADC maps (0.37 mm2/s higher for EPI,
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0.64 for SPLICE, and 0.40 for TSE for primary tumors). Both short-term and long-term wCV
values were higher for the b=150,500 ADC maps in nearly all cases.

Figure 6.1: Representative high b-value images and ADC maps of a patient imaged with
EPI, SPLICE, and TSE on the MR-linac and a volunteer imaged with EPI, BLADE, and
RESOLVE on the MR sim.
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Table 6.3: In vivo mean ADC values and short-term and long-term wCV for each DWI
sequence. Mean ADC values are represented as mean ± standard deviation. wCV values
are represented as wCV (upper and lower 95% confidence interval) and expressed as a
percentage.

Parotid
glands

Primary
tumors

Lymph
nodes

Mean ADC (x10-3
mm2/s)
Short-term wCV
(%)
Long-term wCV
(%)
Mean ADC (x10-3
mm2/s)
Short-term wCV
(%)
Long-term wCV
(%)
Mean ADC (x10-3
mm2/s)
Short-term wCV
(%)
Long-term wCV
(%)

EPI (MRlinac)

SPLICE
(MR-linac)

TSE (MRlinac)

EPI (MR
sim)

BLADE (MR
sim)

RESOLVE
(MR sim)

1.14 ± 0.17

1.20 ± 0.23

0.93 ± 0.18

1.49 ± 0.20

1.14 ± 0.15

1.19 ± 0.16

5.41 (4.42 –
6.97)
6.72 (5.49 –
8.66)

3.83 (3.13 –
4.94)
8.80 (7.19 –
11.34)

5.66 (4.63 –
7.29)
10.03 (8.20
– 12.92)

3.44 (2.81 –
4.43)
5.70 (4.64 –
7.40)

5.04 (4.12 –
6.50)
5.66 (4.62 –
7.29)

4.23 (3.46 –
5.45)
7.36 (5.99 –
9.56)

1.33 ± 0.22

1.80 ± 0.19

1.36 ± 0.19

9.64 (7.23 –
14.45)
10.28 (7.65
–15.64)

7.84 (5.84 –
11.93)
8.96 (6.56 –
14.14)

7.60 (5.70 –
11.40)
11.68 (8.70
– 17.78)

1.38 ± 0.40

1.53 ± 0.36

1.31 ± 0.42

7.80 (6.59 –
9.55)
9.95 (8.37 –
12.25)

7.23 (6.06 –
8.96)
8.48 (7.00 –
10.78)

10.82 (9.15
– 13.25)
10.44 (8.79
– 12.86)

Bland-Altman analysis (Figure 6.2 and Figure B.1) revealed statistically significant
biases for all pairs of DWI sequences except BLADE-EPI (MR-linac) and RESOLVESPLICE. Mean differences between sequences ranged from 0.0004 mm2/s (BLADE-EPI
(MR-linac)) to 0.5566 mm2/s (EPI (MR sim)-TSE). For the MR-linac sequences where both
patient and volunteer data was compared, the SPLICE-EPI and TSE-EPI combinations
showed different behavior among structure types. For SPLICE-EPI, the parotid glands had
differences nearly all between -0.2 and 0.2 mm2/s, while the primary tumors and lymph
nodes had consistently higher values for SPLICE compared to EPI. For TSE-EPI, TSE
measured lower ADC values for nearly all parotid glands compared to EPI, while differences
were centered closer to 0 for primary tumors and lymph nodes.
Bland-Altman plots showing the differences in calculated ADC values between ADC
maps reconstructed with b=0,500 s/mm2 and b=150,500 s/mm2 are shown in Figure B.2.
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Figure 6.2: Bland-Altman plots showing differences in measured ADC values (mean ADC
within each structure) between each pair of the three MR-linac DWI sequences. Mean
differences (MD) are represented by solid red lines with 95% confidence intervals of the MD
represented by dotted red lines. 95% limits of agreement are represented by dotted black
lines. Statistically significant biases are represented by * (p<0.05).
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6.3.2 Phantom ADC Bias, Repeatability, and Signal-to-Noise Ratio
Phantom ADC bias results across the range of phantom ADC values are shown in
Figure 6.3. For all MR sim sequences, the range of ADC bias values fell within ± 0.1 x10-3
mm2/s with the exception of BLADE at 1.127 x10-3 mm2/s. For the MR-linac sequences, EPI
and SPLICE had all ADC bias values fall within ± 0.1 x10-3 mm2/s for the first four vials, but
ADC overestimation occurred for EPI and SPLICE at low ADC values. TSE underestimated
ADC by more than 0.1 mm2/s for all vials except 0.128 x10-3 mm2/s. In general, the MR sim
sequences were more precise than the MR-linac sequences. A similar graph showing the
ADC bias results for each individual vial in the phantom is shown in Figure B.3. This
alternative representation reveals that ADC values for the MR-linac sequences tend to be
consistent for each vial across replicate images but inconsistent across different vials with
the same true ADC value. Differences in phantom ADC bias and repeatability metrics
between ADC maps calculated with b=0,500 and b=150,500 s/mm2 are shown in Figure B.4
and Table B.2.
Phantom ADC bias (in the central vial), %CV, short-term and long-term RC and
wCV, and SNR are shown in Table 6.4. Tolerance values from the QIBA Profile [232] are
also included for reference. All sequences except SPLICE and TSE met the ±40 x10-6 mm2/s
criterion for ADC bias, while SPLICE and TSE had values of -57.4 and -123.0 x10-6 mm2/s,
respectively. For %CV, only EPI on the MR sim and BLADE met the 2% threshold, but all
MR-linac sequences were close (≤3.62%). RESOLVE had a much higher %CV (8.30%). For
short-term RC, all MR-linac sequences and EPI on the MR sim fell under 15 x10-6 mm2/s,
but BLADE and RESOLVE did not (26.88 and 27.93 x10-6 mm2/s, respectively). All
sequences were within the long-term RC limit. All sequences exceeded the SNR threshold
of 50, but EPI had the lowest SNR (87.3 for b=0).
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Figure 6.3: Phantom ADC bias results from replicate image acquisitions. Data points from
multiple vials with the same true ADC value are combined. True ADC values are provided by
the phantom manufacturer.
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Table 6.4: Phantom ADC bias, repeatability metrics, and SNR for each DWI sequence. The
ADC bias and within-ROI %CV are expressed as the mean ± standard deviation of the
values measured in each of the four replicate images. Tolerance values from the QIBA
Profile are included in the last column for comparison.

ADC bias (10-6
mm2/s)
%CV (within-ROI)
Short-term RC
(x10-6 mm2/s)
Short-term wCV
(%)
Long-term RC
(x10-6 mm2/s)
Long-term wCV
(%)
SNR b=0 s/mm2

EPI (MRlinac)

SPLICE
(MR-linac)

26.0 ± 3.8

-57.4 ± 3.0

2.55 ± 0.71
10.65

TSE (MRlinac)

EPI (MR
sim)

BLADE
(MR sim)

RESOLVE
(MR sim)

QIBA
tolerance
values
±40

-15.4 ± 2.4

-0.6 ± 9.7

-23.6 ± 10.1

3.14 ± 0.11

-123.0 ±
1.5
3.62 ± 0.30

1.76 ± 0.12

1.85 ± 0.12

8.30 ± 3.04

2

8.15

4.07

6.67

26.88

27.93

15

0.33

0.28

0.15

0.22

0.86

0.91

N/A

30.50

25.38

2.65

5.49

41.57

4.92

65

0.96

0.85

0.10

0.18

1.36

0.16

N/A

180.5
(168.0 –
193.0)
193.1
(183.6 –
202.6)
184.0
(174.8 –
193.3)
(b=500)

161.3
(146.7 –
175.9)
266.2
(242.2 –
290.1)
261.6
(241.6 –
281.7)
(b=500)

171.0
(160.8 –
181.2)

171.9
(147.5 –
196.3)

130.2
(112.3 –
148.0)

≥ 50 ± 5

N/A

N/A

N/A

N/A

232.2
(222.8 –
241.7)
(b=500)

104.1 (89.4
– 118.7)
(b=800)

97.3 (83.5 –
111.1)
(b=800)

N/A

87.3 (78.6
– 96.1)

SNR b=150 s/mm2

118.9
(102.8 –
135.0)

SNR b=500 s/mm2
or b=800 s/mm2

106.7 (94.6
– 118.8)
(b=500)

6.4 Discussion
The major goals of this study were 1) to compare the performance of DWI on the
1.5T MR-linac with a 1.5T diagnostic quality MR sim in vivo and in phantoms and 2) to select
an optimal DWI sequence for HNC on the MR-linac. To accomplish these goals, we
quantified the ADC repeatability, ADC bias, and SNR of three DWI sequences each on a
1.5T MR-linac and a 1.5T MR sim in vivo and in a phantom.
ADC repeatability has been previously quantified for HNC on diagnostic MRI
systems in a small number of studies. Hoang et al. [26] studied the pre-treatment long-term
repeatability in a mixed cohort of 16 head and neck squamous cell carcinoma (HNSCC)
patients imaged with EPI on a 1.5T GE scanner and found the intra-class correlation
coefficient (ICC) to be 0.99 for primary tumors and 0.86 for lymph nodes. In a study
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examining histogram and texture features of ADC maps of lymph nodes from 9 HNSCC
patients [254], the ICC for mean ADC was 0.79. Other histogram parameters with high ICCs
were median ADC (0.80) and variance (0.93), while maximum ADC, skewness, and kurtosis
had low ICCs (0.46, 0.47, and 0.40, respectively). Paudyal et al. [255] measured the pretreatment short-term wCV as 2.38% for lymph nodes in a mixed cohort of 9 HNSCC patients
imaged with EPI on a 3T Philips MRI. This value is substantially lower than the wCV values
measured for lymph nodes with the three MR-linac sequences in our study (7.80% for EPI,
7.23% for SPLICE, 10.82% for TSE) but is also lower than the values measured for parotid
glands on the MR sim (3.44% for EPI, 5.04% for BLADE, 4.23% for RESOLVE), which may
be attributable to field strength, gradient, and coil hardware differences.
While the current study is the first to measure ADC repeatability for HNC on the MRlinac, repeatability of quantitative imaging biomarkers has been previously quantified on the
MR-linac for other disease sites. Lawrence et al. [248] measured the ADC repeatability of
central nervous system tumors and healthy tissues in the brain on both the MR-linac and a
1.5T diagnostic scanner. Short-term wCV was 1.1% for the gross target volume and 0.9%
for the clinical target volume (measured only on the MR-linac). Long-term wCV values of
healthy tissues ranged from 1.4%-4.8% on the MR-linac and 1.3%-3.7% on the diagnostic
scanner, suggesting that repeatability is comparable between the MR-linac and diagnostic
system. Kooreman et al. [247] assessed the long-term repeatability of intravoxel incoherent
motion parameters in 43 prostate cancer patients on the MR-linac and found the RC of the
diffusion coefficient to be 0.09 x10-3 mm2/s for the non-cancerous prostate and 0.44 x10-3
mm2/s for tumors. Yang et al. [249] showed the feasibility of acquiring DWI in HNC on the
0.35T MR-linac. They did not explicitly calculate repeatability metrics but found the ADC of
the brainstem to be stable (within 0.47-0.57 x10-3 mm2/s) across seven repeat imaging
sessions. These studies demonstrate the robustness of quantitative imaging biomarkers on
the MR-linac, suggesting their potential for longitudinal quantitative imaging and biological
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response-adapted treatments. However, extensive validation of quantitative imaging
biomarkers and standardization of scan protocols across sites is necessary for large-cohort,
multi-center studies [246, 250].
The QIBA Diffusion Profile [232] provides acceptability criteria for phantom metrics,
which are included in Table 6.4 for comparison to measured values. All sequences except
EPI on the MR sim violated at least one tolerance value. However, it is important to note that
these criteria are defined for a specific quality control procedure that uses an EPI sequence
with pre-defined sequence parameters, including b-values of 0, 500, 1000, and 2000 s/mm2.
Thus, these criteria are not directly applicable as hard constraints to evaluate the sequences
used in this paper but may serve as starting points for acceptability criteria that can be
modified based on clinical needs. In particular, the lowest ADC components of the phantom
are best characterized using b=2000 s/mm2; use of lower maximum b-values can result in
higher wCVs [256]. The data collected in this study may serve to inform future versions of
the Profile that account for the use of quantitative DWI in MR-linacs.
For the phantom data, obvious discrepancies exist between the data in Figure 3 and
Table 3. First, the values shown for the 1.127 mm2/s vials in Figure 6.3 and ADC bias in
Table 6.4 do not agree for all sequences. This is because the ADC bias in Table 6.4 was
calculated only using the central vial, as per the QIBA quality assurance guidelines, while
the values for 1.127 mm2/s in Figure 6.3 were calculated using a combination of the central,
inner, and outer vials with the same concentration. Similarly, the short-term RC and wCV,
which are also calculated using only the central vial, are highest for BLADE and RESOLVE,
but BLADE and RESOLVE, along with EPI on the MR sim, actually appear to be much more
precise across all vials. While calculations based on the central vial may be appropriate for
standardized quality assurance procedures with accepted tolerance criteria, analyzing data
from all vials can provide a more complete picture of sequence quality.
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Figure 6.3 shows that the ADC values across the four replicate images are more
precise for the MR sim sequences compared to the MR-linac sequences overall. Figure B.3,
which shows ADC bias values for each vial, reveals that ADC variability among different
vials with the same concentration is greater than ADC variability in the same vial across
replicate images for the MR-linac sequences. In contrast, the MR sim sequences were
generally precise across both replicate images and different vials with the same true ADC
value. These results suggest that spatial inhomogeneities are more significant for the MRlinac compared to the MR sim. Kooreman et al. [54] found similar results in an experiment
where a homogeneous diffusion phantom was scanned on six separate Unity MR-linacs and
a 3T Philips Ingenia MR sim: the MR-linacs showed substantial spatial variations in ADC
that did not improve with gradient nonlinearity correction, while the MR sim was much more
homogeneous. The authors attributed this difference to the split gradient coil design on the
MR-linac, which is necessary to allow the radiation treatment beam to pass through but
induces eddy currents closer to isocenter and thus causes magnetic field inhomogeneities
within the imaging field of view.
Parotid gland wCV values were higher overall for the MR-linac compared to the MR
sim, but differences were not severe and values were within clinically acceptable ranges.
However, the spatial dependence of phantom ADC values was more substantial on the MRlinac, which may have implications for longitudinal in vivo studies as patient anatomy
changes and setup uncertainty increases throughout treatment. Still, these results
demonstrate that in vivo DWI of HNC is possible on the 1.5T MR-linac with acceptable
repeatability and lay the foundation for future clinical studies.
Comparing the MR-linac sequences, EPI and SPLICE had more accurate phantom
ADC values than TSE, with the exception of SPLICE at low ADC values. SPLICE
overestimated ADC values compared to EPI in vivo by a mean of 0.21 x10-3 mm2/s, with
higher differences seen for primary tumors and lymph nodes than for parotid glands. TSE
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underestimated ADC values by 0.1-0.2 x10-3 mm2/s in the phantom and underestimated EPI
by 0.10 and SPLICE by 0.31 x10-3 mm2/s in vivo. For repeatability, SPLICE had the lowest
short-term and long-term wCV values in every case except long-term wCV of parotid glands
and short-term wCV of primary tumors; TSE had the highest overall wCV values. Based on
these data and our clinical preference for a low-distortion DWI sequence, SPLICE is the
optimal sequence for HNC imaging on the MR-linac. However, a disadvantage of SPLICE is
the long acquisition time (7 minutes for 3 b-values).
One surprising result is that the SNR of EPI on the MR-linac (56.5 for b=0) was much
lower than SPLICE (180.5) and TSE (161.3). The most likely explanation for this difference
is that short inversion time inversion recovery (STIR) was used for fat suppression for EPI,
while spectral presaturation with inversion recovery (SPIR) was used for SPLICE and TSE.
STIR uses inversion recovery to nullify fat signal but reduces signal from all tissues,
resulting in low SNR. SPIR uses a spectrally selective inversion pulse to improve SNR from
non-fat tissues [231]. We used the consensus EPI protocol that had been distributed among
MR-Linac Consortium [158] sites without modification for comparison across sites. Because
no consensus SPLICE or TSE protocols existed, these sequences were optimized in-house,
and we chose to use SPIR over STIR to maximize SNR. If SPIR is used for EPI, SNR and
reproducibility would likely improve. However, poor fat suppression in EPI causes large
chemical shift artifacts, while the non-suppressed fat in TSE and SPLICE sequences only
shows a small chemical shift.
One limitation of this study was that clinical scheduling constraints prevented
patients from undergoing two scans each on both the MR-linac and MR sim between the
time of initial simulation and the start of treatment. While patients would provide the most
ideal comparison between the two devices, healthy volunteers were included to assess
differences between the systems in parotid glands. However, data from Table 6.3 and
Figure 6.2 reveal that the repeatability and ADC bias behavior of parotid glands differs from
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that of primary tumors and lymph nodes, so future investigations using patients on both the
MR-linac and MR sim should confirm the findings in this study. Furthermore, the most ideal
comparison between the Elekta/Philips MR-linac and a diagnostic quality MRI scanner
would be to use a comparable 1.5T Philips MRI with the same three DWI sequences.
However, we were limited by the resources in our department and the sequences available
on our 1.5T Siemens MR sim. Finally, we did not formally assess geometric distortion or
distortion correction methods in this study, which are major considerations when selecting
an optimal DWI sequence for radiotherapy applications.

6.5 Conclusion
We have assessed the repeatability, ADC bias, and SNR of DWI sequences on a
1.5T MR-linac and MR sim for HNC both in vivo and in phantoms on the MR-linac and
demonstrated near-comparable performance between the MR-linac and MR sim. These
results show that the MR-linac DWI sequences are robust and worthy of further evaluation
as a quantitative method of assessing treatment response in HNC.
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Chapter 7: Discussion
The MR-linac has transformed the field of radiation oncology by enabling daily online ART, in which the treatment plan is modified while the patient is on the table to account
for changes in patient position, size and shape of tumor, and/or normal tissue deformation.
Over the past three years since the MR-linac’s initial clinical implementation, we have
focused on determining best clinical practices while simultaneously working towards nextgeneration ART methods such as dose-optimized ART using cumulative delivered dose or
biological image-guided ART using quantitative imaging biomarkers. The work in this
dissertation addresses both clinical validation and development of advanced adaptive
methods with HNC as a use case. In this chapter, we will discuss the work done to
accomplish each specific aim as well as future directions in the realm of MR-guided ART for
HNC on the MR-linac.

7.1 Discussion of Specific Aims
7.1.1 Specific Aim 1: Evaluate existing MR-linac clinical workflows for HNC and identify key
areas for further development.
This aim was split into two sub-aims, the first of which was a dosimetric phantom
study on the pre-clinical MR-linac, and the second of which focused on evaluating the
clinical workflow and quality of adaptive treatment plans after the first ten HNC patients were
treated on the MR-linac at our institution.
Chapter 2 detailed the work done for Sub-aim 1-1, “Quantify the magnitude of the
ERE using gel dosimetry,” which was performed under the direction of my first advisor, Dr.
Ibbott. The ERE is a phenomenon caused by Lorentz forces acting on secondary electrons
in the presence of a magnetic field, causing electrons in low-density materials to loop back
around before depositing their full dose. At interfaces of high- and low-density regions, the
ERE causes a relative increase in dose deposited in the high-density material and a relative
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decrease in dose deposited in the low-density material. While this effect has been quantified
using both Monte Carlo simulations and physical phantoms, our study was the first to use a
phantom with a low-density material in which the “cold spot” of the dose distribution could be
measured. We used gel dosimetry, a technique based on the radiation-induced oxidation of
iron and the change in R1 that is linear with dose and can be measured with MRI, to
measure the dose in both the high-density and the low-density gel.
The first part of this study focused on optimizing the formulation for the low-density
gel. We used two types of gel, FXG and FOX, with different sizes of polystyrene beads and
measured the CT number, MR signal intensity, and uniformity of each combination. The
optimal gel formulation was determined to be FXG with <1 mm polystyrene beads because
the uniformity was comparable to conventional gel and the CT number and MR signal
intensity were similar to other low-density formulations (although FXG gels overall had a
higher signal intensity than FOX).
Next, we created dose response curves to compare the change in R1 with the
irradiated dose for conventional FXG and the low-density FXG (with <1 mm beads), which
were both linear. Finally, we irradiated phantoms containing concentric cylinders of lowdensity FXG surrounded by conventional FXG with both a conventional linac and the MRlinac. The phantom irradiated by the MR-linac showed a sharp dose enhancement in the
high-density gel right before the beam entered the low-density gel, as well as a sharp dose
reduction in the low-density gel as the beam exited the low-density gel toward the highdensity gel, indicative of the ERE.
The ERE is an important consideration for treating any body site with air pockets or
other low-density tissues such as lung since secondary electrons passing through air may
be redirected back towards soft tissue. However, in clinical scenarios, multiple beam
directions are used in IMRT treatment plans, which minimizes the impact of the ERE from
any single direction [60, 149, 151]. Monaco, the MR-linac treatment planning system, is able
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to account for the ERE and other impacts of the magnetic field to the dose distribution
through its Monte Carlo dose engine. Our clinical dosimetry team contours air in the body
(such as the oral cavity and sinuses in the head and neck) for manual electron density
assignment when creating a reference plan for the MR-linac. Still, minor setup errors or
changes in the position, size, or shape of air pockets in the body from day to day cannot
completely be accounted for with the ATP workflow. The ATS workflow would enable
recontouring of any air, but depending on the number of air pockets and their geometry, it
can be too time consuming to recontour air while the patient is on the table. Nonetheless, as
with conventional RT, random dosimetric errors are essentially blurred out over the
cumulative dose distribution of all fractions [163], and systematic errors can be addressed
with the ATS on-line workflow. In sum, the overall impact of the ERE is likely to be small for
any individual patient, but it may be considered an additional source of dose uncertainty in
the MR-guided ART process.
Sub-aim 1.2, “Analyze treatment plan quality, setup errors, treatment times, and
dosimetric variability among adaptive plans for HNC patients on the MR-linac,” was
addressed in Chapter 3 of this dissertation. We summarized the initial clinical workflow for
treating HNC on the MR-linac, which has since been iteratively optimized as clinicians
gained more experience with this device and treatment site. In the on-line workflow, the
median (range) times for setup and plan reoptimization, beam delivery, and total treatment
were 31 (20-71), 13 (7-28), and 46 (31-85) minutes, respectively. IMRT QA was performed
daily after each adaptive plan was delivered. The median (range) γ pass rate was 99.9%
(90.9%-100%). The maximum absolute value isocenter shifts were 8.0, 19.7, and 7.3 mm in
the left/right, superior/inferior, and anterior/posterior directions, respectively. Although the
superior/inferior direction had a few outlier isocenter shifts (all occurring for a single patient),
the systematic and random errors were all smaller than 3.3 mm in all three directions.
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These results indicate that setup is reproducible with the thermoplastic mask
immobilization setup over the course of treatment. However, if a large isocenter shift is
observed, the Unity on-line adaptive workflows are able to account for positional changes.
While the treatment times, IMRT QA pass rates, and isocenter shifts have not been
reanalyzed with a larger cohort now that we have treated many more HNC patients on the
MR-linac, it would be interesting to see whether these values have improved over time as
clinicians gain more experience or whether the reported values are truly indicative of the
errors anticipated for HNC patients using our immobilization setup. Also, given the high and
consistent IMRT QA pass rates, it is worth considering whether IMRT QA needs to be
performed for every single adaptive plan. To ease burden on physicists without
compromising on safety, some MR-linac partner sites have adopted various schemes to
determine the optimal frequency of IMRT QA measurements, such as only performing IMRT
QA for ATS plans or performing it on only the first two treatments [257].
Next, we accumulated the doses over all adaptive plans for each patient using a rigid
registration-based plan summation method. Total dose to the CTV was highly consistent
(within -0.6% to 1.8% of the reference plan doses), while the total doses to OARs were
lower than the reference plan in the majority of cases. The highest OAR dose increase was
8% (spinal cord), while the greatest OAR dose decrease was -12% (ipsilateral cochlea). The
clinical ART intention for these cases was what Heukelom and Fuller [73] define as an
“ARTex_aequo” approach, in which the goal is to use ART to deliver doses consistent with the
pre-RT planned dose as the anatomy changes. Even though the intention was not
specifically to reduce OAR doses, these results suggest that our current HNC MR-linac
workflow enables the delivery of consistent CTV doses and has the potential for OAR dose
sparing. OAR doses could be reduced further by using a more aggressive OAR-sparing ART
approach and/or by optimizing each adaptive treatment plan based on the cumulative dose
delivered until that point.
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It is important to note that this dosimetric analysis was performed using a rigid
registration-based rather than deformable registration-based plan summation approach,
which was necessary due to the lack of a fully-validated, end-to-end DIR-based dose
accumulation tool. As the development of such a tool is the focus of Specific Aim 2 and a
“next step” following this project, it will be worth reexamining the delivered doses for this
cohort after a DIR-based tool is available to see if these results are maintained.
We also evaluated how often a single plan constraint failed for an adaptive plan.
Most HNC treatments use a large number of OAR constraints compared to other treatment
sites, and most treatments are delivered in 24-33 fractions, depending on the diagnosis.
Thus, it can be difficult to meet every single plan constraint for every adaptive plan, and it is
currently unclear when it is worth going through the entire plan adaptation process again
while the patient is on the table to try to improve the plan. We analyzed the frequency of
plan constraint failures and their impact on the cumulative dose. All patient cases had at
least two fractions with one or more constraint failures. In nearly all cases, if a constraint
was met in the reference plan, then it was also met in the summation plan despite multiple
constraint violations. Similarly, if a constraint was not met in the reference plan, then it was
also not met in the summation plan. Our results suggest that plan constraint failures are
typically random errors that do not have a major impact on the cumulative dose. Any
systematic errors (i.e. repeated violations of the same constraint) can be accounted for
using ATS. However, as with dose accumulation, there are currently no tools in Monaco to
track the history of constraint failures; the addition of such a tool would improve the process
of deciding whether to re-optimize the plan with the patient on the table or to move ahead
with treatment.
Finally, we evaluated the accuracy of the DIR-based contour propagation tool in
Monaco using both CT-to-MR and MR-to-MR registration. MR-to-MR improved the average
segmentation quality compared to CT-to-MR, which favors the use of the MR sim for
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creating the initial reference plan. However, the MR-to-MR contours’ DSC and MSD values
were more variable than for CT-to-MR, suggesting that neither DIR method is robust enough
to use without manual modification of the contours. The lack of a high-performance
autosegmentation tool in Monaco is the major limiting factor preventing our clinic from
performing high-frequency on-line ATS. These results led to the work performed in Specific
Aim 2-1, which focused on autosegmentation of the daily setup MRIs from the MR-linac.
Despite the improvement seen in DSC and MSD values for certain autosegmentation
methods in Chapter 4, these algorithms are not currently implemented into Monaco and thus
will not improve the on-line clinical workflow.

7.1.2 Specific Aim 2: Develop and validate a procedure for daily dose reconstruction for the
MR-linac Adapt to Position workflow.
Specific Aim 2 was the focus of Chapter 4 of this dissertation, in which we evaluated
various autosegmentation methods for Specific Aim 2-1 (“Determine the optimal method for
autosegmentation of OARs on T2-weighted MRIs used for daily positioning on the MRlinac”) and used the results of select autosegmentation methods to reconstruct the dose
from the ATP plans for Specific Aim 2-2 (“Evaluate the accuracy of off-line dose
reconstruction using autosegmented structures on MRIs”). Three major classes of
autosegmentation approaches were investigated: population atlas library (PAL), which is
atlas-based autosegmentation using atlases from a variety of patients different from the
image being segmented; individualized patient prior (IPP), which is atlas-based
autosegmentation using atlases from the same patient’s prior treatment fractions; and deep
learning (DL), in which a DL model is trained using images from a variety of patients
different from the image being segmented. For PAL and IPP, three different label fusion
methods were used—STAPLE (ST), patch fusion (PF), and random forest (RF)—and
different numbers of atlases. (The naming convention is described in Chapter 4; briefly,
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each PAL and IPP iteration is abbreviated by appending the label fusion method and
number of atlases, separated by an underscore, such as IPP_RF_2.) The results of each
autosegmentation method were compared to ground truth contours using various similarity
and overlap indices. The values of these metrics for each method were compared against
the inter-observer variability of seven observers and against each other in pair-wise
comparison. The execution time of each autosegmentation method was also measured.
Next, four autosegmentation methods (DL, IPP_1, IPP_RF_4, and PAL_ST_5) were
selected based on geometric performance and feasibility to be evaluated in the dosimetric
analysis. ATP plan doses were reconstructed on the daily setup MRIs, which were
segmented using each of the four methods. Differences in mean and maximum dose to
each structure were measured compared to the doses reconstructed on the same images
using the ground truth contours.
The quantitative comparison of IPP, PAL, and DL autosegmentation methods
demonstrated that DL and IPP_1 both offer the best balance between accuracy and
execution time. Given highly curated, accurate initial contours, IPP_1 provides the most
robust results in terms of both geometric and dosimetric accuracy but takes two minutes per
case. The use of additional atlases did not significantly improve performance in IPP. DL is
the fastest method (30 seconds per case) and offers comparable geometric performance to
all IPP methods. Unlike IPP, which will propagate any errors in the initial segmentation, DL
does not require prior segmentations from the same patient but comes at the expense of
somewhat random geometric and dosimetric outliers. Although DL is less robust than IPP,
further parameter optimization and inclusion of more cases may improve performance.
Furthermore, PAL methods demonstrated the worst overall geometric performance, largest
dosimetric errors, and longest execution times (4-14 minutes), so use of PAL should be
reserved for cases where DL models or prior segmentations are not available. Finally,
results from the dosimetric analysis show that even small errors in autosegmentation may
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substantially impact the calculation of the delivered dose if the region of autosegmentation
failure occurs in a steep dose gradient. Thus, contours should always be visually inspected
prior to dose recalculation and manually edited when necessary to ensure robust and
accurate dose accumulation.
As discussed in the Dose Accumulation section of Chapter 1 (Section 1.4), two
additional steps in a dose accumulation workflow are recommended when accumulating
doses from ATP fractions because the ATP doses are calculated on the image associated
with the reference plan rather than the setup image corresponding to the anatomy during the
treatment. While day-to-day anatomical changes may be smaller for HNC patients compared
to other treatment sites such as the abdomen or pelvis, many head and neck tumor types,
particularly human papillomavirus-positive (HPV+) oropharyngeal cancer (OPC), show
substantial volumetric shrinkage during the course of RT [258]. RT for HNC is also wellknown to cause shrinkage of the parotid glands [259] and interstitial edema [260] during RT,
leading to deformation of the surrounding normal tissues. Thus, in order to accurately
accumulate dose for HNC patients treated with ATP on the MR-linac, it is important to
reconstruct the delivered dose on the anatomy at the time of treatment. This can be
accomplished using the workflow described in Chapter 4 using one of the optimal
autosegmentation methods, DL or IPP_1. Until these or similar algorithms can be
incorporated into the treatment planning system for use in the ATS workflow, the doses will
have to be reconstructed off-line after delivery of an ATP plan.

7.1.3 Specific Aim 3: Develop a robust DWI scanning protocol on the MR-linac for HNC.
As we move toward the advanced ART strategy of biological image-guided ART
using DWI, a lot of preliminary work is necessary to ensure that the DWI sequence used for
response assessment and adaptation is robust and fully validated. The differences in MRI
hardware components between the MR-linac and conventional diagnostic MRI scanners,
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such as the split coil design, reduced gradient amplitude and slew rate, and the low-SNR
receive coil [49, 50, 52–54], all introduce challenges in acquiring quantitatively accurate and
reproducible DWIs on the MR-linac. Consequently, DWI sequences must be optimized
specifically for the MR-linac and their baseline quantitative accuracy and repeatability
formally assessed. These topics are the focus of Specific Aim 3, with Chapter 5/Specific Aim
3-1 (“Optimize DWI pulse sequences on the MR-linac for HNC using phantom and in vivo
measurements”) focused on sequence optimization and Chapter 6/Specific Aim 3-2
(“Benchmark DWI image quality through quantitative evaluation of ADC estimation accuracy,
signal-to-noise ratio, and ADC repeatability and comparison to a diagnostic MRI scanner”)
focused on technical validation of the optimized sequences.
In Chapter 5, we optimized the TSE and SPLICE sequences using a systematic
approach with both quantitative and qualitative evaluation. We imaged volunteers and
phantoms with a series of SPLICE sequences with variable flip angles and fat suppression
methods and a series of TSE sequences with variable half scan factor and fat suppression
methods. Contrast-to-noise ratio (CNR) was calculated on the in vivo images by subtracting
the mean pixel value of a region of interest (ROI) in a low-contrast region (neck muscle)
from a high-contrast region (parotid glands) and dividing by the standard deviation of the
low-contrast region. Signal-to-noise ratio (SNR), ADC bias, and various repeatability metrics
were calculated by acquiring the same series of sequences on the Quantitative Imaging
Biomarker Alliance (QIBA) diffusion phantom. For qualitative evaluation, six expert
observers were shown each in vivo image in a random order, blinded to the acquisition
parameters, and asked to score each image on various criteria and rank each image from
best to worst.
Among all the metrics used to score the various SPLICE and TSE sequences, no
sequence consistently performed the best. The quantitative and qualitative metrics did not
always agree. For example, when we performed a Pearson correlation between the CNR
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values measured quantitatively on the in vivo volunteer images and the qualitative CNR
scores provided by the observers, there was only a weak correlation (r = 0.39). The
qualitative SNR scores and quantitative phantom SNR values had a moderate correlation (r
= 0.70). However, looking at all performance metrics combined, we were able to identify two
best-performing flip angles for SPLICE (80° and 90°) and half scan factors for TSE (0.8 and
0.9). For fat suppression, we weighted the phantom data less heavily in our assessment
compared to the in vivo data because the phantom does not contain any fat. Overall, SPIR
and SPAIR performed best, but SPIR was preferred because the acquisition time of the
SPAIR sequences was at least two minutes longer than the corresponding SPIR sequences.
Ultimately, we chose our optimal sequences to be SPLICE with a flip angle of 80° and SPIR
fat suppression and TSE with a half scan factor of 0.8 and SPIR fat suppression.
Using the optimized TSE and SPLICE sequences, we undertook an in vivo testretest study in Chapter 6 (Specific Aim 3-2) to measure the short-term and long-term
repeatability of these sequences and compare them to an EPI sequence on the MR-linac
and three additional sequences on a 1.5T MR sim. Because our ultimate goal is to use
measured changes in ADC of the tumor to assess response to RT, a test-retest study is a
crucial component of the sequence validation process. The purpose of a test-retest study is
to determine the threshold of change in ADC that can be interpreted as reflecting a
statistically significant biological change as opposed to imaging and/or biological noise. The
Quantitative Imaging Biomarker Alliance (QIBA) has published consensus recommendations
for the appropriate methodology and analysis procedures for such studies [41, 232],
including calculation of the within-subject coefficient of variation (wCV), which we have
followed in the execution of this study.
In this study, we imaged ten HPV+ oropharyngeal cancer patients on the MR-linac
and ten healthy volunteers on both the MR-linac and a 1.5T MR sim. Participants were
scanned with each DWI sequence twice during each scan session to measure short-term
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repeatability, and participants underwent two scan sessions on each device to measure
long-term repeatability. Because a true test-retest study requires all repeat scans to occur in
a time frame with no expected biological change [41], all patient scans occurred between
the time of diagnosis and the start of treatment. Unfortunately, this narrow time frame made
it impossible for us to scan patients twice each on both the MR-linac and MR sim, so we
included the ten healthy volunteers for the comparison between the MR-linac and MR sim.
Mean ADC values of the primary tumor and lymph node were assessed for patients, and
mean ADC values of the parotid glands were assessed for volunteers.
We used three DWI sequences on the MR-linac and three on the MR sim. The MRlinac sequences were TSE and SPLICE, which were optimized in Chapter 5, and EPI, which
was optimized at another MR-Linac Consortium partner site and distributed to Consortium
members as the consensus protocol [54]. On the MR sim, we used EPI, BLADE, and
RESOLVE sequences and used the specific protocols that have been optimized for our
institution’s HNC clinical trials. The details of these sequences are summarized in Section
1.5.2.1 and Table 1.1, and the acquisition parameters are provided in Table 6.2. In addition
to the in vivo component of this project, we also performed technical validation of each
sequence with the QIBA diffusion phantom. We measured ADC bias compared to the
ground truth phantom ADC values, SNR, and ADC repeatability in the phantom. The primary
goals of this study were to compare the performance of the MR-linac to the MR sim in terms
of DWI accuracy and robustness and to select the best DWI sequence to use for response
assessment and biologically-guided ART on the MR-linac.
From the in vivo volunteer data, the short-term and long-term repeatability (wCV)
values were slightly higher for the MR-linac compared to the MR sim overall but were still
within a comparable range. Higher wCV values mean that the mean ADC values are less
reproducible/more variable. These results are expected due to the many previously
discussed factors that lead to the MR-linac having lower baseline SNR compared to
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diagnostic MRI systems and the corresponding loss of quantitative accuracy with poor SNR
[261]. However, the fact that the wCV values of the MR-linac sequences were not
substantially higher than those of the MR sim sequences indicates that our sequence
optimization efforts in Chapter 5 produced sequences that are almost as robust as those on
a 1.5T MR sim.
Comparing the three MR-linac sequences using both the patient and volunteer data,
SPLICE had the lowest wCV values for most of the comparisons (short-term and long-term
wCV of parotids, tumor, and nodes) and TSE the highest. However, the wCV values were
not too different from each other, with the range of values across any single comparison
typically within 3%, so it is difficult to definitively choose an optimal sequence from this data.
We expected EPI to perform the best because EPI is known to have higher baseline SNR
compared to TSE-based DWI sequences [262]. However, in our phantom data, EPI had a
significantly lower SNR compared to SPLICE and TSE. Many sequence parameters beyond
the signal acquisition method impact SNR; when TSE-based sequences are optimized to
improve SNR, they can achieve higher SNR than EPI [263, 264]. In this study, we used the
Consortium-provided EPI sequence without optimizing it further, which meant that there
were several differences in the sequence parameters between the EPI and our TSE and
SPLICE optimized in-house. In particular, the number of averages for the b=0 images (2 for
EPI compared to 4 for TSE and SPLICE) and the fat suppression methods (STIR for EPI
compared to SPIR for TSE and SPLICE) contributed to the low SNR of the EPI sequence.
As discussed in Chapter 5, STIR provides more homogeneous fat suppression but also
suppresses signal from water in tissues with T1 values similar to that of fat, resulting in lower
SNR. However, the justification for using STIR in the EPI sequence is that chemical shift
artifacts caused by poorly suppressed fat are much more substantial than in SPLICE or
TSE.
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Both the in vivo and phantom data revealed biases in ADC values between the
different DWI sequences. In vivo mean biases between pairs of the MR-linac sequences
ranged from 0.10 to 0.31 x 10-3 mm2/s, and mean biases between all pairs of the six DWI
sequences ranged from 0.00 to 0.56 x 10-3 mm2/s. In the phantom, ADC biases from the
known ADC value as calculated in the central phantom vial were all within ±0.12 x 10-3
mm2/s, and all except for TSE and SPLICE fell within the QIBA tolerance value of 0.04 x 10-3
mm2/s. Although the tolerance was exceeded for TSE and SPLICE, the actual values of the
ADC measurements are arguably less important than the repeatability of the values. This is
because several studies that use DWI for longitudinal assessment have found that percent
changes are a more reliable predictor of response than the actual ADC values at any single
time point [32, 103]. As long as consistent sequence parameters are used and data from
multiple sequences are not combined in a single study, any of these MR-linac sequences
may be sufficiently robust for response assessment purposes.
One of the major goals of this study was to select an optimal DWI sequence for the
MR-linac. SPLICE and TSE are preferred over EPI due to their improved spatial accuracy
compared to EPI. Although geometric distortion was not explicitly evaluated in this
dissertation, visual inspection of the images and several previous studies have shown that
SPLICE and TSE offer a clinically significant improvement in geometric accuracy compared
to EPI [107, 108, 230]. In Chapter 6, SPLICE demonstrated superior repeatability compared
to TSE, and in Chapter 5, the expert observers ranked all iterations of the SPLICE sequence
higher than all iterations of the TSE sequence. For these reasons, we believe that SPLICE
is the best sequence to use moving forward with the next steps toward biological imageguided ART.
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7.2 Future Directions
The next steps for this project can be divided into three major categories: 1)
refinement of the current anatomical MR-guided ART workflow for HNC on the MR-linac; 2)
dose accumulation for MR-linac HNC treatments and dose-optimized ART; and 3) treatment
response monitoring and biological image-guided ART using DWI for HNC. As the clinical
utilization of the MR-linac expands worldwide, we are actively working with collaborators
within the MR-Linac Consortium to both improve the existing workflows and perform the
necessary technical validation to usher these advanced adaptive strategies into clinical
practice. Furthermore, the work completed in this dissertation lays the groundwork for future
technological development and scientific studies that will be completed in collaboration with
Elekta and Philips through our lab’s academic-industrial partnership R01 grant. Through this
joint effort, we have the capacity to build research-grade solutions that are compatible with
the MR-linac treatment planning system and prototype advanced adaptive workflows for
evaluation through in silico planning studies.

7.2.1 Refinement of the Current Anatomical MR-Guided ART Workflow for HNC on the MRLinac
As discussed in Chapter 3, the lack of a fast and accurate autosegmentation
algorithm in the MR-linac treatment planning system is a significant bottleneck in the on-line
ATS workflow. We have shown in chapter 4 that other algorithms, particularly the 3-D
ResUNet deep learning framework that we investigated, are fast and robust for
segmentation of OARs in the head and neck on the MR-linac setup images. Since the
completion of that project, we have treated dozens more HNC patients on the MR-linac at
MD Anderson and plan to update our deep learning model with additional training data and
a wider range of OARs. Although any research-grade autosegmentation algorithms cannot
be implemented into the on-line clinical ATS workflow, we are working with Elekta to provide
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curated data through the MOMENTUM observational clinical trial database [195] to serve as
training data for a potential industry-supported deep learning autosegmentation tool.
As discussed in Section 7.1.1, our ART intent, as classified by Heukelom and Fuller
[73], was ARTex_aequo, in which the goal is to modify the treatment plan as the anatomy
changes to maintain the pre-therapy planned target volume and OAR doses. Other ART
strategies are possible with the current MR-linac technology and treatment planning system,
such as ARTOAR (where the CTV shape and dose are maintained but OAR doses are
actively reduced) or ARTreduco (where the CTV is shrunk for on-treatment responders with the
ultimate goal of reducing OAR doses). Our lab has recently begun the second phase of the
MR-ADAPTOR clinical trial [47] for HPV+ oropharyngeal cancer patients treated on the MRlinac. Patients are randomized to standard IMRT or weekly plan adaptation using an
ARTreduco approach on the MR-linac. The endpoints of this study are to see whether this
novel dose de-escalated treatment method will result in equivalent locoregional control as
standard IMRT and if it can reduce side effects for patients. With the development of a dose
accumulation tool to assess delivered doses for patients on this study, it will be very
interesting to see the extent to which this ARTreduco strategy can reduce OAR doses and how
the delivered OAR doses correlate with various side effects.

7.2.2 Dose Accumulation for MR-Linac HNC Treatments and Dose-Optimized ART
As discussed in Section 1.4, a typical dose accumulation pipeline involves DIR to
generate a geometric transformation between a set of planning images, then that same
transformation is applied to one of the dose maps to map it into the frame of reference of the
other time point so that the doses can be added voxel-wise. We added an additional two
steps to this workflow for the MR-linac ATP plans in which each daily dose distribution is
reconstructed on the corresponding setup image, which was the focus of Specific Aim 2/
Chapter 4. We evaluated the autosegmentation algorithms available in Elekta’s ADMIRE
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software with the ultimate goal of using ADMIRE to create a fully automated end-to-end
dose accumulation workflow that is compatible with the research version of Monaco (the
MR-linac treatment planning system). Members of our lab and our collaborators at Elekta
are actively working on this tool. Our next steps with this project are to validate the
remaining steps of the workflow, including deformable image registration for dose mapping
and dose summation.
Once this tool is completed and validated, there are a number of potential studies we
plan to undertake as next steps. First, we would like to quantify the differences between the
accumulated delivered dose and the planned dose or our rough estimate of delivered dose
using the rigid registration-based plan summation method used in Chapter 3. I am also
interested in investigating whether the existing normal tissue complication probability
(NTCP) models for various OARs, which are based on planned dose, remain accurate for
delivered dose or whether they need to be revised. Another avenue to explore with this dose
accumulation tool developed in partnership with Elekta would be to incorporate it into
Research Monaco and create a method to optimize treatment plans based on the dose
delivered before each fraction. A tool like this would require a strong informatics pipeline to
keep track of the accumulated for every fraction so that we can spare OARs that have
repeatedly received high doses in previous fractions. We would perform in silico treatment
planning studies using this dose-optimized ART approach before ultimately testing it in
clinical trials.

7.2.3 Treatment Response Monitoring and Biological Image-Guided ART using DWI for
HNC
Now that we have selected our optimized SPLICE sequence as the best DWI
sequence on the MR-linac, the next step would be to acquire daily or weekly SPLICE
images in a large cohort of HNC patients on the MR-linac and assess changes in ADC
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values of tumors and normal tissues over the course of RT. Such a study would help us
understand the magnitude and timeframe of ADC changes expected during RT and show
differences between responders and non-responders.
This information will allow us to design further studies to evaluate the optimal
biological image-guided ART strategy for HNC patients on the MR-linac, whereby the dose
is adapted based on biological tumor response as measured by changes in ADC. Possible
adaptive approaches would be dose escalation or de-escalation to the whole CTV or dose
escalation to non-responding tumor sub-volumes using dose painting [44, 46]. Similar to the
dose-optimized ART approach discussed previously, necessary steps to achieve biological
image-guided ART are the development of tools within the treatment planning system to
support this strategy followed by in silico planning studies and clinical trials. Through our
collaboration with Elekta, we have already enabled Research Monaco to be able to read
DWIs and ADC maps and have created a tumor sub-volume thresholding tool based on
ADC values. Future work includes the development and technical validation of a dose
painting optimization algorithm within Research Monaco.

Conclusion
The work in this dissertation has demonstrated the initial clinical feasibility of treating
HNC on the MR-linac and has laid the foundation to move towards advanced adaptive
strategies with this device. Further technological development of dose accumulation and
biological image-guided ART will expand the capabilities of the MR-linac so that we can
deliver truly personalized RT for each individual HNC patient.
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Appendix A: Supplementary Data for Chapter 4

In this section, we will explore the causes of major dosimetric discrepancies between
plans recalculated with the ground truth contours and the same plans recalculated with
various autosegmented contours. We will look at cases where a dosimetric discrepancy was
greater than 500 cGy for the three high-performing autosegmentation methods (IPP_RF_4,
IPP_1, and DL) and greater than 1000 cGy for the low-performing autosegmentation method
(PAL_ST_5).

Note: In all figures shown below, the spacing between slices is 1 mm.
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1. Case 1 (larynx), DL, Dmax of Brainstem
Dmax of Brainstem is 3540.0 cGy with ground truth contours and 2923.0 cGy with DL
contours (ΔDmax = -617.0 cGy). The DSC, MSD, HD, and JI of the DL Brainstem and ground
truth Brainstem contours were 0.962, 0.439 mm, 5.122 mm, and 0.927, respectively.

Figure A.1: The discrepancy in the Dmax value of the brainstem is caused by disagreement
over the slice in which the inferior aspect of the brainstem contour begins. In the ground
truth segmentations, the spinal cord ends on slice 229, and the brainstem begins on slice
230. The DL model ended the spinal cord segmentation on slice 232 and began the
brainstem segmentation on slice 234. The border of these two contours occurs in a steep
dose gradient, resulting in an underestimation of the brainstem Dmax with the DL contours.
Nonetheless, both Dmax values (3540 cGy for ground truth, 2923 cGy for DL) are much lower
than the clinical dose constraint of Dmax < 5400 cGy, so this difference would not change the
acceptability of this plan from a clinical standpoint.
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2. Case 3 (left true vocal cord), DL, Dmax of Parotid_L
Dmax of Parotd_L is 1443.0 cGy with ground truth contours and 657.8 cGy with DL
contours (ΔDmax = -785.2 cGy). The DSC, MSD, HD, and JI of the DL Parotid_L and ground
truth Parotid_L contours were 0.862, 1.164 mm, 6.645 mm, and 0.757, respectively.

Figure A.2: The discrepancy in the Dmax value of the Parotid_L is caused by disagreement
over the slice in which the inferior aspect of the Parotid_L contour begins. The Parotid_L
contour begins in slice 190 in the ground truth segmentation and slice 193 in the DL
segmentation. In both cases, the Dmax to Parotid_L is relatively low; in our clinical practice,
we use a dose constraint of Dmean < 2600 cGy for the parotid glands, and the Dmax value is
lower than this threshold in both cases. However, the position of the Parotid_L contour just
superior to the high dose region makes this dose discrepancy quite large, even though
either recalculated dose would be considered low enough that the difference between Dmax
of 1443 cGy and 658 cGy would not change the acceptability of this plan from a clinical
standpoint.
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3. Case 3 (left true vocal cord), PAL_ST_5, Dmax of Parotid_R
Dmax of Parotid_R is 1057.1 cGy with ground truth contours and 2133.4 cGy with
PAL_ST_5 contours (ΔDmax = 1076.3 cGy). The DSC, MSD, HD, and JI of the PAL_ST_5
Parotid_R and ground truth Parotid_R contours were 0.731, 2.297 mm, 26.058 mm, and
0.576, respectively.

Figure B.3: The discrepancy in the Dmax value of Parotid_R is caused by disagreement over
the slice in which the inferior aspect of the Parotid_R contour begins. The Parotid_R contour
begins in slice 189 in the ground truth segmentation and slice 184 in the PAL_ST_5
segmentation. In both cases, the Dmax to Parotid_R is relatively low; in our clinical practice,
we use a dose constraint of Dmean < 2600 cGy for the parotid glands, and the Dmax value is
lower than this threshold in both cases. However, the position of the Parotid_R contour just
superior to the high dose region makes this dose discrepancy quite large, even though
either recalculated dose would be considered low enough that the difference between Dmax
of 1057 cGy and 2133 cGy would not change the acceptability of this plan from a clinical
standpoint.
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4. Case 3 (left true vocal cord), PAL_ST_5, Dmax of Mandible
Dmax of Mandible is 3957.3 cGy with ground truth contours and 2038.5 cGy with
PAL_ST_5 contours (ΔDmax = -1918.8 cGy). The DSC, MSD, HD, and JI of the PAL_ST_5
Mandible and ground truth Mandible contours were 0.681, 2.224 mm, 11.621 mm, and
0.516, respectively.

Figure A.4: The discrepancy in the Dmax value of the mandible is caused by the PAL_ST_5
autosegmentation leaving out the posterior section of the mandible in the inferior slices
where the mandible is adjacent to the high dose region. The point of maximum dose occurs
in slice 180 for PAL_ST_5, while it occurs in slice 185 for ground truth; the PAL_ST_5
contour is missing the section of the mandible in the higher dose region in slice 185,
resulting in an underestimation of the delivered dose by almost 20 Gy. There is also a
disagreement over the inferior slice in which the mandible contour begins (slice 177 in the
ground truth contours vs. slice 180 in the PAL_ST_5 contours). However, in this case, the
inferior-most slice of the contour does not affect the calculated Dmax. Although the difference
in Dmax of nearly 20 Gy is the largest dosimetric difference found in this study, both the
ground truth and PAL_ST_5 Dmax values fall below the clinical threshold of Dmax to the
mandible < 6500 cGy and would thus not affect the acceptability of this plan from a clinical
standpoint.
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5. Case 5 (right tonsil), PAL_ST_5, Dmean of Brainstem
Dmean of Brainstem is 1116.5 cGy with ground truth contours and 2228.2 cGy with
PAL_ST_5 contours (ΔDmean = 1111.7 cGy). The DSC, MSD, HD, and JI of the PAL_ST_5
Brainstem and ground truth Brainstem contours were 0.541, 7.759 mm, 26.009 mm, and
0.370, respectively.

Figure A.5: The discrepancy in the Dmean value of the brainstem is caused by disagreement
over the slices in which the inferior and superior aspects of the brainstem contour begin and
end. The ground truth contours start in slice 221 (inferior) and end in slice 289 (superior),
whereas the PAL_ST_5 contours start in slice 215 (inferior) and end in slice 268 (superior).
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In the PAL_ST_5 segmentations, the brainstem overlaps with the spinal cord in slices 215
and 216. Because the PAL_ST_5 brainstem contour is missing 31 slices of the superior
aspect where the dose is low and adds an additional 6 slices to the inferior aspect where the
dose is higher, the Dmean value of the brainstem is much higher for the PAL_ST_5 contours
compared to the ground truth contours. Still, the clinical dose constraint of Dmax < 5400 cGy
for the brainstem is met in both cases (Dmax = 3902 cGy for ground truth and 3977 cGy for
PAL_ST_5), so this 1112 cGy discrepancy in Dmean would not change the acceptability of
this plan from a clinical standpoint.
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Appendix B: Supplementary Data for Chapter 6

Repeatability Metrics for b=0,500 vs. b=150,500 MR-Linac Sequences
Repeatability metrics were calculated for ADC maps reconstructed with b = 150 and
500 s/mm2 and compared with those reconstructed with b = 0 and 500 s/mm2. To test
whether the b-values used in the ADC reconstruction impacted the repeatability, a Wilcoxon
signed rank test was performed using the wCV2 values for each structure calculated from
the b=0,500 and b=150,500 ADC maps. Separate Wilcoxon signed rank tests were
performed for parotid glands, primary tumors, and lymph nodes and for short-term and longterm wCV2. Analyses were performed in JMP.

Table B.1: In vivo repeatability for MR-linac DWI sequences with ADC maps reconstructed
using b=0,500 s/mm2 vs. ADC maps reconstructed with b=150,500 s/mm2. Mean ADC
values are reported as mean ± standard deviation. wCV values are reported as the wCV
with 95% confidence intervals in parentheses. Pairs of b=0,500 and b=150,500 ADC maps
with a statistically significant difference in the Wilcoxon signed rank test are denoted with *
under both the b=0,500 and b=150,500 columns.

Parotid
glands

Primary
tumors

Lymph
nodes

Mean ADC (x10-3
mm2/s)
Short-term wCV
(%)
Long-term wCV
(%)
Mean ADC (x10-3
mm2/s)
Short-term wCV
(%)
Long-term wCV
(%)
Mean ADC (x10-3
mm2/s)
Short-term wCV
(%)
Long-term wCV
(%)

EPI b=0,500

EPI
b=150,500

SPLICE
b=0,500

SPLICE
b=150,500

TSE b=0,500

TSE
b=150,500

1.14 ± 0.17

0.72 ± 0.14

1.20 ± 0.23

0.71 ± 0.18

0.93 ± 0.18

0.62 ± 0.14

5.41 (4.42 –
6.97)
6.72 (5.49 –
8.66)

4.64 (3.80 –
5.99)
6.94 (5.67 –
8.95)

3.83 (3.13 –
4.94)
8.80 (7.19 –
11.34)

4.96 (4.05 –
6.39)
10.02 (8.19
– 12.91)

5.66 (4.63 –
7.29)*
10.03 (8.20
– 12.92)

6.53 (5.34 –
8.41)*
9.11 (7.44 –
11.74)

1.33 ± 0.22

0.96 ± 0.27

1.80 ± 0.19

1.16 ± 0.18

1.36 ± 0.19

0.96 ± 0.19

9.64 (7.23 –
14.45)
10.28 (7.65
–15.64)*

22.40 (16.81
– 33.58)
18.97 (14.13
– 28.87)*

7.84 (5.84 –
11.93)*
8.96 (6.56 –
14.14)*

15.28 (11.38
– 23.25)*
15.24 (11.16
– 24.04)*

7.60 (5.70 –
11.40)
11.68 (8.70
– 17.78)

14.72 (11.04
– 22.06)
14.51 (10.81
– 22.09)

1.38 ± 0.40

1.11 ± 0.41

1.53 ± 0.36

1.12 ± 0.37

1.31 ± 0.42

1.02 ± 0.41

7.80 (6.59 –
9.55)
9.95 (8.37 –
12.25)*

13.15 (11.11
– 16.09)
14.27 (12.01
– 17.57)*

7.23 (6.06 –
8.96)*
8.48 (7.00 –
10.78)*

9.54 (8.00 –
11.84)*
9.77 (8.06 –
12.42)*

10.82 (9.15
– 13.25)*
10.44 (8.79
– 12.86)*

13.12 (11.09
– 16.06)*
13.83 (11.64
– 17.03)*
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Bland-Altman Analysis for all MR-Linac and MR Sim DWI Sequences

Figure B.1: Bland-Altman plots showing differences in measured ADC values between each
pair of the three MR-linac DWI sequences (EPI, SPLICE, TSE) and three MR sim DWI
sequences (EPI, BLADE, RESOLVE). ADC values represent the mean ADC value within
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each structure for lymph nodes and primary tumors (patients) and parotid glands
(volunteers). Mean differences (MD) are represented by solid red lines with 95% confidence
intervals of the MD represented by dotted red lines. 95% limits of agreement are
represented by dotted black lines. Statistically significant biases are represented by *
(p<0.05).
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Figure B.2: Bland-Altman plots showing differences in measured ADC values between ADC
maps reconstructed using b-values of 0 and 500 s/mm2 (ADC b=0,500) and b-values of 150
and 500 s/mm2 (ADC b=150,500) for each of the three MR-linac DWI sequences (EPI,
SPLICE, TSE). ADC values represent the mean ADC value within each structure for lymph
nodes and primary tumors (patients) and parotid glands (volunteers). Mean differences (MD)
are represented by solid red lines with 95% confidence intervals of the MD represented by
dotted red lines. 95% limits of agreement are represented by dotted black lines. Statistically
significant biases are represented by * (p<0.05).
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Figure B.3: Phantom ADC bias results from four replicate image acquisitions for each
individual phantom vial. Each data point within each box-and-whisker plot represents the
difference between the mean ADC value in an ROI and the true ADC value for each
phantom vial. The numbers in the phantom vial names refer to the concentrations of
polymer, which correspond to the manufacturer-provided true ADC value (1.127x10-3 mm2/s
for 0, 0.843x10-3 mm2/s for 10, 0.607x10-3 mm2/s for 20, 0.403x10-3 mm2/s for 30, 0.248x10-3
mm2/s for 40, and 0.128x10-3 mm2/s for 50). The letters in the vial names refer to the spatial
location within the vial (“c” for “center,” “i” for “inner,” and “o” for “outer”).
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Figure B.4: Phantom ADC bias results from four replicate image acquisitions for each MRlinac DWI sequence with ADC maps reconstructed using b-values of 0 and 500 s/mm2
(b=0,500) and b-values of 150 and 500 s/mm2 (b=150,500). Each data point represents the
difference between the mean ADC value in an ROI and the true ADC value for each
phantom vial. Data points from multiple vials with the same true ADC value are combined.

Table B.2: Phantom repeatability metrics for each MR-linac DWI sequence between ADC
maps reconstructed using b-values of 0 and 500 s/mm2 (b=0,500) and b-values of 150 and
500 s/mm2 (b=150,500).

EPI b=0,500
%CV (within-ROI)
Short-term RC (x10-6 mm2/s)
Short-term wCV (%)
Long-term RC (x10-6 mm2/s)
Long-term wCV (%)

2.55 ± 0.71
10.65
0.33
30.50
0.96

EPI
b=150,500
2.15 ± 0.31
4.60
0.15
6.15
0.20

SPLICE
b=0,500
3.14 ± 0.11
8.15
0.28
25.38
0.85

SPLICE
b=150,500
2.62 ± 0.06
5.34
0.17
16.01
0.50

TSE
b=0,500
3.62 ± 0.30
4.07
0.15
2.65
0.10

TSE
b=150,500
2.99 ± 0.18
7.59
0.25
0.30
0.01
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